Bromoform and dibromochloromethane by Risher, J. et al.
TOXICOLOGICAL PROFILE FOR 

BROMOFORM AND DIBROMOCHLOROMETHANE 

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES 

Public Health Service 

Agency for Toxic Substances and Disease Registry 

August 2005 
ii BROMOFORM AND DIBROMOCHLOROMETHANE 
DISCLAIMER 
The use of company or product name(s) is for identification only and does not imply endorsement by the 
Agency for Toxic Substances and Disease Registry. 
iii BROMOFORM AND DIBROMOCHLOROMETHANE 
UPDATE STATEMENT 
 
A Toxicological Profile for Bromoform and Dibromochloromethane, Draft for Public Comment was 
released in September 2003.  This edition supersedes any previously released draft or final profile.   
Toxicological profiles are revised and republished as necessary.  For information regarding the update 
status of previously released profiles, contact ATSDR at: 
Agency for Toxic Substances and Disease Registry 

Division of Toxicology/Toxicology Information Branch 










vii BROMOFORM AND DIBROMOCHLOROMETHANE 
QUICK REFERENCE FOR HEALTH CARE PROVIDERS 
Toxicological Profiles are a unique compilation of toxicological information on a given hazardous 
substance. Each profile reflects a comprehensive and extensive evaluation, summary, and interpretation 
of available toxicologic and epidemiologic information on a substance.  Health care providers treating 
patients potentially exposed to hazardous substances will find the following information helpful for fast 
answers to often-asked questions. 
Primary Chapters/Sections of Interest 
Chapter 1: Public Health Statement: The Public Health Statement can be a useful tool for educating 
patients about possible exposure to a hazardous substance.  It explains a substance’s relevant 
toxicologic properties in a nontechnical, question-and-answer format, and it includes a review of 
the general health effects observed following exposure. 
Chapter 2: Relevance to Public Health: The Relevance to Public Health Section evaluates, interprets, 
and assesses the significance of toxicity data to human health. 
Chapter 3: Health Effects: Specific health effects of a given hazardous compound are reported by type 
of health effect (death, systemic, immunologic, reproductive), by route of exposure, and by length 
of exposure (acute, intermediate, and chronic).  In addition, both human and animal studies are 
reported in this section. 
NOTE: Not all health effects reported in this section are necessarily observed in the clinical 
setting. Please refer to the Public Health Statement to identify general health effects observed 
following exposure. 
Pediatrics: Four new sections have been added to each Toxicological Profile to address child health 
issues: 
Section 1.6 How Can (Chemical X) Affect Children? 

Section 1.7 How Can Families Reduce the Risk of Exposure to (Chemical X)? 

Section 3.7 Children’s Susceptibility 

Section 6.6 Exposures of Children 

Other Sections of Interest: 
Section 3.8 Biomarkers of Exposure and Effect 
Section 3.11 Methods for Reducing Toxic Effects 
ATSDR Information Center  
Phone: 1-888-42-ATSDR or (404) 498-0110 Fax: (770) 488-4178 
E-mail: atsdric@cdc.gov Internet: http://www.atsdr.cdc.gov 
The following additional material can be ordered through the ATSDR Information Center: 
Case Studies in Environmental Medicine: Taking an Exposure History—The importance of taking an 
exposure history and how to conduct one are described, and an example of a thorough exposure 
history is provided.  Other case studies of interest include Reproductive and Developmental 
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Hazards; Skin Lesions and Environmental Exposures; Cholinesterase-Inhibiting Pesticide 
Toxicity; and numerous chemical-specific case studies. 
Managing Hazardous Materials Incidents is a three-volume set of recommendations for on-scene 
(prehospital) and hospital medical management of patients exposed during a hazardous materials 
incident. Volumes I and II are planning guides to assist first responders and hospital emergency 
department personnel in planning for incidents that involve hazardous materials.  Volume III— 
Medical Management Guidelines for Acute Chemical Exposures—is a guide for health care 
professionals treating patients exposed to hazardous materials. 
Fact Sheets (ToxFAQs) provide answers to frequently asked questions about toxic substances. 
Other Agencies and Organizations 
The National Center for Environmental Health (NCEH) focuses on preventing or controlling disease, 
injury, and disability related to the interactions between people and their environment outside the 
workplace. Contact: NCEH, Mailstop F-29, 4770 Buford Highway, NE, Atlanta, 
GA 30341-3724 • Phone: 770-488-7000 • FAX: 770-488-7015. 
The National Institute for Occupational Safety and Health (NIOSH) conducts research on occupational 
diseases and injuries, responds to requests for assistance by investigating problems of health and 
safety in the workplace, recommends standards to the Occupational Safety and Health 
Administration (OSHA) and the Mine Safety and Health Administration (MSHA), and trains 
professionals in occupational safety and health.  Contact: NIOSH, 200 Independence Avenue, 
SW, Washington, DC 20201 • Phone: 800-356-4674 or NIOSH Technical Information Branch, 
Robert A. Taft Laboratory, Mailstop C-19, 4676 Columbia Parkway, Cincinnati, OH 45226-1998 
• Phone: 800-35-NIOSH. 
The National Institute of Environmental Health Sciences (NIEHS) is the principal federal agency for 
biomedical research on the effects of chemical, physical, and biologic environmental agents on 
human health and well-being.  Contact:  NIEHS, PO Box 12233, 104 T.W. Alexander Drive, 
Research Triangle Park, NC 27709 • Phone: 919-541-3212. 
Referrals 
The Association of Occupational and Environmental Clinics (AOEC) has developed a network of clinics 
in the United States to provide expertise in occupational and environmental issues.  Contact: 
AOEC, 1010 Vermont Avenue, NW, #513, Washington, DC 20005 • Phone:  202-347-4976 
• FAX: 202-347-4950 • e-mail: AOEC@AOEC.ORG • Web Page:  http://www.aoec.org/. 
The American College of Occupational and Environmental Medicine (ACOEM) is an association of 
physicians and other health care providers specializing in the field of occupational and 
environmental medicine.  Contact: ACOEM, 25 Northwest Point Boulevard, Suite 700, 
Elk Grove Village, IL 60007-1030 • Phone:  847-818-1800 • FAX:  847-818-9266. 
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1. PUBLIC HEALTH STATEMENT 
 
This public health statement tells you about bromoform and dibromochloromethane and the 
effects of exposure to them.   
The Environmental Protection Agency (EPA) identifies the most serious hazardous waste sites in 
the nation. These sites are then placed on the National Priorities List (NPL) and are targeted for 
long-term federal clean-up activities.  Bromoform and dibromochloromethane has been found in 
at least 140 and 174 of the 1,662 current or former NPL sites.  Although the total number of NPL 
sites evaluated for these substances is not known, the possibility exists that the number of sites at 
which bromoform and dibromochloromethane is found may increase in the future as more sites 
are evaluated. This information is important because these sites may be sources of exposure and 
exposure to these substances may harm you. 
When a substance is released either from a large area, such as an industrial plant, or from a 
container, such as a drum or bottle, it enters the environment. Such a release does not always 
lead to exposure. You can be exposed to a substance only when you come in contact with it.  
You may be exposed by breathing, eating, or drinking the substance, or by skin contact. 
If you are exposed to bromoform or dichlorobromomethane, many factors will determine 
whether you will be harmed.  These factors include the dose (how much), the duration (how 
long), and how you come in contact with them.  You must also consider any other chemicals you 
are exposed to and your age, sex, diet, family traits, lifestyle, and state of health. 
1.1 WHAT ARE BROMOFORM AND DIBROMOCHLOROMETHANE? 
Bromoform (also known as tribromomethane) and dibromochloromethane are colorless to 
yellow, heavy, nonburnable liquids with a sweetish odor.  These chemicals are possible 
contaminants of drinking water that has been chlorinated to kill bacteria and viruses that could 
cause serious waterborne infectious diseases.  Bromoform and dibromochloromethane may form 
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when chlorine reacts with other naturally occurring substances in water, such as decomposing 
plant material.  Plants in the ocean also produce small amounts of these chemicals.   
These chemicals are found mainly in water that originally came from surface sources, such as 
rivers and lakes. Springs and deep drilled wells usually contain very little of the substances that 
react with chlorine to form these chemicals; therefore, well and spring water is less likely a 
source of bromoform and dibromochloromethane than water from a reservoir (artificial lake).  
The amount of bromoform and dibromochloromethane in drinking water can change 
considerably from day to day, depending on the source, temperature, amount of plant material in 
the water, amount of chlorine added, and a variety of other factors.   
In the past, bromoform was used by industry to dissolve dirt and grease and to make other 
chemicals.  It was also used in the early part of this century as a medicine to help children with 
whooping cough get to sleep. Currently, bromoform is only produced in small amounts for use 
in laboratories and in geological and electronics testing.  Dibromochloromethane was used in the 
past to make other chemicals such as fire extinguisher fluids, spray can propellants, refrigerator 
fluid, and pesticides. It is now only used on a small scale in laboratories. 
In the environment, bromoform and dibromochloromethane are not found as pure liquids, but 
instead, they are found either dissolved in water or evaporated into air as a gas.  Both bromoform 
and dibromochloromethane are relatively stable in the air, but reactions with other chemicals in 
the air cause them to break down slowly (about 50% in 1 or 2 months).  Bromoform and 
dibromochloromethane in water or soil may also be broken down by bacteria, but the speed of 
this process is not known. 
Further information on the properties, uses, and chemical identity of bromoform and 
dibromochloromethane in the environment may be found in Chapters 4, 5, and 6. 
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1.2 	 WHAT HAPPENS TO BROMOFORM AND DIBROMOCHLOROMETHANE 
WHEN THEY ENTER THE ENVIRONMENT? 
Bromoform and dibromochloromethane enter the environment through the disposal of water that 
has been disinfected with chlorine or as vapors emitted from chlorinated water.  These chemicals 
are also made naturally by plant-like organisms called algae that are found in the oceans.  Some 
part of bromoform and dibromochloromethane that enters the air is removed by rain.  What is 
left in the air takes about 1–2 months for half of it to degrade.  In water, bromoform and 
dibromochloromethane are slowly broken down at the water surface where oxygen is available, 
but break down much faster in deep water and in water that is underground where there is a lot 
less oxygen. Bromoform and dibromochloromethane are mobile in soils and may seep into 
groundwater. Bromoform and dibromochloromethane do not appear to concentrate in fish. 
1.3 	 HOW MIGHT I BE EXPOSED TO BROMOFORM AND DIBROMOCHLORO- 
METHANE? 
You are most likely to be exposed to bromoform and dibromochloromethane by drinking water 
that has been treated with chlorine. Usually, the levels in chlorinated drinking water are between 
1 and 10 parts of bromoform and dibromochloromethane per billion parts of water (ppb).  These 
are levels that are known to be without adverse health effects.  Bromoform and dibromochloro­
methane have also been detected in chlorinated swimming pools.  Exposure can occur at a 
swimming pool, by breathing bromoform or dibromochloromethane that has evaporated into the 
air, or by uptake from the water through the skin.  Neither dibromochloromethane nor 
bromoform are likely to be found in food.  
If you live near a factory or laboratory that makes or uses dibromochloromethane or bromoform, 
you might be exposed to dibromochloromethane or bromoform in the air.  Currently, bromoform 
is only used for geological and electronics testing.  Dibromochloromethane is used on a small-
scale in laboratories. Since neither dibromochloromethane nor bromoform have widespread use 
in this country, they are usually present in outside air at very low levels (less than 0.01 ppb).  
Therefore, exposure to bromoform or dibromochloromethane in the air is a minor route.  
Exposure may occur if you come into contact with water or soil at a chemical waste site where 
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dibromochloromethane or bromoform has been disposed.  Further information on how you might 
be exposed to these chemicals is given in Chapter 6. 
1.4 	 HOW CAN BROMOFORM AND DIBROMOCHLOROMETHANE ENTER AND 
LEAVE MY BODY? 
Studies in animals or humans indicate that both bromoform and dibromochloromethane can 
easily enter your body after swallowing them in water or breathing them in air.  They can also 
enter your body through your skin (for example, by washing or showering in water containing 
these chemicals).  Some portion of bromoform and dibromochloromethane entering your body 
may be broken down to other compounds.  Bromoform, dibromochloromethane, and their 
breakdown products can be removed from the body by being exhaled from the lungs.  These 
chemicals leave the body fairly rapidly.  Bromoform and dibromochlormethane do not tend to 
build up in the body, 50–90% of the amount that enters the body is removed within 8 hours.  
Further information on how bromoform and dibromochloromethane enter and leave your body is 
given in Chapter 3. 
1.5 	 HOW CAN BROMOFORM AND DIBROMOCHLOROMETHANE AFFECT MY 
HEALTH? 
Scientists use many tests to protect the public from harmful effects of toxic chemicals and to find 
ways for treating persons who have been harmed. 
One way to learn whether a chemical will harm people is to determine how the body absorbs, 
uses, and releases the chemical.  For some chemicals, animal testing may be necessary.  Animal 
testing may also help identify health effects such as cancer or birth defects.  Without laboratory 
animals, scientists would lose a basic method for getting information needed to make wise 
decisions that protect public health.  Scientists have the responsibility to treat research animals 
with care and compassion.  Scientists must comply with strict animal care guidelines because 
laws today protect the welfare of research animals. 
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The effects of bromoform and dibromochloromethane on your health depend largely on the 
amount you take into your body and the duration of exposure.  In general, the more you take in, 
the greater the chance that an effect will occur.  The main effect of swallowing or breathing large 
amounts of bromoform is a slowing of normal brain activities, resulting in sleepiness or sedation 
occuring quickly after the chemicals enter your body.  In humans, these effects tend to disappear 
within a day. Exposures capable of producing these effects include swallowing 1–4 drops of 
liquid bromoform, an amount much greater than is usually found in a glass of drinking water.  At 
much higher amounts, a person may become unconsciousness or die.  The amount of dibromo­
chloromethane taken by mouth that would affect humans is not known, but is probably similar to 
bromoform. 
Some studies in animals indicate that exposure to high doses of bromoform or dibromochloro­
methane may also lead to liver and the kidney injury within a short period of time.  Exposure to 
low levels of bromoform or dibromochloromethane do not appear to seriously affect the brain, 
liver, or kidneys. Other animal studies suggest that typical bromoform or dibromochloromethane 
exposures do not pose a high risk of affecting the chance of becoming pregnant or harming an 
unborn baby. However, studies in animals indicate that long-term intake of either bromoform or 
dibromochloromethane can cause liver and kidney cancer.  Although cancer in humans cannot be 
definitely attributed to these chemicals, it is an effect of special concern, since many people are 
exposed to low levels of bromoform and dibromochloromethane in chlorinated drinking water.   
The International Agency for Research on Cancer (IARC) concluded that bromoform and 
dibromochloromethane are not classifiable as to human carcinogenicity.  The EPA classified 
bromoform as a probable human carcinogen and dibromochloromethane as a possible human 
carcinogen. 
Further information on how bromoform and dibromochloromethane can affect the health of 
humans and animals is presented in Chapter 3. 
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1.6 	 HOW CAN BROMOFORM AND DIBROMOCHLOROMETHANE AFFECT 
CHILDREN? 
This section discusses potential health effects in humans from exposures during the period from 
conception to maturity at 18 years of age.  
In the early 1900s, bromoform was given to children suffering from whooping cough, resulting 
in several deaths when children were accidentally overdosed.  Children appeared drowsy, then 
lifeless, just before dying. 
There are no studies in humans or laboratory animals that examine whether the effects of 
bromoform and dibromochloromethane change with age.  Based on current knowledge of body 
function, and metabolism in the body, there is no indication that children will be affected more 
than adults. 
1.7 	 HOW CAN FAMILIES REDUCE THE RISK OF EXPOSURE TO BROMOFORM 
AND DIBROMOCHLOROMETHANE? 
If your doctor finds that you have been exposed to substantial amounts of bromoform and/or 
dibromochloromethane, ask whether your children might also have been exposed.  Your doctor 
might need to ask your state health department to investigate. 
The chance of consuming bromoform or dibromochloromethane in chlorinated public drinking 
water varies with season, water temperature, water chemistry, disinfection method, and other 
factors. However, the health risks associated with drinking non-disinfected water when there is 
evidence of disease-causing contamination (i.e., bacteria, viruses, etc.) are much greater than the 
risk of adverse health effects from exposure to bromoform or dibromochloromethane.  
There are water treatment methods that people can be used in the home to reduce exposure to 
bromoform and dibromochloromethane from chlorinated tap water.  These include simple do-it­
yourself methods such as connecting solid carbon black filters to faucets and shower taps.  
Homeowners may discuss other home water treatment methods, including filtering, aeration or 
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boiling, distillation, and/or activated charcoal, with a professional plumber or water well 
contractor. The chance of exposure to bromoform and dibromochloromethane may be reduced 
by minimizing contact with water expected to have higher levels of these chemicals, such as 
chlorinated swimming pool water. When bathing or showering some portion of dibromo­
chloromethane and/or bromoform may evaporate into the air.  Opening bathroom windows, and 
taking shorter baths and showers may reduce the amount of chemical vapor that is inhaled or 
absorbed through the skin. 
1.8 	 IS THERE A MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN 
EXPOSED TO BROMOFORM AND DIBROMOCHLOROMETHANE? 
If you are exposed to bromoform or dibromochloromethane, measurable levels of the chemicals 
can sometimes be detected in samples of your blood, breath, or fat.  However, there is not 
enough information at present to use the results of such tests to estimate the level of exposure or 
to predict the nature or the severity of any health effects that might result.  Since special 
equipment is needed, these tests are not routinely performed in doctors' offices.  Because 
bromoform and dibromochloromethane are quickly eliminated from the body, these special 
laboratory tests are only effective in detecting recent exposures (within 1 or 2 days).  Further 
information on how bromoform and dibromochloromethane can be measured in exposed humans 
is presented in Chapters 3 and 7. 
1.9 	 WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO 
PROTECT HUMAN HEALTH? 
The federal government develops regulations and recommendations to protect public health.  
Regulations can be enforced by law. The EPA, the Occupational Safety and Health 
Administration (OSHA), and the Food and Drug Administration (FDA) are some federal 
agencies that develop regulations for toxic substances.  Recommendations provide valuable 
guidelines to protect public health, but cannot be enforced by law.  The Agency for Toxic 
Substances and Disease Registry (ATSDR) and the National Institute for Occupational Safety 
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and Health (NIOSH) are two federal organizations that develop recommendations for toxic 
substances. 
Regulations and recommendations can be expressed as “not-to-exceed” levels, that is, levels of a 
toxic substance in air, water, soil, or food that do not exceed a critical value that is usually based 
on levels that affect animals; they are then adjusted to levels that will help protect humans.  
Sometimes these not-to-exceed levels differ among federal organizations because they used 
different exposure times (an 8-hour workday or a 24-hour day), different animal studies, or other 
factors. 
Recommendations and regulations are also updated periodically as more information becomes 
available. For the most current information, check with the federal agency or organization that 
provides it. Some regulations and recommendations for bromoform and dibromochloromethane 
include the following: 
OSHA has set a legally enforceable limit of 0.5 ppm for bromoform in workroom air to protect 
workers during an 8-hour shift over a 40-hour work week. 
EPA recommends that drinking water levels for bromoform should not be more than 0.7 parts 
per million (ppm) for bromoform and 0.7 ppm for dibromochloromethane.   
1.10 WHERE CAN I GET MORE INFORMATION? 
If you have any more questions or concerns, please contact your community or state health or 
environmental quality department, or contact ATSDR at the address and phone number below. 
ATSDR can also tell you the location of occupational and environmental health clinics.  These 
clinics specialize in recognizing, evaluating, and treating illnesses that result from exposure to 
hazardous substances. 
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Toxicological profiles are also available on-line at www.atsdr.cdc.gov and on CD-ROM.  You 
may request a copy of the ATSDR ToxProfilesTM CD-ROM by calling the toll-free information 
and technical assistance number at 1-888-42ATSDR (1-888-422-8737), by e-mail at 
atsdric@cdc.gov, or by writing to: 
Agency for Toxic Substances and Disease Registry 

  Division of Toxicology 
 
1600 Clifton Road NE 

  Mailstop F-32 

  Atlanta, GA 30333 

  Fax: 1-770-488-4178 
 
Organizations for-profit may request copies of final Toxicological Profiles from the following: 
National Technical Information Service (NTIS) 
 
5285 Port Royal Road 

  Springfield, VA 22161 

  Phone: 1-800-553-6847 or 1-703-605-6000 

  Web site: http://www.ntis.gov/ 
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2.1 	 BACKGROUND AND ENVIRONMENTAL EXPOSURES TO BROMOFORM AND 
DIBROMOCHLOROMETHANE IN THE UNITED STATES 
Bromoform (CHBr3; CAS Number 75-25-2), also known as tribromomethane, and dibromochloro­
methane (CHClBr2; CAS Number 124-48-1) belong to a group of chemicals referred to as trihalo­
methanes; the other two chemicals in this group are chloroform (also known as trichloromethane) and 
dichlorobromomethane.  Trihalomethanes are formed when raw source water is disinfected by 
chlorination. In the United States, over 280 million people are served by public water systems that apply 
chlorine or some of its compounds as disinfectants to water in order to provide protection against 
microbial contaminants that otherwise might cause serious water-borne diseases.  While these chlorine-
containing disinfectants are effective in controlling many microorganisms, they react with natural organic 
or carbon-containing matter in the water to form disinfection byproducts.  Therefore, the principal source 
of human exposure to bromoform and dibromochloromethane is chlorinated water supplied to homes, 
work, and public places. Bromoform and dibromochloromethane concentrations in public supply or tap 
water are in the low microgram/L range.  Dibromochloromethane is often found more frequently than 
bromoform in samples from chlorinated water systems.   
In the past, it was thought that most of the human exposure to bromoform and dibromochloromethane 
occurred through consumption of chlorinated drinking water.  However, because of their physical 
properties (see Henry’s law constants in Chapter 4), some bromoform and dibromochloromethane 
volatilize into the air from normal household use of water containing these chemicals.  Recent models for 
residential exposure predict that exposure by the inhalation and dermal routes may be significant.  Dermal 
exposure is expected from showering or bathing. Total administered doses of bromoform or dibromo­
chloromethane for residential tap water having low microgram/L concentrations are predicted to be on the 
order of 10-4 mg/kg/day. 
2.2 	 SUMMARY OF HEALTH EFFECTS  
The general population is primarily exposed to bromoform and dibromochloromethane via tap water.  The 
primary routes of exposure are ingestion and inhalation (from volatized compounds) and dermal exposure 
during showering and bathing.  Bromoform and dibromochloromethane are readily absorbed from the 
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gastrointestinal tract and may be absorbed through the respiratory tract and skin.  They are rapidly 
distributed throughout the body.  In the liver, bromoform and dibromochloromethane are metabolized by 
the cytochrome P-450 mixed function oxidase system to a highly reactive metabolite, which is ultimately 
metabolized to carbon dioxide or carbon monoxide. 
Studies in animals, combined with limited observations in humans, indicate that the principal adverse 
health effects associated with inhalation or oral exposure to bromoform or dibromochloromethane are 
central nervous system depression and liver and kidney damage.  Although limited dermal data were 
located, it is likely that similar adverse health effects would occur from dermal exposure.  Based on the 
no-observed-adverse-effect level (NOAEL) and lowest-observed-adverse-effect level (LOAEL) values 
identified in animal studies, the liver appears to be the most sensitive target organ.  Two types of liver 
effects have been observed in laboratory animals:  lipidosis and hepatocellular necrosis.  Lipidosis is an 
accumulation of lipids in the hepatocytes resulting in cellular vacuolization and swelling.  Hepatocellular 
necrosis is observed at higher doses. It is not known if these effects represent a continuum of liver 
damage or are due to separate modes of action.  Kidney effects are typically observed at higher doses than 
the hepatic effects; tubular cell degeneration and nephrosis are the most commonly reported effects in 
laboratory animals.  Central nervous system depression, as evidenced by lethargy, ataxia, and shallow 
breathing, is typically observed at very high, often lethal, doses.  High-dose exposure is also associated 
with decreases in body weight gain.  There are limited data on the immunotoxicity of bromoform and 
dibromochloromethane.  Impaired humoral and cell-mediated (only observed with dibromochloro­
methane) immunity were observed in a study of mice administered bromoform or dibromochloromethane 
via gavage for 14 days.  For bromoform, the immune and liver effects occurred at the same dose level; for 
dibromochloromethane, the immune effects occurred at a lower dose than liver effects. 
The available data on the potential of bromoform and dibromochloromethane to induce reproductive 
and/or developmental effects are inconclusive.  Human data primarily come from epidemiological studies 
of pregnancy outcomes in women exposed to trihalomethanes in drinking water.  These studies involved 
mixed exposures to the trihalomethane compounds (chloroform, dichlorobromomethane, bromoform, and 
dibromochloromethane), and many did not analyze for possible risks associated with bromoform or 
dibromochloromethane water concentrations.  These data are inadequate for establishing a causal 
relationship between trihalomethane exposure and reproductive and/or developmental toxicity.  The 
animal data suggest that exposure to bromoform or dibromochloromethane does not cause histological 
damage to reproductive organs or impair reproductive function; although high-dose exposure may result 
in reduced fertility.  The available developmental toxicity data suggest that bromoform and 
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dibromochloromethane may be toxic to the developing fetus, but these data are inadequate to establish 
firm conclusions. 
The carcinogenicity of bromoform and dibromochloromethane has been studied in both humans and 
laboratory animals.  The human data consist of studies of trihalomethane exposure via tap water.  As with 
the reproductive and developmental toxicity studies, these data are inconclusive and do not establish 
causal relationships. Carcinogenic effects have been observed in animals exposed to bromoform and 
dibromochloromethane.  Chronic oral exposure to bromoform resulted in increases in the occurrence of 
intestinal tumors in female rats.  Dibromochloromethane induced liver tumors in male and female mice.  
The Department of Health and Human Services (DHHS) has not categorized the human carcinogenic 
potential of bromoform or dibromochloromethane.  The International Agency for Research on Cancer 
(IARC) concluded that there were inadequate human data and limited animal data and assigned 
bromoform and dibromochloromethane to weight of evidence category 3, not classifiable as to 
carcinogenicity in humans.  EPA classified bromoform as a probable human carcinogen, group B2 and 
dibromochloromethane as a possible human carcinogen, group C. 
The primary targets of bromoform and dibromochloromethane toxicity—liver, kidney, and central 
nervous system—are discussed in greater detail below.  The reader is referred to Section 3.2, Discussion 
of Health Effects by Route of Exposure, for additional information on other health effects. 
Liver Effects. Acute, intermediate-, and chronic-duration studies in laboratory animals provide strong 
evidence that the liver is the critical target of bromoform and dibromochloromethane toxicity.  There are 
very limited human data on the toxicity of these two compounds; data for other trihalomethanes, 
particularly chloroform, suggest that the liver would also be a target of toxicity in humans.   
There is strong evidence that the hepatotoxicity of bromoform and dibromochloromethane is due to their 
metabolism to reactive intermediates and highly reactive trihalomethyl free radicals.  At lower doses, the 
hepatotoxicity of bromoform and dibromochloromethane is characterized by fatty infiltration, cellular 
vacuolization and swelling, and increases in liver weight.  Consistent with the accumulation of lipids is 
the observed decrease in serum triglyceride levels and alterations in serum cholesterol levels.  At higher 
doses, focal centrolobular necrosis and increases in SGOT and SGPT levels have been observed.  For 
bromoform, the LOAEL is 50 mg/kg (5 days/week; 36 mg/kg/day) for fatty changes observed in rats 
administered bromoform in corn oil via gavage for 13 weeks.  Necrosis was observed in rats receiving 
gavage doses of 200 mg/kg (143 mg/kg/day), 5 days/week for 2 years, but not after 13 weeks of dosing.  
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For dibromochloromethane, the LOAEL is 40 mg/kg (5 days/week; 28 mg/kg/day) for fatty liver changes 
in rats receiving gavage doses of dibromochloromethane in corn oil for 2 years.  Necrosis was observed at 
173 mg/kg/day in rats exposed via the diet for 1 month. 
Species and possible gender differences in the hepatotoxicity of bromoform and dibromochloromethane 
have been identified. Rats appear to be more sensitive than mice to the liver effects.  Under similar 
exposures scenarios, respective NOAEL and LOAEL values of 25 and 50 mg/kg (5 days/week) for fatty 
changes were identified in rats exposed to bromoform for 13 weeks; the NOAEL and LOAEL values in 
mice were 100 and 200 mg/kg (5 days/week), respectively.  For dibromochloromethane, the NOAEL and 
LOAEL values for fatty changes following a 13-week gavage exposure (5 days/week) were 30 and 
60 mg/kg for rats and 125 and 250 mg/kg for mice. 
Kidney Effects.    Renal effects have not been consistently found in studies of laboratory animals, 
particularly in the case of bromoform exposure.  One study reported mesangial nephrosis in mice exposed 
to 145 mg/kg/day bromoform via gavage for 14 days and identified a NOAEL of 37 mg/kg/day.  
Comprehensive intermediate- and chronic-duration studies in rats and mice did not find significant renal 
effects at doses as high as 400 mg/kg (5 days/week; 286 mg/kg/day).  In contrast, exposure to 
dibromochloromethane resulted in mesangial hyperplasia in mice exposed to ≥37 mg/kg/day via gavage 
for 14 days.  Toxic nephropathy was observed in rats and mice exposed to 250 mg/kg (179 mg/kg/day) 
for 13 weeks and in mice receiving gavage doses of 100 mg/kg (71 mg/kg/day) for 2 years. 
Central Nervous System Depression.    In children, oral doses of around 60 mg/kg/day of 
bromoform typically produced only mild sleepiness, while doses of 150 mg/kg sometimes produced 
stupor or deep narcosis, usually accompanied by depressed respiration and erratic heartbeat.  The onset of 
sedation after ingestion is rapid, reportedly minutes in children and about an hour in mice.  In 
intermediate and chronic oral studies in animals, doses of bromoform ≥100 mg/kg (5 days/week; 
71 mg/kg/day) caused lethargy.  Airborne concentrations of bromoform leading to central nervous system 
depression in humans are not known, but brief exposures of laboratory animals to high concentrations 
(7,000 ppm) leads to deep sedation within minutes.  Central nervous system effects were also observed in 
laboratory animals at a concentration of 240 ppm in a short-term, repeated dose study.  These depressant 
effects on the nervous system appear to be fully reversible both in animals and humans, but it is difficult 
to rule out the possibility of subtle, but enduring, neurological changes following narcotizing doses. 
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2.3 MINIMAL RISK LEVELS (MRLs) 
Estimates of exposure levels posing minimal risk to humans (MRLs) have been made for bromoform and 
dibromochloromethane.  An MRL is defined as an estimate of daily human exposure to a substance that is 
likely to be without an appreciable risk of adverse effects (noncarcinogenic) over a specified duration of 
exposure. MRLs are derived when reliable and sufficient data exist to identify the target organ(s) of 
effect or the most sensitive health effect(s) for a specific duration within a given route of exposure.  
MRLs are based on noncancerous health effects only and do not consider carcinogenic effects.  MRLs can 
be derived for acute, intermediate, and chronic duration exposures for inhalation and oral routes.  
Appropriate methodology does not exist to develop MRLs for dermal exposure. 
Although methods have been established to derive these levels (Barnes and Dourson 1988; EPA 1990), 
uncertainties are associated with these techniques.  Furthermore, ATSDR acknowledges additional 
uncertainties inherent in the application of the procedures to derive less than lifetime MRLs.  As an 
example, acute inhalation MRLs may not be protective for health effects that are delayed in development 
or are acquired following repeated acute insults, such as hypersensitivity reactions, asthma, or chronic 
bronchitis. As these kinds of health effects data become available and methods to assess levels of 
significant human exposure improve, these MRLs will be revised. 
The details regarding calculations of the MRLs for bromoform and dibromochloromethane are described 
in Appendix A. 
Inhalation MRLs 
MRLs for acute- (≤14 days), intermediate- (15–364 days), and chronic-duration (≥364 days) inhalation 
exposure to bromoform or dibromochloromethane have not been derived because quantitative data were 
not available to determine NOAELs or LOAELs.   
Information on the toxicity of bromoform or dibromochloromethane in humans following inhalation 
exposure was not available. Brief summaries of adverse effects in laboratory animals following 
inhalation exposure to bromoform, reported in abstract form, do not provide sufficient basis for MRL 
derivation. No studies were located regarding effects of dibromochloromethane in animals exposed via 
inhalation. Therefore, inhalation MRLs were not derived for either bromoform or dibromochloro­
methane. 
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Oral MRLs 
Bromoform 
•	 An MRL of 0.7 mg/kg/day has been derived for acute-duration oral exposure (14 days or less) to 
bromoform. 
The acute toxicity of bromoform has been investigated in a number of animal studies.  These studies have 
identified several targets of toxicity.  The available data suggest that the liver is the most sensitive target.  
The threshold for liver effects appears to be between 50 and 125 mg/kg/day.  Increases in absolute and 
relative liver weights were observed in mice exposed to 125 mg/kg/day bromoform in emulphor in water 
for 14 days (Munson et al. 1982).  Centrilobular pallor, considered to be indicative of hepatocellular 
degeneration, was observed at 145 mg/kg/day in mice receiving gavage doses of bromoform in corn oil 
for 14 days (Condie et al. 1983).  Hepatocellular vacuolization and/or swelling was observed at 
200 mg/kg (9 days/11 days) and higher (Coffin et al. 2000).  Other effects observed in acute-duration 
animal studies include mesangial nephrosis in mice exposed to 145 mg/kg/day via gavage for 14 days 
(Condie et al. 1983), central nervous system depression, as evidenced by lethargy, labored and shallow 
breathing, and ataxia in rats and mice at ≥600 mg/kg/day for 1–14 days (Balster and Borzelleca 1982; 
Bowman et al. 1978; NTP 1989a), and developmental effects (increases in the occurrence of skeletal 
anomalies) in the offspring of rats exposed to 200 mg/kg/day on gestational days 6–15 (Ruddick et al. 
1983). 
The Condie et al. (1983) and Munson et al. (1982) studies identify the lowest LOAELs for liver effects.  
The Condie et al. (1983) study identified a NOAEL of 72 mg/kg/day and LOAEL of 145 mg/kg/day for 
centrilobular pallor in mice receiving daily gavage doses of bromoform in corn oil for 14 days.  Focal 
inflammation and increase in SGPT levels were observed at 280 mg/kg/day.  The Munson et al. (1982) 
study identified a NOAEL of 50 mg/kg/day and LOAEL of 125 mg/kg/day for increases in absolute and 
relative liver weights in mice receiving daily gavage doses of bromoform in a 10% emulphor/de-ionized 
water solution for 14 days.  At 250 mg/kg/day, increases in SGOT and SGPT levels were also observed.  
The Condie et al. (1983) study was selected as the basis of the MRL because it identified a higher 
NOAEL for liver effects than the Munson et al. (1982) study and included histopathological examination 
of the liver which was not included in the Munson et al. (1982) study.  The NOAEL of 72 mg/kg/day was 
divided by an uncertainty factor of 100 (10 for extrapolation from animals to humans and 10 for human 
variability) to yield an acute-duration oral MRL of 0.7 mg/kg/day. 
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•	 An MRL of 0.2 mg/kg/day has been derived for intermediate-duration oral exposure (15–
 
364 days) to bromoform.
 
The oral toxicity database in animals provides strong evidence that the liver is the most sensitive target of 
bromoform toxicity.  Several intermediate-duration studies have reported liver effects, typically at the 
lowest dose level. At lower doses, fatty changes, characterized as hepatocellular vacuolization and 
swelling, were observed in rats and mice.  Focal necrosis was observed at higher oral doses.  The lowest 
LOAEL for liver effects identified in an intermediate-duration study is 50 mg/kg in rats receiving gavage 
doses of bromoform in corn oil 5 days/week for 13 weeks (NTP 1989a); this study identified a NOAEL of 
25 mg/kg.  The intermediate-duration oral MRL of 0.2 mg/kg/day for bromoform was derived by 
applying an uncertainty factor of 100 (10 for extrapolation from animals to humans and 10 for human 
variability) to the duration-adjusted NOAEL of 18 mg/kg/day.   
•	 An MRL of 0.02 mg/kg/day has been derived for chronic-duration oral exposure (365 days or 
more) to bromoform. 
Three studies have examined the chronic toxicity of bromoform in animals.  Rat and mouse studies 
conducted by NTP (1989a) are comprehensive studies that found fatty liver changes (hepatocellular 
vacuolization) at the lowest dose tested, 100 mg/kg (5 days/week; 71 mg/kg/day).  The third study (Tobe 
et al. 1982) identified a similar LOAEL (140 mg/kg/day) in rats exposed to bromoform in the diet for 
2 years; this study also identified a NOAEL of 35 mg/kg/day.  At 140 mg/kg/day, yellowing of the liver 
and increased absolute and relative liver weights were observed.  The NTP (1989a) rat study was selected 
as the basis of the chronic-duration oral MRL for bromoform.  Even though the Tobe et al. (1982) study 
identified a NOAEL for liver effects, this study was not selected as the critical study because no 
histological examination of the liver was conducted and the results were poorly reported.  The duration-
adjusted LOAEL of 71 mg/kg/day was divided by an uncertainty factor of 300 (3 for use of a minimal 
LOAEL, 10 for animal to human extrapolation, and 10 for human variability) and a modifying factor of 
10 to account for the identification of a lower LOAEL in a 13-week study (NTP 1989a) resulting in an 
MRL of 0.02 mg/kg/day. 
Dibromochloromethane 
•	 An MRL of 0.1 mg/kg/day has been derived for acute-duration oral exposure (14 days or less) to 
dibromochloromethane. 
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The available data on the oral toxicity of dibromochloromethane in animals strongly suggest that the liver 
is the most sensitive target of toxicity.  In most studies, liver effects are observed at lower doses than 
kidney effects (the next most sensitive end point).  The study of Condie et al. (1983) was selected as the 
basis for the acute-duration oral MRL for dibromochloromethane because it showed dose-related 
incidences of liver and kidney lesions and identified the lowest LOAEL for liver effects among the 
available studies. A LOAEL of 37 mg/kg/day, the lowest dose tested, was identified for liver damage 
(hepatocellular vacuolization) in mice administered dibromochloromethane in corn oil for 14 consecutive 
days.  A reliable NOAEL for liver or kidney effects could not be determined from the available acute 
data. Applying an uncertainty factor of 300 (3 for use of a minimal LOAEL, 10 for extrapolation from 
animals to humans, and 10 for human variability) to the LOAEL of 37 mg/kg/day yields an acute-duration 
oral MRL of 0.1 mg/kg/day for dibromochloromethane.   
No data were located regarding the toxicity of dibromochloromethane following intermediate-duration 
oral exposure in humans.  A number of intermediate-duration studies of rats and mice were located.  The 
liver was identified as the most sensitive target. Hepatocellular vacuolization was observed at 
43 mg/kg/day (60 mg/kg, 5 days/week) and higher (Aida et al. 1992; Daniel et al. 1990; NTP 1985); the 
highest NOAEL for liver effects is 21 mg/kg/day (30 mg/kg, 5 days/week) (NTP 1985).  At higher doses 
(≥100 mg/kg/day), proximal tubular degeneration and nephropathy were observed (Daniel et al. 1990; 
NTP 1985).  Impaired humoral immune function was observed in mice administered 125 mg/kg/day via 
gavage for 14 days (Munson et al. 1982).  Several animal studies also reported neurological effects:  
decreases in brain weight and decreases in operant behavior at ≥100 mg/kg/day (Balster and Borzelleca 
1982; Daniel et al. 1990).  Borzelleca and Carchman (1982) found decreases in fertility at high 
dibromomochloromethane doses (685 mg/kg/day). 
Derivation of an intermediate-duration oral MRL for dibromochloromethane based on the NTP (1985) rat 
study, which identified NOAEL and LOAEL values of 21 and 43 mg/kg/day, was considered.  However, 
the resultant MRL would be higher than the acute-duration oral MRL. 
•	 An MRL of 0.09 mg/kg/day has been derived for chronic-duration oral exposure (365 days or 
less) to dibromochloromethane. 
Studies of dibromochloromethane consistently indicate that the liver is a target organ.  The NTP (1985) 
study, in which rats received gavage doses of 0, 40, or 80 mg/kg of dibromochloromethane in corn oil, 
5 days/week, for 104 weeks, was selected as the basis for the chronic-duration oral MRL.  This study 
(NTP 1985) was selected because it showed dose-related incidences of microscopic hepatic lesions and 
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also identified the lowest LOAEL of 40 mg/kg (duration-adjusted LOAEL of 28 mg/kg/day) for hepatic 
effects in chronic studies (NTP 1985; Tobe et al. 1982) of dibromochloromethane toxicity.  A chronic-
duration oral MRL of 0.09 mg/kg/day was derived by applying an uncertainty factor of 300 (3 for use of a 
minimal LOAEL, 10 for extrapolation from animals to humans, and 10 for human variability) to the 
LOAEL of 28 mg/kg/day. 
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3.1 INTRODUCTION 
The primary purpose of this chapter is to provide public health officials, physicians, toxicologists, and 
other interested individuals and groups with an overall perspective on the toxicology of bromoform and 
dibromochloromethane.  It contains descriptions and evaluations of toxicological studies and 
epidemiological investigations and provides conclusions, where possible, on the relevance of toxicity and 
toxicokinetic data to public health. 
A glossary and list of acronyms, abbreviations, and symbols can be found at the end of this profile. 
3.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE  
To help public health professionals and others address the needs of persons living or working near 
hazardous waste sites, the information in this section is organized first by route of exposure (inhalation, 
oral, and dermal) and then by health effect (death, systemic, immunological, neurological, reproductive, 
developmental, genotoxic, and carcinogenic effects).  These data are discussed in terms of three exposure 
periods: acute (14 days or less), intermediate (15–364 days), and chronic (365 days or more). 
Levels of significant exposure for each route and duration are presented in tables and illustrated in 
figures. The points in the figures showing no-observed-adverse-effect levels (NOAELs) or lowest-
observed-adverse-effect levels (LOAELs) reflect the actual doses (levels of exposure) used in the studies. 
LOAELs have been classified into "less serious" or "serious" effects.  "Serious" effects are those that 
evoke failure in a biological system and can lead to morbidity or mortality (e.g., acute respiratory distress 
or death). "Less serious" effects are those that are not expected to cause significant dysfunction or death, 
or those whose significance to the organism is not entirely clear.  ATSDR acknowledges that a 
considerable amount of judgment may be required in establishing whether an end point should be 
classified as a NOAEL, "less serious" LOAEL, or "serious" LOAEL, and that in some cases, there will be 
insufficient data to decide whether the effect is indicative of significant dysfunction.  However, the 
Agency has established guidelines and policies that are used to classify these end points.  ATSDR 
believes that there is sufficient merit in this approach to warrant an attempt at distinguishing between 
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"less serious" and "serious" effects.  The distinction between "less serious" effects and "serious" effects is 
considered to be important because it helps the users of the profiles to identify levels of exposure at which 
major health effects start to appear.  LOAELs or NOAELs should also help in determining whether or not 
the effects vary with dose and/or duration, and place into perspective the possible significance of these 
effects to human health. 
The significance of the exposure levels shown in the Levels of Significant Exposure (LSE) tables and 
figures may differ depending on the user's perspective.  Public health officials and others concerned with 
appropriate actions to take at hazardous waste sites may want information on levels of exposure 
associated with more subtle effects in humans or animals (LOAELs) or exposure levels below which no 
adverse effects (NOAELs) have been observed. Estimates of levels posing minimal risk to humans 
(Minimal Risk Levels or MRLs) may be of interest to health professionals and citizens alike. 
Levels of exposure associated with carcinogenic effects (Cancer Effect Levels, CELs) of bromoform or 
dibromochloromethane are indicated in Tables 3-1 and 3-2 and Figures 3-1 and 3-2.  Because cancer 
effects could occur at lower exposure levels, Figures 3-1 and 3-2 also shows a range for the upper bound 
of estimated excess risks, ranging from a risk of 1 in 10,000 to 1 in 10,000,000 (10-4 to 10-7), as developed 
by EPA. 
A User's Guide has been provided at the end of this profile (see Appendix B).  This guide should aid in 
the interpretation of the tables and figures for Levels of Significant Exposure and the MRLs. 
3.2.1 Inhalation Exposure 
No studies were located regarding health effects of bromoform or dibromochloromethane in humans 
following inhalation exposure.  In animals, there are limited data from several older studies on the effects 
of inhalation exposure to bromoform; no studies were located regarding effects of dibromochloro­
methane. 
3.2.1.1 Death 
Inhalation of very high concentrations (56,000 or 84,000 ppm) of bromoform vapor for 1 hour has been 
reported to cause death in dogs (Merzbach 1928). The chief symptoms noted were initial excitation 
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followed by deep sedation.  This indicates that central nervous system depression is probably the chief 
cause of death in such acute exposures.  Because only two animals were used (one animal per dose) and 
only high doses were administered, these data do not provide a reliable estimate of the minimum lethal 
concentration in dogs or other animal species. 
3.2.1.2 Systemic Effects  
No studies were located regarding respiratory, cardiovascular, gastrointestinal, hematological, 
musculoskeletal, endocrine, dermal, ocular, or body weight effects in animals or humans following 
inhalation exposure to bromoform or dibromochloromethane. 
Hepatic Effects. Two studies (Dykan 1962, 1964; published in Russian and available only as the 
English abstract) indicate that inhalation exposure of animals to high concentrations of bromoform leads 
to hepatic injury.  Exposure of rats to 240 ppm of bromoform for 10 days resulted in dystrophic and 
vascular changes in the liver, with altered hepatic metabolism (Dykan 1964).  Longer-term exposure 
(2 months) to concentrations of 24 ppm also led to hepatic changes (decreased blood clotting and 
impaired glycogenesis) (Dykan 1962).  No significant alterations were observed after exposure to 4.8 ppm 
(Dykan 1964).  These changes appear to resemble the changes produced after oral exposure to bromoform 
(see Section 3.2.2.2), suggesting that the hepatotoxicity of bromoform is not route-specific. 
Renal Effects. Similar to the hepatic effects, exposure to 240 ppm bromoform for 10 days resulted in 
dystrophic and vascular changes in the kidney with altered renal filtration (Dykan 1964).  A 2-month 
exposure to 24 ppm resulted in proteinuria and decreased creatinine clearance (Dykan 1962). A 
concentration of 4.8 ppm was estimated to be without significant effects on the kidney (Dykan 1964).  
These changes appear to resemble the changes produced after oral exposure to bromoform (see 
Section 3.2.2.2).  
3.2.1.3 Immunological and Lymphoreticular Effects  
No studies were located regarding immunological effects in humans or animals after inhalation exposure 
to bromoform or dibromochloromethane. 
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3.2.1.4 Neurological Effects 
Inhalation exposure to high levels (29,000 ppm or above) of bromoform has been observed to lead to 
rapid and profound depression of the central nervous system in dogs (Graham 1915; Merzbach 1928).  
This is presumably due to a nonspecific anesthetic effect similar to that produced by various other volatile 
halocarbons. Obvious clinical signs included deep relaxation and sedation (Merzbach 1928). Clinical 
signs of nervous system depression appeared quickly (within minutes), and tended to disappear within a 
day after exposure ceased (Graham 1915).  
No studies were located regarding the following effects in humans or animals after inhalation exposure to 
bromoform or dibromochloromethane: 
3.2.1.5 Reproductive Effects  
3.2.1.6 Developmental Effects 
3.2.1.7 Cancer 
3.2.2 Oral Exposure  
Most information on the health effects of bromoform and dibromochloromethane comes from studies in 
animals (rats and mice) exposed by the oral route.  For bromoform, there are some observations in 
humans stemming from the past use of bromoform as a sedative, but no studies were located on the effect 
of dibromochloromethane in humans.  Summaries of studies that provide reliable quantitative toxicity 
data are presented in Table 3-1 and Figure 3-1 for bromoform and in Table 3-2 and Figure 3-2 for 
dibromochloromethane.  The main conclusions from these studies are discussed below. 
3.2.2.1 Death 
Bromoform.  In the early part of this century, bromoform was often given as a sedative to children 
suffering from whooping cough, and several deaths due to accidental overdoses have been described 
(Dwelle 1903; Kobert 1906; Roth 1904 as cited in von Oettingen 1955).  The principal clinical signs in 
fatal cases were those of severe central nervous system depression (unconsciousness, stupor, and loss of 
reflexes), and death was generally the result of respiratory failure (von Oettingen 1955).  If death could be 
averted, recovery was generally complete within several days (Benson et al. 1907; Burton-Fanning 1901;  


























































1 Human 1 d 445 F (single child died due to 
overdose) 
Dwelle 1903 
2 Rat 1 day 
(Sprague- (GO) 
	 1147 F (LD50) Chu et al 1982a 
Dawley) 
3 Rat (G) 
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Dawley) 
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Chu et al. 1980 
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5 Rat 14 d 
(Fischer- 344) 1x/d
	 600 (100% mortality) NTP 1989a 
(GO) 
6 Mouse 1 d 
(ICR) (GW) 
	  b 1400 M (LD50) Bowman et al 1978 
1550 F (LD50) 
7 Mouse 1 d 
(B6C3F1) (GO) 
	  b 707 M (LD50) NTP 1989a 
1072 F (LD50) 
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Bowman et al 1978 
22 Mouse 14 d 
1x/d (B6C3F1) 







23 Rat 9 d 
Gd 6-15 (Sprague-
100 200 (skeletal anom.) 
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Ruddick et al 1983 
Dawley) (GO) 







24 Rat 30 d 
(Wistar) (F) 







Aida et al 1992 
swelling) 
Bd Wt 187.2 M 617.9 M (24% decreased body 
S
weight) 
25 Rat 28 d 
(Sprague- (W) 
	 Hemato 14 M Chu et al 1982a 
Dawley) 
Hepatic 14 M 
Renal 14 M 
Bd Wt 14 M 
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26 Rat 13 wk 
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27 Mouse 3 wk 
5 d/wk(B6C3F1) 
(GO) 
	 Hepatic 200 F 500	F (hepatocyte hydropic 
degeneration; increased 
SGPT and sorbitol 
Melnick et al 1998 
dehydrogenase) 
Bd Wt 500 F 
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0.9 M 9.2 M (decreased exploratory 
activity) 
30
Balster and Borzelleca 1982
Bromoform
Table 3-1 Levels of Significant Exposure to Bromoform - Oral (continued) 
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Balster and Borzelleca 1982 
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33 Mouse 30d 
1x/d (ICR) 
100 M Balster and Borzelleca 1982 
(GW) 
Reproductive 
34 Rat 13 wk 
5d/wk (Fischer- 344) 
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200 M (decreased survival) NTP 1989a 
(GO) 
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39	 Rat 2 year 
(Wistar) (F) 
Hepatic 35 F 140	F (yellowing of liver; 
increased absolute and 
Tobe et al 1982 
relative liver weight) 
Bd Wt 90 M 590 M (40% decrease in body 
weight gain) 
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Hepatic 100	F (hepatocellular 
vacuolization) 
          3.  









Endocr 100 F 200	F (follicular cell hyperplasia 
in thyroid) 
Dermal 100 M 
Bd Wt 100 M 
Neurological 
41 Rat 103 wk 
(Fischer- 344) 5d/wk 
100 (lethargy)	 NTP 1989a 
(GO) 
Reproductive 
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44 Rat 103 wk 







200 F (CEL: adenomatous NTP 1989a 
polyps and 
adenocarcinoma in large A
N
E          3.  
intestine) 




LTb Differences in levels of health effects and cancer effects between male and females are not indicated in Figure 3-1. Where such differences exist, only the levels of effect for the H
 Emost sensitive gender are presented. FFEc Used to derive an acute-duration oral MRL of 0.7 mg/kg/day; dose divided by an uncertainty factory of 100 (10 for extrapolation from animals to humans and 10 for human C
TSvariability). 
d Used to derive an intermediate-duration oral MRL of 0.2 mg/kg/day; dose adjusted for intermittent exposure and divided by an uncertainty factor of 100 (10 for extrapolation from 
animals to humans, and 10 for human variability). 
e Used to derive a chronic-duration oral MRL of 0.02 mg/kg/day; dose adjusted for intermittent exposure and divided by an uncertainty factory of 300 (3 for extrapolation from a 
minimal LOAEL, 10 for extrapolation from animals to humans, and 10 for human variability) and a modifying factor of 10 to account for the identification of a lower LOAEL in a 
subchronic study (NTP 1989a). 
d = day(s); F = female; (F) = food; (G) = gavage; Gastro = gastrointestinal; LD50 = lethal dose, 50% kill; LOAEL = lowest-observed-adverse-effect level; M = male; NOAEL = 
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Figure 3-1. Levels of Significant Exposure to Bromoform - Oral 
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c-Cat -Humans f-Ferret n-Mink   Cancer Effect Level-Animals   Cancer Effect Level-Humans  LD50/LC50d-Dog k-Monkey j-Pigeon o-Other  LOAEL, More Serious-Animals  LOAEL, More Serious-Humans Minimal Risk Level
r-Rat m-Mouse e-Gerbil LOAEL, Less Serious-Animals LOAEL, Less Serious-Humans    for effects 
p-Pig h-Rabbit s-Hamster   NOAEL - Animals   NOAEL - Humans  other than














































Figure 3-1. Levels of Significant Exposure to Bromoform - Oral (Continued) 
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*Doses represent the lowest dose tested per study that produced a tumorigenic -60.0001 10 
response and do not imply the existence of a threshold for the cancer endpoint. 
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Table 3-2 Levels of Significant Exposure to Dibromochloromethane - Oral 
Exposure/ LOAEL 
Duration/ 
a Frequency Reference Key to Species NOAEL Less Serious Serious (Route) Figure (Strain) System (mg/kg/day) (mg/kg/day) (mg/kg/day) Chemical Form 
ACUTE EXPOSURE 
Death 
1 Rat 1 d 848 F (LD50) Chu et al 1982a 
(Sprague- (GO) 
Dawley) 
2 Rat (G) 1186 M (LD50) Chu et al. 1980 
(Sprague-
b Dawley) 848 F (LD50) 
3 Rat 1 d 3700 M (100% mortality) Hewitt et al 1983 
(Sprague- (GO) 
Dawley) 
4 Rat 1 d 1250 M (4/5 died) NTP 1985 
(Fischer- 344) (GO) 
5 Rat 14 d 500 (8 of 10 died) NTP 1985 1x/d (Fischer- 344) 
(GO) 
 
 b 6 Mouse 1 d 800 M (LD50) Bowman et al 1978 
(ICR) (GW) 
1200 F (LD50) 
7 Mouse 1 d 630 M (3/5 died) NTP 1985 
(B6C3F1) (GO) 
8 Mouse 14 d 500 (7 of 10 died) NTP 1985 1x/d (B6C3F1) 
(G) 


















Hepatic 2500 M (increased SGPT and 
OCT levels) 
145 M (LD50) Korz and Gatterman 1997 
Hewitt et al 1983 






Hepatic 250 500 (mottled liver) NTP 1985 
Renal 250 500 (darkened renal 
medullae) 
Bd Wt 125 M 250 M (45% decrease body 
weight gain) 
12 Rat 1 d 
(G) 





Endocr 160 M 310 M (decreased serum 
testosterone) 
Potter et al 1996 
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Condie et al 1983 












Hepatic 125 F 250 F (increased relative and 
absolute liver weight, 
decreased serum 
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SGPT and SGOT) 















50 F 125 F (impaired humoral 
immunity) 
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Munson et al 1982 



































20 Rat 14 d 
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NBalster and Borzelleca 1982 
(GW) 
E
23 Mouse 1 d 
(ICR) (GW) 
454 M (ED50 for impaired motor 
performance) 





Balster and Borzelleca 1982 
Chlorodibromomethane 
24 Mouse 1 d 
(ICR) (GW) 




TSBowman et al 1978 
25 Mouse 14 d 
1x/d(B6C3F1) 
(GO) 




26 Rat 9 d 
Gd 6-15 (Sprague-




27 Rat 13 wk 
5d/wk (Fischer- 344) 
250 (18/ 20 died) NTP 1985 
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weight gain) 
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5 d/wk(B6C3F1) 
(GO) 
	 Hepatic 50 F 192 F (hepatocyte hydropic 
degeneration) 
	 Melnick et al 1998 
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 46 F 
42 Mouse 2 generations 
(continuous) (ICR) 
170 F 685 F (decreased fertility) Borzelleca and Carchman 
1982 
(W) 
43 Mouse 13 wk 
5d/wk (B6C3F1) 
250 NTP 1985 
(GO) 
Developmental 
44 Mouse 2 generations 
(continuous) (ICR) 
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Tobe et al 1982 
Bd Wt 20 M 85 M (10% decrease in body
 540 M (marked decrease in 
weight gain)
 body weight gain) 
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48 Mouse 105 wk 
5d/wk (B6C3F1) 
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49 Rat 2 yr 
(Fischer- 344) 5d/wk
80 	 NTP 1985 
(GO) 
50 Mouse 105 wk 
5d/wk(B6C3F1) 
	 100 	 NTP 1985 
(GO) 
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100 (CEL: hepatocellular NTP 1985
adenoma or carcinoma)
a The number corresponds to entries in Figure 3-2. 
b Differences in levels of health effects and cancer effects between male and females are not indicated in Figure 3-2. Where such differences exist, only the levels of effect for the 
most sensitive gender are presented. 
c Used to derive an acute-duration oral MRL of 0.1 mg/kg/day; dose divided by an uncertainty factory of 300 (3 for use of a minimal LOAEL, 10 for extrapolation from animals to 
humans, and 10 for human variability). 
          3.  d Used to derive a chronic-duration oral MRL of 0.09 mg/kg/day; dose adjusted for intermittent exposure and divided by an uncertainty factory of 300 (3 for use of a minimal LOAEL, 
10 for extrapolation from animals to humans, and 10 for human variability). HE
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Figure 3-2. Levels of Significant Exposure to Dibromochloromethane - Oral 
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c-Cat -Humans f-Ferret n-Mink   Cancer Effect Level-Animals   Cancer Effect Level-Humans  LD50/LC50d-Dog k-Monkey j-Pigeon o-Other  LOAEL, More Serious-Animals  LOAEL, More Serious-Humans Minimal Risk Level
r-Rat m-Mouse e-Gerbil LOAEL, Less Serious-Animals LOAEL, Less Serious-Humans    for effects 
p-Pig h-Rabbit s-Hamster   NOAEL - Animals   NOAEL - Humans  other than












































Figure 3-2. Levels of Significant Exposure to Dibromochloromethane - Oral (Continued) 
Intermediate (15-364 days) 
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c-Cat -Humans f-Ferret n-Mink   Cancer Effect Level-Animals   Cancer Effect Level-Humans  LD50/LC50d-Dog k-Monkey j-Pigeon o-Other  LOAEL, More Serious-Animals  LOAEL, More Serious-Humans Minimal Risk Level
r-Rat m-Mouse e-Gerbil LOAEL, Less Serious-Animals LOAEL, Less Serious-Humans    for effects 
p-Pig h-Rabbit s-Hamster   NOAEL - Animals   NOAEL - Humans  other than
































Figure 3-2. Levels of Significant Exposure to Dibromochloromethane - Oral (Continued) 
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c-Cat -Humans f-Ferret n-Mink   Cancer Effect Level-Animals   Cancer Effect Level-Humans  LD50/LC50d-Dog k-Monkey j-Pigeon o-Other  LOAEL, More Serious-Animals  LOAEL, More Serious-Humans Minimal Risk Level
r-Rat m-Mouse e-Gerbil LOAEL, Less Serious-Animals LOAEL, Less Serious-Humans    for effects 
p-Pig h-Rabbit s-Hamster   NOAEL - Animals   NOAEL - Humans  other than



















































Figure 3-2. Levels of Significant Exposure to Dibromochloromethane - Oral (Continued) 









































51m100 45m 48m 48m 48m 48m 48m 48m 48m 50m47r 47r46r 46r 46r 46r 46r 46r 46r 49r 



















*Doses represent the lowest dose tested per study that produced a tumorigenic 
response and do not imply the existence of a threshold for the cancer end point.
1E-7 
c-Cat -Humans f-Ferret n-Mink   Cancer Effect Level-Animals   Cancer Effect Level-Humans  LD50/LC50
d-Dog k-Monkey j-Pigeon o-Other  LOAEL, More Serious-Animals  LOAEL, More Serious-Humans  Minimal Risk Level 
r-Rat m-Mouse e-Gerbil LOAEL, Less Serious-Animals  LOAEL, Less Serious-Humans    for effects 
p-Pig h-Rabbit s-Hamster   NOAEL - Animals   NOAEL - Humans  other than 
q-Cow a-Sheep g-Guinea Pig Cancer 
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Kobert 1906).  The dose needed to cause death in children is not known with certainty, but both Dwelle 
(1903) and Roth (1904) estimated that a dose of about 5 g had been fatal.  For a 10–20-kg child, this 
corresponds to an approximate dose of 250–300 mg/kg.   
In animal studies, estimates of the acute oral LD50 for bromoform typically range between 707 and 
1,550 mg/kg (Bowman et al. 1978; Chu et al. 1982a; NTP 1989a).  There does not appear to be much 
difference in the doses that cause death across species or between sexes.  The LD50 values for a 1-day 
exposure to bromoform ranged from 933 to 1,388 mg/kg in rats (Chu et al. 1980; NTP 1989a) and from 
707 to 1,550 mg/kg in mice (Bowman et al. 1978; NTP 1989a).  LD50 values ranged from 1,072 to 
1,550 for females and from 707 to 1,388 for males exposed to bromoform for 1 day (Bowman et al. 1978; 
Chu et al. 1980, 1982a; NTP 1989a).  Acute, repeated oral exposure to 600 mg/kg/day resulted in 
100%mortality in rats (NTP 1989a).  However, only 2/10 mice died from exposure to 800 mg/kg/day 
(NTP 1989a).  No deaths were observed in rats and mice administered 200 or 400 mg/kg (5 days/week) 
via gavage for 90 days (NTP 1989a).  However, significant reductions in survival were observed in rats 
administered 200 mg/kg via gavage (5 days/week) for 2 years (NTP 1989a). 
In animals, the cause of death following acute oral exposure to bromoform has not been thoroughly 
investigated. Prominent clinical signs include central nervous system depression (Bowman et al. 1978).  
While central nervous system depression is probably an important factor in rapid lethality, some studies 
report death occuring several days after an acute exposure (Bowman et al. 1978; NTP 1989a). This 
suggests that other effects (e.g., hepatic and/or renal injury) may also be important. 
Dibromochloromethane.  No studies were located regarding death in humans after oral exposure to 
dibromochloromethane.  The acute lethality of dibromochloromethane has been evaluated by several 
animal studies in rats and mice, with LD50 estimates ranging between 800 and 2,650 mg/kg (Bowman et 
al. 1978; Chu et al. 1980, 1982a; Hewitt et al. 1983; NTP 1985).  Korz and Gatterman (1997) reported an 
LD50 of 145 mg/kg for a Golden Syrian hamster; however, the experimental details were not reported to 
validate the data. Deaths in animals have been reported from single oral doses as low 300–600 mg/kg 
(NTP 1985).   
In intermediate and chronic oral exposure studies, significant increases in mortality have been observed in 
mice and rats at 250 mg/kg (5 days/week) for exposures of 14–90 days (Chu et al. 1982a; Condie et al. 
1983; Daniel et al. 1990; NTP 1985) and in rats at 100 mg/kg (5 days/week) for exposures up to 2 years 
(NTP 1985).   
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Gender-related differences in mortality have been observed in rats and mice acutely exposured to 
dibromochloromethane.  In rats, females appear to be more sensitive than males; increases in mortality 
were observed at 848 mg/kg in females compared to 1,186 mg/kg in males (Chu et al. 1982a).  In 
contrast, increases in mortality were observed at lower doses in males (800 mg/kg) than females 
(1,200 mg/kg) (Bowman et al. 1978).  
The cause of death following oral exposure of animals to dibromochloromethane has not been thoroughly 
investigated. Some of the chief clinical signs observed are those of central nervous system depression 
and other effects, such as hepatic and/or renal injury (Bowman et al. 1978; NTP 1985). 
3.2.2.2 Systemic Effects  
Respiratory Effects. Labored breathing has been observed in animals exposed to lethal doses of 
bromoform and dibromochloromethane (NTP 1985, 1989a); this is likely due to central nervous system 
depression rather than impaired lung function.   
Bromoform.  No studies were located regarding respiratory effects in humans after oral exposure to 
bromoform.  NTP (1989a) examined the respiratory tract of rats and mice receiving gavage doses of 
bromoform for 90 days or 2 years.  No histological alterations were observed in the intermediate-duration 
studies or in female rats and male and female mice in the chronic-duration study.  An increased incidence 
of chronic inflammation of the lungs was observed in male rats exposed to 100 or 200 mg/kg 
(5 days/week).  This inflammation was similar in appearance to that caused by a sialodacryoadenitis 
(SDA) virus infection, and antibodies to rat SDA virus were detected in study animals.  Thus, the 
inflammation observed was probably secondary to the infection and was not a direct result of bromoform. 
However, the absence of symptoms in control animals suggested that bromoform-treated rats may have 
been more susceptible to infection by the virus or slower to recover (NTP 1989a). 
Dibromochloromethane.  No studies were located regarding respiratory effects in humans after oral 
exposure to dibromochloromethane.  No histological alterations in the respiratory tract were observed in 
rats and mice administered gavage doses of up to 250 mg/kg (days/week) for 90 days or 80–100 mg/kg 
(5 days/week) (NTP 1985).   
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Cardiovascular Effects. 
Bromoform.  No studies were located regarding cardiovascular effects in humans after oral exposure to 
bromoform.  Histological examination of rats and mice exposed to up to 100–200 mg/kg (5 days/week) 
bromoform by gavage for up to 2 years revealed no evidence of adverse effects upon the heart (NTP 
1989a). While this indicates that cardiac tissue is not directly injured by bromoform, indirect effects on 
cardiovascular functions might occur as a consequence of the central nervous system depressant activity 
of these compounds.   
Dibromochloromethane.  No studies were located regarding cardiovascular effects in humans after oral 
exposure to dibromochloromethane.  Decreased heart rates and increased blood pressure were observed in 
male rats following the administration of a single gavage dose (83–667 mg/kg) of dibromochloromethane 
(Müller et al. 1997). However, a dose-related trend was not exhibited for these.  While this suggests that 
cardiac function may be impaired by dibromochloromethane exposure, it is unclear if effects are caused 
by the direct action on cardiac function or if they are indirectly caused as a result of central nervous 
system depression.  No histological alterations to cardiac tissue were observed in intermediate- and 
chronic-duration studies of dibromochloromethane administered to rats and mice via gavage (NTP 1985). 
Gastrointestinal Effects.     
Bromoform.  No studies were located regarding gastrointestinal effects in humans after oral exposure to 
bromoform.  NTP (1989a) examined the esophagus, stomach, and intestines of rats and mice orally 
exposed to bromoform.  Stomach nodules were observed in male and female mice following 14 days of 
exposure to 400 and 600 mg/kg/day, respectively (NTP 1989a).  The biological significance of these 
nodules is not certain, but it is likely that they are a response to a direct irritant effect of bromoform on the 
gastric mucosa.  In chronic-duration studies, histological alterations were observed in male rats and male 
mice. Forestomach ulcers were observed in male rats at 200 mg/kg (5 days/week) (NTP 1989a) and 
hyperplasia of the glandular stomach was observed in male mice at 100 mg/kg (5 days/week) (NTP 
1989a). No stomach lesions were observed in female rats or mice exposed to bromoform at doses up to 
200 mg/kg.  The histological observations in NTP (1989a) suggest that males may be more sensitive to 
gastrointestinal effects from acute and chronic bromoform exposures than females.  In acute studies, the 
onset of stomach nodules occurred at a lower dose level in males (400 mg/kg) than in females 
(600 mg/kg).  In chronic studies, gastrointestinal effects were only observed in males.  While these 
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observations clearly indicate that the stomach may be affected by bromoform, it is possible that the 
exposure regimen (bolus administration) leads to irritant effects in the stomach that might not occur if 
exposure were continuous at lower concentrations in food or drinking water.   
Dibromochloromethane.  No studies were located regarding gastrointestinal effects in humans after oral 
exposure to dibromochloromethane.  No histological changes of the esophagus, stomach, or intestines 
were observed in mice or rats administered dibromochloromethane via gavage at doses up to 100 mg/kg 
(5 days/week) for up to 2 years (NTP 1985). 
Hematological Effects. Several studies (Chu et al. 1982a, 1982b; Munson et al. 1982; Tobe et al. 
1982) have investigated the hematological effects of oral exposure of rats and mice to bromoform and 
dibromochloromethane.  With the exceptions of some minor fluctuations in lymphocyte count following 
exposure to bromoform (Chu et al. 1982a, 1982b), none of these studies detected any significant effects of 
bromoform or dibromochloromethane on hemoglobin, hematocrit, red blood cells, or white blood cells. 
Musculoskeletal Effects. No studies regarding musculoskeletal effects in humans or animals after 
oral exposure to bromoform or dibromochloromethane.  
Hepatic Effects. The liver is the primary target organ for bromoform and dibromochloromethane­
induced toxicity. Oral exposure to these compounds results in an accumulation of fat in the liver, 
manifested as increased liver weight, appearence of hepatocyte vacuoles, alterations in serum cholesterol 
levels, and decreases in serum triglyceride levels.  In addition to fatty liver changes, exposure to 
bromoform and dibromochloromethane results in focal hepatocellular necrosis.  The necrosis is typically 
observed at higher doses than the fatty liver.  The toxicity of both compounds is greater following gavage 
administration compared to exposure via the diet or drinking water.  This is probably due to the large 
bolus dose overwhelming the liver’s ability to detoxify reactive metabolites and the oil vehicle, which 
likely increases absorption. 
Bromoform.  Several animal studies have examined the hepatotoxicity of bromoform in rats and mice 
following gavage, drinking water, or dietary exposure.  The most sensitive hepatic end point appears to be 
fatty degeneration as indicated by centrilobular pallor observed in mice at 145 mg/kg/day for 14 days 
(Condie et al. 1983) and hepatocellular vacuolization and/or swelling, which has been observed following 
acute gavage exposure to 200 mg/kg (9 days in an 11-day period) (Coffin et al. 2000), acute drinking 
water exposure to 300 mg/kg/day (Coffin et al. 2000), intermediate-duration gavage exposure to 50 mg/kg 
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(5 days/week) (NTP 1989a), dietary exposure to 56.4 mg/kg/day (Aida et al. 1992), and chronic gavage 
exposure to 100 mg/kg (5 days/week) (NTP 1989a).  Increases in relative and/or absolute liver weights, 
although not always consistently found, occur at similar doses (Munson et al. 1982; Tobe et al. 1982).  
Alterations in clinical chemistry parameters associated with the fatty changes (alterations in serum 
triglyceride and cholesterol levels) are typically observed at higher doses.  Decreases in serum 
triglyceride levels were observed at 207.5 and 590 mg/kg/day in rats exposed via the diet for 1 or 
24 months, respectively (Aida et al. 1992; Tobe et al. 1982); the no effect levels for this end point are 
56.4 and 90 mg/kg/day, respectively.  An increase in serum total cholesterol was observed in rats exposed 
to ≥187.2 mg/kg/day in the diet for 1 month (Aida et al. 1992) and a decrease was found in rats exposed 
to 590 mg/kg/day in the diet for 24 months (Tobe et al. 1982).  The data are inadequate to assess whether 
the difference in the direction of change was related to exposure duration or was an inconsistent finding. 
Higher doses of bromoform result in hepatocellular necrosis.  Necrosis was observed in rats exposed to 
200 mg/kg (5 days/week) for 2 years (NTP 1989a); focal inflammation has also been observed in mice 
receiving gavage doses of 280 mg/kg for 14 days (Condie et al. 1983).  Significant increases in SGPT 
and/or SGOT, which is indicative of hepatocellular damage, were observed in mice at 250– 
289 mg/kg/day for 14 days (Condie et al. 1983; Munson et al. 1982), mice at 500 mg/kg (5 days/week) 
for 3 weeks (Melnick et al. 1998), and rats at 720 mg/kg/day for 24 months (Tobe et al. 1982).  A 
decrease in serum glucose levels observed in rats exposed to ≥61.9 mg/kg/day for 1 month (Aida et al. 
1992) or ≥40 mg/kg/day for 24 months (Tobe et al. 1982) and an increase in hexabarbital sleep time 
observed in mice at 125 mg/kg/day for 14 days (Munson et al. 1982) are also indicative of liver damage. 
There are limited data to assess species differences.  The results of the NTP intermediate-duration study 
(NTP 1989a) suggest that rats may be more sensitive to the hepatotoxicity of bromoform than mice.  The 
NOAEL and LOAEL values for hepatocellular vacuolization were 25 and 50 mg/kg (5 days/week) in rats 
and 100 and 200 mg/kg in mice.  Liver damage was the critical end point used for the derivation of acute-, 
intermediate-, and chronic-duration oral MRLs for bromoform, as described in the footnotes for 
Table 3-1 and in Appendix A. 
Dibromochloromethane.   A variety of hepatic effects have been observed in rats and mice orally 
exposed to dibromochloromethane.  Hepatocellular vacuolization and/or swelling were observed at the 
lowest adverse effect levels.  The LOAEL values for this end point are ≥37 mg/kg in acutely exposed 
mice (Coffin et al. 2000; Condie et al. 1983), ≥50 mg/kg in rats and mice exposed for an intermediate 
duration (Aida et al. 1992; Daniel et al. 1990; NTP 1985), and ≥40 mg/kg in rats and mice following 
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chronic exposure (NTP 1985).  Clinical chemistry alterations, which are associated with the fatty changes 
in the liver, include increases in serum cholesterol after a single gavage dose of 1,500 mg/kg (Chu et al. 
1982a) or after a 1-month dietary exposure to 56.2 mg/kg/day (Aida et al. 1992), decreases in serum 
cholesterol at 540 mg/kg/day after a 24-month dietary exposure (Tobe et al. 1982), and decreases in 
serum triglycerides at 173.3 and 20 mg/kg/day following 1- or 24-month dietary exposures, respectively 
(Aida et al. 1992; Tobe et al. 1982).  Additionally, increases in liver weight were observed in mice 
administered gavage doses of 250 mg/kg/day for 14 days (Munson et al. 1982) or 100 mg/kg 
(5 days/week) for 3 weeks (Melnick et al. 1998).  The increased incidences of hepatocellular vacuoles 
observed at 37 mg/kg/day following acute exposure and 40 mg/kg following chronic exposure (NTP 
1985) were used to derive acute- and chronic-duration oral MRLs for dibromochloromethane, as 
described in the footnotes to Table 3-2 and in Appendix A. 
At higher doses, oral exposure to dibromochloromethane resulted in hepatocellular necrosis.  Necrosis 
was found in rats and mice exposed to ≥100 mg/kg (Aida et al. 1992; Daniel et al. 1990; NTP 1985) for 
intermediate durations.  Necrosis was not reported following acute-duration exposure; however, increases 
in SGOT and/or SGPT (indicative of hepatocellular damage) were found in rats and mice exposed to 
≥145 mg/kg (Condie et al. 2000; Hewitt et al. 1983; Munson et al. 1982).  Necrosis was not found 
following chronic exposure in rats and mice exposed to 80 or 100 mg/kg (5 days/week), respectively 
(NTP 1985). Other liver effects include bile duct hyperplasia in rats exposed to 250 mg/kg (5 days/week) 
for 13 weeks (NTP 1985), hepatocyte hydropic degeneration in mice exposed to 192 mg/kg (5 days/week) 
for 3 weeks (Melnick et al. 1998), and decreased serum glucose levels in rats exposed to 540 mg/kg/day 
for 24 months (Tobe et al. 1982). 
Renal Effects. 
Bromoform.  There is some evidence that oral exposure to bromoform can induce kidney damage.  
Condie et al. (1983) noted minimal to slight nephrosis and mesangial hypertrophy in male mice exposed 
to repeated oral doses of 145–289 mg/kg/day of bromoform.  In contrast, no significant histopathological 
alterations were detected by NTP (1989a) in rats or mice receiving gavage of 200 mg/kg (5 days/week) of 
bromoform for 2 years.   
Dibromochloromethane.  Histological studies performed by NTP (1985) indicate that oral exposure to 
dibromochloromethane can cause kidney injury in both rats and mice.  The medullae appear to be 
reddened in both males and females after a single oral dose of 500 mg/kg, but this dose was so high that 
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7 of 10 animals died.  Of greater toxicological concern were effects on the nephron that develop after 
intermediate or chronic exposure to doses of 50–250 mg/kg/day (NTP 1985).  These effects were usually 
much more apparent in males than females, and were characterized by tubular degeneration and 
mineralization leading to nephrosis (NTP 1985).  These histological findings of nephrotoxicity are 
supported by the kidney function studies of Condie et al. (1983), which found that ingestion of dibromo­
chloromethane tended to impair uptake of para-amino hippuric acid in renal slices prepared from male 
mice exposed to 37–147 mg/kg/day for 2 weeks.   
Endocrine Effects. 
Bromoform.  Several endocrine effects have been observed in animals exposed to bromoform; however, 
none of the effects were consistently found.  The observed endocrine effects included enlarged thyroid 
gland in rats administered a lethal dose of 800 mg/kg/day for 14 days (NTP 1989a), decreased thyroid 
follicular size and colloid density 90 days after termination of exposure to 360 mg/kg/day (Chu et al. 
1982b), thyroid follicular cell hyperplasia in mice administered 200 mg/kg (5 days/week) for 2 years 
(NTP 1989a), pituitary gland hyperplasia in rats administered 100 mg/kg (5 days/week), but not 
200 mg/kg (NTP 1989a), and decreased serum testosterone levels in rats exposed to 380 mg/kg/day for 
7 days (Potter et al. 1996).  
Dibromochloromethane.  Several studies have examined the potential of dibromochloromethane to 
induce histological alterations in endocrine glands following longer-term exposure.  No alterations in 
endocrine glands were observed following intermediate-duration exposure of rats to 200 or 
256 mg/kg/day (Chu et al. 1982b; Daniel et al. 1990) or rats or mice to 250 mg/kg for 5 days/week (NTP 
1985).  Administration of dibromochloromethane via gavage for 2 years resulted in thyroid follicular cell 
hyperplasia in mice exposed to 50 or 100 mg/kg (5 days/week).  No effects were observed in rats 
administered 40 or 80 mg/kg (5 days/week) (NTP 1985).  No effects on serum testosterone levels were 
observed in rats given gavage doses of 160 mg/kg/day for 7 days.   However, a decrease in levels resulted 
from doses of 310 mg/kg/day (Potter et al. 1996).   
Dermal Effects.    No histological alterations were found in the skin of rats and mice exposed to 
bromoform or dibromochloromethane by gavage for up to 2 years (NTP 1985, 1989a). 
Ocular Effects.    No histological alterations were found in the eyes of rats and mice exposed to 
bromoform or dibromochloromethane by gavage for up to 2 years (NTP 1985, 1989a). 
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Body Weight Effects.     
Bromoform.  In animals, treatment with bromoform is associated with significant decrements in body 
weight, without concurrent reductions in food intake.  The threshold for body weight effects appears to be 
duration-related, as generally observed in the oral exposure studies.  In acute repeated-dose oral gavage 
studies (Condie et al. 1983; Munson et al. 1982, NTP 1989a), 4 and 14% decreases in body weight were 
observed in female and male rats, respectively, given 400 mg/kg.  No significant, consistently-observed 
effects on body weight were seen in mice administered up to 800 mg/kg. Intermediate-duration studies of 
bromoform appear to present a similar dose-response relationship for body weight effects as the acute 
studies. Body weights of rats were unaffected by bromoform doses of ≤200 mg/kg administered by 
gavage, in feed, or in drinking water (Aida et al. 1992; Chu et al. 1982a; NTP 1989a).  Body weights of 
mice treated with 400 mg/kg of bromoform by gavage were slightly (8%) reduced (NTP 1989a).  Lower 
adverse effect levels were observed in chronic studies.  Body weights were decreased by 4–10% in rats 
and female mice treated with 100 mg/kg of bromoform by gavage, whereas 16–25% decreases in body 
weight gain were noted at 200 mg/kg (NTP 1989a).  A chronic feeding study in rats (Tobe et al. 1982) 
showed a dose-response similar to the gavage studies.  Body weight reductions of 15% were observed at 
90–150 mg/kg, while reductions of 30–40% were observed at doses above 365 mg/kg. 
Dibromochloromethane.  Treatment with dibromochlormethane is also associated with decreased body 
weight gain in animals.  Rats appear to be more sensitive than mice to body weight effects.  The dose-
response relationship seemed to be sensitive to exposure duration, but was similar for varoius 
adminstration routes (gavage, feed, drinking water). The greater sensitiviy of rats to dibromochloro­
methane compared with mice was appearent in both acute and intermediate duration exposures (Chu et al. 
1980; Condie et al. 1983; Daniel et al. 1990; Munson et al. 1982; NTP 1985). Rats experienced 20% 
(400 mg/kg/day) and 47% (250 mg/kg/day) decreases in body weight gain from acute and intermediate 
gavage exposures, respectively. In contrast, no effect was seen in mice for these dose levels and 
durations. Duration-related changes to the dose-response were indicated in both species for body weight 
gain decreases of 10% or more.  These effects on body weight gain occurred in the range of 250– 
500 mg/kg (acute), 200–250 mg/kg (intermediate), and 70–200 mg/kg (chronic) (Aida et al. 1992; Daniel 
et al. 1990; NTP 1985; Tobe et al. 1982).  In chronic exposure studies (NTP 1985; Tobe et al. 1982), 
neither species nor administration route seemed to affect the dose response.  
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3.2.2.3 Immunological and Lymphoreticular Effects  
There are limited data on the immune and lymphoreticular system toxicity of bromoform and dibromo­
chloromethane.  Munson et al. (1982) examined immune function following exposure to both compounds.  
Other studies (Daniel et al. 1990; NTP 1985, 1989a) monitored organ weights or examined tissues for 
histological damage. 
Bromoform.  Impaired humoral immune function, as indicated by the response to sheep red blood cells, 
was observed in rats and mice exposed to 125 or 250 mg/kg/day bromoform for 14 days (Munson et al. 
1982), though no adverse effect on cell-mediated immunity was noted.  Additionally, male rats exposed to 
bromoform for 2 years appeared to have decreased resistance to a common viral infection (NTP 1989a), 
suggesting functional impairment of the immune system.  No histological alterations were observed in 
tissues of the immune or lymphoreticular systems in rats and mice exposed to 200 and 400 mg/kg 
(5 days/week), respectively, for 90 days (NTP 1985) or 100–200 or 200 mg/kg (5 days/week), 
respectively, for 2 years (NTP 1985). 
Dibromochloromethane.  Exposure of mice to doses of 125 or 250 mg/kg/day of dibromochloromethane 
for 14 days resulted in impaired humoral immunity (splenic IgM response to sheep red blood cells) 
(Munson et al. 1982).  Impaired cellular immunity (popliteal lymph node response to sheep red blood 
cells) was also observed at 250 mg/kg/day.  A significant decrease in thymus weight was observed in rats 
exposed to 300 mg/kg/day for 90 days (Daniel et al. 1990).  No histological alterations were observed in 
immune or lymphoreticular tissues of rats and mice following intermediate or chronic duration to 250 or 
80–100 mg/kg (days/week), respectively (NTP 1985).   
3.2.2.4 Neurological Effects 
Bromoform.  Bromoform, like other volatile halogenated hydrocarbons, can lead to marked central 
nervous system depression.  Because of this property, bromoform was used as a sedative in the early 
1900s and was commonly administered to children for relief from whooping cough.  Several poisonings 
and a few deaths resulted from accidental overdoses or separation of the emulsion (Benson 1907; Burton-
Fanning 1901; Dwelle 1903; Stokes 1900; von Oettingen 1955).  In mild cases of accidental overdose, 
clinical signs included rapid breathing, constricted pupils, and tremors; more severe cases were 
accompanied by a drunken-like stupor, cyanosis, shallow breathing, and erratic heart rate (Benson 1907; 
Kobert 1906).  Actual doses associated with these neurological symptoms are not known with certainty.  
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Based on experiences with seven cases of accidental bromoform poisonings in children with whooping 
cough, Burton-Fanning (1901) advised initial treatment volumes of 0.03 mL for children under 1 year, 
0.06 mL for those 1–4 years old, and 0.13 mL for children 4–8 years of age, or approximately 25– 
60 mg/kg.  Dwelle (1903) reported the case of a 33-month-old girl who was prescribed bromoform for 
relief of whooping cough-induced coughing and vomiting.  It is estimated that the girl ingested 
approximately 700 mg bromoform (60 mg/kg/day) and slept undisturbed that night, suggesting the 
occurrence of sedative effects.   
As with humans, high doses of bromoform result in central nervous system depression in animals.  
Impaired performance on neurobehavioral tests is observed at lower doses,.  The severity of the central 
nervous system depression is dose-related, with anesthesia and shallow breathing occurring at very high, 
often lethal, doses and ataxia, lethargy, and sedation at lower doses.  In rats, lethargy, shallow breathing, 
and ataxia were observed at 600 and 1,000 mg/kg/day (NTP 1989a) following acute exposure. Lethargy 
was also observed at 100 mg/kg (5 days/week) during a 13-week or 2-year exposure (NTP 1989a).  In 
mice, anesthesia, ataxia, and sedation were observed following a single dose of 1,000 mg/kg (Bowman et 
al. 1978) and lethargy and ataxia were observed following doses of 600 mg/kg/day for 14 days (NTP 
1989a). No overt signs of neurotoxicity were observed at 100 or 400 mg/kg following gavage 
administration, 5 days/week, for 13 weeks or 2 years (NTP 1989a). 
A series of experiments conducted by Balster and Borzelleca (1982) assessed neurobehavioral 
performance in mice following acute- or intermediate-duration exposures.  The ED50 for impaired motor 
performance was 431 mg/kg following a single dose.  A decrease in exploratory behavior was observed 
following 9.2 mg/kg/day for 90 days and a decrease in response rate in an operant behavior test following 
doses of 100 mg/kg/day for 60 days.  No effect on swimming endurance was observed (9.7 mg/kg/day for 
14 days) or on passive-avoidance learning (100 mg/kg/day for 30 days). 
Dibromochloromethane. No human data on the neurotoxicity of dibromochloromethane were located.  
In animals, central nervous system depression occurs at relatively high doses, as evidenced by lethargy, 
ataxia, and sedation. An acute exposure to 500 mg/kg/day resulted in lethargy, ataxia, sedation, and 
shallow breathing in rats and mice (Bowman et al. 1978; NTP 1985).  Lethargy was also observed in rats 
receiving a single gavage dose of 310 mg/kg (NTP 1985).  No overt signs of neurotoxicity were observed 
following intermediate-duration exposure to 250 mg/kg (5 days/week) or chronic exposure to 80– 
100 mg/kg (5 days/week) (NTP 1985). Daniel et al. (1990) found a significant decrease in brain weights 
in rats exposed to 100 or 200 mg/kg/day for 90 days.  However, no alterations in brain weight or 
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histopathology were observed at doses as high as 250 mg/kg (5 days/week) for 13 weeks (NTP 1985) or 
80 mg/kg (5 days/week) for 2 years (NTP 1985). 
Some alterations in neurobehavioral performance were observed in mice (Balster and Borzelleca 1982).  
An ED50 of 454 mg/kg was calculated for impaired motor performance following a single dose exposure 
and a decrease in response rate in operant behavior test during a 60-day exposure to 400 mg/kg/day.  No 
alterations were observed in swimming endurance (10 mg/kg/day for 14 days), exploratory behavior 
(10 mg/kg/day for 90 days), or passive avoidance learning tests (100 mg/kg/day for 30 days). 
3.2.2.5 Reproductive Effects  
The reproductive toxicity of bromoform and dibromochloromethane has been assessed in a small number 
of human and animal studies.  A number of studies have examined the potential association between 
adverse reproductive outcomes (spontaneous abortions, stillbirths, and preterm delivery) and consumption 
of municipal drinking water containing triholomethanes (bromoform, dibromochloromethane, dichloro­
methane, and chloroform) (Bove et al. 1992, 1995, 2002; Dodds et al. 1999; Kramer et al. 1992; Mills et 
al. 1998; Nieuwenhuijsen et al. 2000; Savitz et al. 1995; Waller et al. 1999).  These studies involved 
mixed exposures to trihalomethane compounds and most did not provide bromoform or dibromochloro­
methane exposure data. Two pregnancy outcome studies (Kramer et al. 1992; Waller et al. 1999) have 
examined risks associated with levels of bromoform or dibromochloromethane in drinking water.  A third 
study (Windham et al. 2003) examined the association of altered menstrual cycle function in women 
exposed to trihalomethanes in drinking water.  Collectively, the studies provide insufficient evidence for 
establishing a causal relationship between exposure to trihalomethane compounds and adverse 
reproductive outcome. 
The Kramer et al. (1992) study is a population case-control study of pregnant white, non-Hispanic women 
living in communities in Iowa where all drinking water was supplied from a single source.  No significant 
associations were found between bromoform or dibromochloromethane levels in the drinking water and 
the risk of prematurity.  The odds ratios were 1.1 (95% confidence limit of 0.8–1.4) for communities with 
bromoform levels of 1 µg/L and higher and 1.1 (95% confidence limit of 0.7–1.4) for communities with 
dibromochloromethane levels of 1–3 µg/L.  No cases were found in communities with dibromochloro­
methane levels of 4 µg/L and higher.  Similar results were found in the Waller et al. (1999) study.  In this 
study, pregnancy health outcomes were examined in pregnant women living in communities with 
groundwater, surface water, or mixed sources of drinking water.  The risk of spontaneous abortion was 
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not significantly associated with bromoform or dibromochloromethane water levels; the percentage of 
pregnancies ending with spontaneous abortions were 9.2, 9.8, and 10.3% in communities with bromoform 
drinking water levels of 0, 1–15, and ≥16 µg/L, respectively, and 9.7, 9.6, and 10.4% for dibromochloro­
methane levels of 0, 1–30, and ≥31 µg/L, respectively. 
Windham et al. (2003) examined the possible association between trihalomethanes in drinking water and 
menstrual cycle function.  Menstrual parameter values in premenopausal women were determined based 
on hormone levels in urine collected during an average of 5.6 menstrual cycles (n=403).  Estimates of 
bromoform and dibromochloromethane levels for each cycle were based on residential data (individual 
trihalomethane concentrations measured within a relatively narrow time period around the menstrual 
cycle start date) and utility measurements (quarterly measurements made by water utilities during a 
90-day period beginning 60 days before the cycle start date).  Significant associations were found 
between exposure to the top quartile of bromoform (≥12 µg/L) and decreasing menstrual cycle and 
follicular phase length.  The age, race, body mass index, income, pregnancy history, and caffeine and 
alcohol consumption-adjusted differences were -0.79 days (95% confidence interval [CI] of -1.4 to -0.14) 
for cycle length and -0.78 days (95% CI -1.4 to -0.14) for follicular phase length.  For dibromochloro­
methane, the differences for the 2–3 quartile (level not reported) and highest quartile (≥20 µg/L) were 
-0.69 days (95% CI of -1.4 to -0.02) and -1.21 days (95% CI of -2.0 to -0.38), respectively, for menstrual 
cycle length and -0.62 days (95% CI of -1.3 to 0.05) and -1.1 days (95% CI of -1.9 to -0.25), respectively, 
for follicular phase length.  No associations between bromoform or dibromochloromethane concentration 
and luteal phase length, menses length, or cycle variability were found.  Interpretation of the study results 
is limited due to coexposure to other trihalomethanes. 
Bromoform.  Data on the reproductive toxicity of bromoform in humans are limited to the trihalomethane 
studies described above.  Animal studies have examined the potential of bromoform to induce histological 
alterations (NTP 1989a) and impair reproductive function (NTP 1989b).  No histological alterations were 
observed in rats and mice exposed to 200 or 400 mg/kg, respectively, 5 days/week for 13 weeks (NTP 
1989a). Dose related incidences of squamous metaplasia of the prostate gland were observed in male rats 
exposed to 200 mg/kg (5 days/week) for 2 years (NTP 1989a).  This lesion may represent a chemical 
effect associated with concurrent inflammatory lesions in this gland, which occurred at similar rates in all 
groups of male rats tested, including vehicle controls.  Chronic exposure of mice to 200 mg/kg 
(5 days/week) resulted in no detectable noncancerous histological effects in male reproductive tissues 
(testes, prostate, and seminal vesicles) (NTP 1989a).  No nonneoplastic histological alterations were 
observed in female rats or mice receiving gavage doses of 200 mg/kg (5 days/week) for 2 years (NTP 
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1989a). No adverse effects on reproductive performance or fertility were observed in male and female 
mice receiving gavage doses of 200 mg/kg/day (NTP 1989b).   
Dibromochloromethane.  Human data on the reproductive toxicity of dibromochloromethane are limited 
to the trihalomethane studies described above.  No histological alterations (testes, prostate, seminal 
vesicles, ovaries, uterus, and mammary gland examined) were observed in rats or mice receiving gavage 
doses of up to 250 mg/kg 5 days/week for 13 weeks (Daniel et al. 1990; NTP 1985) or 80 or 100 mg/kg, 
respectively, 5 days/week for 2 years (NTP 1985).  In contrast to these negative findings, female mice 
exposed to dibromochloromethane in drinking water at a high dose (685 mg/kg/day) experienced a 
marked reduction in fertility, with significant decreases in litter size, gestational survival, postnatal 
survival, and postnatal body weight (Borzelleca and Carchman 1982).  These effects may have been due 
to marked maternal toxicity, as evidenced by decreased weight gain, enlarged and discolored livers, and 
decreased survival.  Exposure to lower doses (17 or 170 mg/kg/day) resulted in occasional decreases in 
one or more of the reproductive parameters monitored, but the effects were not large and were not clearly 
dose-related. These data are not sufficient to draw firm conclusions about the effects of dibromochloro­
methane on reproduction, but it appears that reproductive tissues and functions are not markedly impaired 
at doses that do not cause frank maternal toxicity.  This is supported by a reproductive toxicity study 
conducted by NTP (1996).  No alterations in reproductive or fertility indices were observed in female rats 
exposed to 40.3 mg/kg/day dibromochloromethane in drinking water for 35 days (13 days prior to mating, 
during mating, and gestation).   
3.2.2.6 Developmental Effects 
There are limited data on the developmental toxicity of bromoform or dibromochloromethane in humans 
and animals.  Several human studies have examined the potential association between exposure to 
trihalomethanes in drinking water and birth outcomes (Dodds et al. 1999; Kramer et al. 1992; Savitz et al. 
1995).  However, only one study (Kramer et al. 1992) examined the exposure to individual 
trihalomethanes. In this population-based case control of pregnant white, non-Hispanic women living in 
communities in Iowa where all drinking water was supplied from a single source, no significant 
association between exposure to ≥1 µg/L of bromoform or ≥4 µg/L of dibromochloromethane in tap water 
and increased risk of low birth weight babies and intrauterine growth retardation were found.  
Interpretation of this study is limited by the co-exposure to other trihalomethane compounds.  
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Bromoform.  Human data on the developmental toxicity of bromoform are limited to the trihalomethane 
studies discussed above. One animal study (Ruddick et al. 1983) was identified.  No significant 
alterations in the number of resorption sites, fetuses per litter, fetal body weights, fetal malformations, or 
visceral anomalies were observed in the offspring of rats administered up to 200 mg/kg/day bromoform in 
corn oil on gestational days 6–15.  Increases in several skeletal anomalies were found in the offspring of 
rats exposed to bromoform, including the presence of a 14th rib, wavy ribs, interparietal deviations, and 
sternebra aberrations. The study authors did not conduct a statistical analysis of the data.  However, an 
independent analysis of the data using Fisher Exact test revealed a significant increase in the incidence 
(per fetus and number of affected litters) in sternebra aberrations.   
Dibromochloromethane.  Human data on the developmental toxicity of dibromochloromethane are 
limited to the trihalomethane studies discussed above.  Two animal studies examined the potential of 
dibromochloromethane to induce developmental effects.  In a study by Ruddick et al. (1983) of rats 
receiving gavage doses of up to 200 mg/kg/day on gestational days 6–15, no alterations in the number of 
resorption sites, fetuses per litter, fetal body weights, fetal gross malformations, or skeletal or visceral 
anomalies were found.  Borzelleca and Carchman (1982) exposed mice to 685 mg/kg/day of 
dibromochloromethane in drinking water for several generations and detected no significant effect on the 
incidence of gross, skeletal, or soft-tissue anomalies. 
3.2.2.7 Cancer 
No studies were located regarding carcinogenic effects in humans following oral exposure to bromoform 
or dibromochloromethane.  There are a number of epidemiological studies that indicate that there may be 
an association between chronic ingestion of chlorinated drinking water (which typically contains 
trihalomethanes including bromoform and dibromochloromethane) and increased risk of rectal, bladder, 
or colon cancer in humans (Cantor et al. 1987; Crump 1983; Kanarek and Young 1982; Marienfeld et al. 
1986), but these studies cannot provide information on whether any effects observed are due to 
bromoform, dibromochloromethane, or to one or more of the hundreds of other byproducts that are also 
present in chlorinated water.  
Bromoform.  A significant increase in the incidence of adenomatous polyps or adenocarcinomas was 
observed in female rats receiving gavage dose of 200 mg/kg, 5 days/week for 2 years (NTP 1989a); a 
nonstatistically significant increase was observed in male rats.  The incidences of this relatively rare 
tumor (combined incidences of adenomatous polyps and adenocarcinoma) were 0/50, 0/50, and 3/50 for 
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males administered 0, 100, or 200 mg/kg and 0/50, 1/50, and 8/50 for females.  No significant alterations 
in neoplastic lesions were observed in mice administered up to 100 (males) or 200 (females) mg/kg, 
5 days/week for 2 years (NTP 1989a).  The International Agency for Research on Cancer (IARC) 
concluded that there were inadequate human data and limited animal data and assigned bromoform to 
weight of evidence category 3, not classifiable as to carcinogenicity in humans (IARC 1991a, 1999a) and 
EPA classified bromoform as a probable human carcinogen, group B2 (IRIS 2004a).  Based on the 
increased occurrence of neoplastic lesions in the large intestines of female rats, EPA derived an oral slope 
factor of 7.9x10-3 (mg/kg/day)-1 (IRIS 2004a). 
Dibromochloromethane.  In mice administered gavage doses of 100 mg/kg, 5 days/week for 2 years, 
increases in the incidences of hepatocellular adenomas and carcinomas were observed (NTP 1985).  The 
incidence was significantly elevated for hepatocellular adenomas in females (2/50, 4/49, and 11/50 for 0, 
50, and 100 mg/kg), hepatocellular carcinoma in males (10/50 and 19/50 for 0 and 100 mg/kg) and 
combined incidences for hepatocellular adenoma or carcinoma (23/50 and 27/50 for males at 0 and 
100 mg/kg and 6/50, 10/49, and 19/50 for females at 0, 50, and 100 mg/kg).  No significant alterations in 
the incidence of neoplastic lesion were observed in male or female rats administered up to 80 mg/kg 
5 days/week for 2 years (NTP 1985).  The IARC considered the available data on dibromochloromethane 
carcinogenicity to be not classifiable as to carcinogenicity in humans (group 3) (IARC 1991b, 1999b).  
EPA classified dibromochloromethane as a possible human carcinogen, group C (IRIS 2004b).  Based on 
the increased combined incidence of hepatocellular adenoma or carcinoma in female mice, EPA derived 
an oral slope factor of 8.4x10-2 (mg/kg/day)-1 (IRIS 2004b). 
3.2.3 Dermal Exposure  
No studies were located regarding the following health effects in humans or animals after dermal 
exposure to bromoform or dibromochloromethane: 
3.2.3.1 Death 
3.2.3.2 Systemic Effects  
3.2.3.3 Immunological and Lymphoreticular Effects  
3.2.3.4 Neurological Effects 
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3.2.3.5 Reproductive Effects  
3.2.3.6 Developmental Effects 
3.2.3.7 Cancer 
3.3 GENOTOXICITY  
Bromoform. The in vivo and in vitro genotoxicities of bromoform are examined in numerous studies, the 
results of which are summarized in Tables 3-3 and 3-4, respectively. 
The potential of bromoform to induce gene mutations have reported have shown mixed results in in vitro 
assays.  Increases (LeCurieux et al. 1995; Simmon and Tardiff 1978; Simmon et al. 1977) and no effect 
(Kubo et al. 2002; NTP 1989a; Rapson et al. 1980; Varma et al. 1988) on the occurrence of reverse 
mutations have been found in Salmonella tymphimurium; an increase in forward mutations was also 
found in S. tymphimurium (Roldan-Arjona and Pueyo 1993).  The clastogenic activity of bromoform has 
been tested in one study (Galloway et al. 1985; NTP 1989a) that found no significant alterations with 
S9 metabolic activation and negative and weakly positive results without metabolic alteration.  A 
significant alteration in mitotic aneuploidy was observed in Aspergillus nidulans (Benigni et al. 1993).  
Other tests of genotoxicity included an increase in sister chromatid exchange in human lymphocytes 
(Morimoto and Koizumi 1983) and rat erythroblastic leukemia K3D cells (Fujie et al. 1993), but not in 
Chinese hamster ovary cells (Galloway et al. 1985; NTP 1989a) or oyster toadfish leukocytes (Maddock 
and Kelly 1980); SOS induction in Escherichia coli (Lecurieux et al. 1995); trifluorotymidine resistance 
in mouse lymphoma cells (NTP 1989a).  DNA strand breaks were observed in human lymphocytes 
(Landi et al. 1999) and lymphoblastic leukemia cells, but not in primary rat hepatocytes (Geter et al. 
2003a). 
The potential for bromoform to induce chromosome aberrations, micronuclei, sister chromatid exchange, 
and DNA damage was investigated in several in vivo studies, often with conflicting results. An increase 
in chromosome aberrations, in particular chromatid and chromosome breaks, was observed in rats 
receiving five daily gavage doses of 253 mg/kg/day or a single intraperitoneal dose of 25.3 or 253 mg/kg 
(Fujie et al. 1990), but not in mice administered up to 800 mg/kg via intraperitoneal injection (NTP 
1989a). A significant increase in sister chromatid exchange was observed in the bone marrow cells of 
mice receiving 25 mg/kg/day gavage doses for 4 days (Morimoto and Koizumi 1983) and mice receiving  
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Table 3-3. Genotoxicity of Bromoform In Vivo 
Exposure 
End point Species (test system) route Results Reference 
Nonmammalian systems: 
 Sex-linked recessive Drosophilia melanogaster Feeding + Woodruff et al. 1985; 
lethal NTP 1989a Injection – 
 Reciprocal translocation D. melanogaster Feeding – Woodruff et al. 1985; 
NTP 1989a 
 Micronuclei Pleurodeleswaltl larvae + LeCurieux et al. 1995 
Mammalian systems: 
 Sister chromatid Mouse (bone marrow cell) IP + NTP 1989a 
exchange Mouse (bone marrow cell) oral + Morimoto and Koizumi 
1983 
Chromosomal aberrations Mouse (bone marrow cell) IP – NTP 1989a 
Rat (bone marrow cell) IP + Fujie et al. 1990 
Rat (bone marrow cell) Oral + Fujie et al. 1990 
Micronuclei Mouse (bone marrow cell) IP + NTP 1989a 
Mouse (bone marrow cell) Oral – Stocker et al. 1996 
Mouse (bone marrow cell) IP – Hayashi et al. 1988 
Repairable DNA damage Rat (liver cells) Oral – Stocker et al. 1996 
DNA strand breaks 	 Rat (kidney cells) Oral – Potter et al. 1996 
 




+ = positive result;  – = negative result; IP = intraperitoneal 
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Table 3-4. Genotoxicity of Bromoform In Vitro 
Resultsa 
With Without 
End point Species (test system) activation activation Reference 
Prokaryotic organisms: 
Reverse gene mutation Salmonella tymphimurium Simmon and Tardiff 1978; 
Simmon et al. 1977 
TA100 No data + 
TA1535 No data + 
S. typhimurium	 LeCurieux et al. 1995 
TA100 – + 
S. typhimurium – – Kubo et al. 2002 
TA100 
TA98 – – 
S. typhimurium









S. typhimurium	 Rapson et al. 1980 








Forward gene mutation S. typhimurium 
 SOS induction Escherichia coli 
(+) – NTP 1989a 
 
–, –, (+) –, –, – 
 
–, –, – (+), –, – 
 
–, –, – –, –, – 
 
–, –, – –, –, – 
 
No data (+) Roldan-Arjona and Pueyo 
 
1993 
+ + LeCurieux et al. 1995 
Eukaryotic organisms: 
Fungi: 
 Mitotic aneuploidy Aspergillus nidulans No data + Benigni et al. 1993 
Fish: 
 Sister-chromatid Oyster toadfish No data – Maddock and Kelly 1980 
exchange leukocytes 
Mammalian cells: 
Sister-chromatid Human lymphocytes No data + Morimoto and Koizumi 
exchange 1983 
Chinese hamster ovary –, – –, (+) Galloway et al. 1985; 
cells  NTP 1989a 
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Table 3-4. Genotoxicity of Bromoform In Vitro 
Resultsa 
With Without 
End point Species (test system) activation activation Reference 
Rat erythroblastic + + Fujie et al. 1993 
leukemia K3D cells 
 Chromosomal Chinese hamster ovary –, – –, (+) Galloway et al. 1985; 
aberrations cells NTP 1989a 
 Trifluorothymidine Mouse lymphoma cells + + NTP 1989a 
resistance 
DNA strand breaks 	 Human lymphocytes No data + Landi et al. 1999 
Human lymphoblastic + + Geter et al. 2003a 
leukemia cells 
Primary rat hepatocyte – – Geter et al. 2003a 
aResults from two or more different contract laboratories are separated by commas 
+ = positive result; – = negative result; (+) = marginally positive result 
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intraperitoneal doses of 800 mg/kg (NTP 1989a).  Increases in micronuclei induction were observed in 
mice exposed to 800 mg/kg via intraperitoneal injection (NTP 1989a) and newt larvae following a 6-day 
exposure to 2.5 mg/L (LeCurieux et al. 1995), but not in mice receiving a single intraperitoneal dose of 
175–1,400 mg/kg (Hayashi et al. 1988) or 250–1,000 mg/kg via gavage (Stocker et al. 1997).  No 
alterations in unscheduled DNA synthesis were observed in mice administered 324 or 1,080 mg/kg via 
gavage (Stocker et al. 1997). No alterations in DNA strand breaks were observed in the kidneys of rats 
administered 380 mg/kg for 1 day via gavage (Potter et al. 1996) or in the liver, kidney, or duodenum of 
rats administered 152 mg/kg either as a single oral bolus or on drinking water for 2 weeks (Geter et al. 
2003a). An increase in sex-linked recessive mutations was observed in Drosophila melanogaster 
following feeding, but not injection exposure (NTP 1989a); no effect on reciprocal translocations was 
found. 
Dibromochloromethane.  The genotoxicity of dibromochloromethane has been assessed in a number of 
in vivo and in vitro assays.  The results of these studies are presented in Tables 3-5 and 3-6, respectively. 
Mixed results were found in in vitro bacterial assays for reverse gene mutations, with some studies 
finding significant alterations (Landi et al. 1999; Simmon and Tardiff 1978; Simmon et al. 1977; Varma 
et al. 1988) and others not finding an effect (Kubo et al. 2002; LeCurieux et al. 1995; NTP 1985; Zeiger 
et al. 1987). A significant increase in forward gene mutations was found in mouse lymphoma cells 
(McGregor et al. 1991).  An increase in gene conversion, but not gene reversion, was observed in 
Saccharomyces cervisiae (Nestman and Lee 1985).  An increase in mitotic aneuploidy was observed in 
A. nidulans and sister chromatid exchange was observed in human lymphocytes (Morimoto and Koizumi 
1983; Sobti 1984), rat liver cells (Sobti 1984), and rat erythroblastic leukemia K3D cells (Fuije et al. 
1993). DNA strand breaks were observed in human lymphoblastic leukemia cells, but not in primary rat 
hepatocytes (Geter et al. 2003a).  Additionally, increases in chromosomal aberrations were observed in 
mouse lymphoma cells (Sofuni et al. 1996) and Chinese hamster lung cells (Matsuoka et al. 1996). 
In vivo, oral exposure to 25–200 mg/kg/day for 4 days resulted in dose-related increases in the frequency 
of sister chromatid exchanges in mouse bone marrow cells (Morimoto and Koizumi 1983).  An increase 
in the occurrence of chromosomal aberrations was also observed in bone marrow cells of rats receiving a 
single intraperitoneal injection of 20.8 mg/kg (Fujie et al. 1990); a weak positive response was observed 
following gavage administration of 10.5–1,041.5 mg/kg/day for 5 days (Fujie et al. 1990).  No significant 
alterations in micronuclei induction (Hayashi et al. 1988), repairable DNA damage (Stocker et al. 1996),  
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Table 3-5. Genotoxicity of Dibromochloromethane In Vivo 
Exposure 
End point Species (test system) route Results Reference 
Nonmammalian systems: 
 Micronuclei Pleurodeleswaltl larvae – 	 LeCurieux et al. 1995 
Mammalian systems: 
 Sister chromatid Mouse (bone marrow cell) Oral + 	 Morimoto and Koizumi 
exchange 1983 
Chromosomal aberrations Rat (bone marrow cell) IP + Fujie et al. 1990 
Rat (bone marrow cell) Oral 
 (+) Fujie et al. 1990 
 Micronuclei Mouse (bone marrow cell) IP 
 – Hayashi et al. 1988 
Repairable DNA damage Rat (liver cells) Oral 
 – Stocker et al. 1996 
DNA strand breaks Rat (kidney cells) Oral 
 – Potter et al. 1996 
Rat (liver, kidney, Oral – Geter et al. 2003a 
duodenum) 
+ = positive result; – = negative result; (+) = weak positive; IP = intraperitoneal 
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Table 3-6. Genotoxicity of Dibromochloromethane In Vitro 
Resultsa 
Species (test With Without 
End point system) activation activation Reference 
Prokaryotic organisms: 
Reverse gene mutation 	 Salmonella 
 Simmon and Tardiff 1978; 
typhimurium
 Simmon et al. 1977 
(desiccator sytstem) 
 
TA100 No data + 
S. typhimurium	 LeCurieux et al. 1995 
TA100 – – 
S. typhimurium	 Kubo et al. 2002 
TA100 – – 

TA98 – – 

S. typhimurium (plate Varma et al. 1988 
incorporation assay) 
TA98 + – 
TA100 + – 
TA1535 + + 

TA1537 + + 

S. typhimurium NTP 1985; Zeiger et al. 
(preincubation assay) 1987 
TA98 – – 
TA100 – – 
TA1535 – – 

TA1537 – – 

S. typhimurium	 Landi et al. 1999 
TPT100 + + 
 RSJ100 – – 
Eukaryotic organisms: 
Fungi: 
 Mitotic aneuploidy Aspergillus nidulans No data + Benigni et al. 1993 
 Gene conversion Saccharomyces – + Nestman and Lee 1985 
cervisiae 
 Gene reversion S. cerevisiae – – Nestman and Lee 1985 
Mammalian cells: 
Forward gene mutation Mouse L5178Y No data + McGregor et al. 1991 
lymphoma cells 
Sister-chromatid exchange	 Human lymphocytes No data + Morimoto and Koizumi 1983 
Human lymphocytes No data + Sobti 1984 
Rat liver cells No data (+) Sobti 1984 
Rat erythroblastic + + Fujie et al. 1993 
leukemia K3D cells 
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Table 3-6. Genotoxicity of Dibromochloromethane In Vitro 
Resultsa 
Species (test With Without 
End point system) activation activation Reference 
Chromosomal aberrations 	 Mouse L5178Y +,+ (+),– Sofuni et al. 1996 
lymphoma cells 
Chinese hamster lung No data + Matsuoka et al. 1996 
cells 
DNA single strand breaks 	 Human lymphoblastic + + Geter et al. 2003a 
leukemia cells 
Priamry rat hepatocyte – – Geter et al. 2003a 
aResults from two or more different contract laboratories are separated by commas 
+ = positive result; – = negative result; (+) = marginally positive result 
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or DNA strand breaks (Potter et al. 1996) were observed in mouse bone marrow cells (intraperitoneal 
injection of 62.5–1,000 mg/kg), rat liver cells (gavage dose of 135 or 450 mg/kg), or rat kidney cells 
(gavage dose of 310 mg/kg), respectively.  Likewise, no DNA strand breaks were observed in the liver, 
kidney, or duodenum of rats administered 125 mg/kg either as a single oral bolus or on drinking water for 
2 weeks (Geter et al. 2003a). 
3.4 TOXICOKINETICS 
3.4.1 Absorption 
3.4.1.1 Inhalation Exposure 
There are limited data on inhalation absorption of bromoform or dibromochloromethane.  Based on the 
physical-chemical properties of these compounds, and by analogy with other related halomethanes such 
as chloroform (Agency for Toxic Substances and Disease Registry 1997), it is expected that bromoform 
and dibromochloromethane would be well-absorbed across the lung.  The occurrence of systemic and 
neurological effects following inhalation exposure of animals to bromoform (see Section 3.2.1) supports 
this view. Aggazzotti et al. (1998) examined the uptake of trihalomethanes in five swimmers exposed to 
trihalomethanes via chlorinated pool water. Although bromoform was detected in the pool water, it was 
only detected in one of four indoor air samples.  Dibromochloromethane was detected in the pool water 
(0.8 µg/L) and in air samples before swimming (5.2 µg/m3) and after swimming (11.4 µg/m3). After 
sitting near the pool for 1 hour, the mean alveolar air level was 0.8 µg/m3. After swimming, alveolar air 
levels were 1.4 µg/m3; however, oral and percutaneous exposure also influenced this level.  Estimated 
dibromochloromethane uptake during the 1 hour of sitting near the pool ranged from 1.5 to 2.0 µg/hour; 
after 1 hour of swimming, the estimated uptake rate ranged from 14 to 22 µg/hour. 
Several studies have examined the impact of showering with water contaminated with trihalomethanes on 
the absorption of individual trihalomethane compounds.  Showering involves inhalation exposure to 
volatilized trihalomethanes, percutaneous exposure, and possibly oral exposure.  Several studies have 
found elevated blood bromoform and/or dibromochloromethane levels following showering (Backer et al. 
2000; Lynberg et al. 2001; Miles et al. 2002).  A comparative study by Backer et al. (2000) found the 
highest blood levels of dibromochloromethane after a 10-minute shower, compared to bathing for 
10 minutes or drinking 1 L of water in 10 minutes.  This difference may be due to differences in total 
exposure levels, metabolism, or excretion rather than differences in absorption efficiencies.   
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Several studies have estimated the blood:air partition coefficients for bromoform and dibromochloro­
methane in humans and rats, these values are summarized in Table 3-7. 
3.4.1.2 Oral Exposure  
There are limited data on the absorption of bromoform and dibromochloromethane following oral 
exposure. Most of the available data (Backer et al. 2000; da Silva et al. 1999; Mink et al. 1986) involved 
exposure to a mixture of trihalomethanes.  Elevated blood concentrations of dibromochloromethane were 
also observed in humans ingesting drinking water containing trihalomethanes (Backer et al. 2000).  
da Silva et al. (1999) examined bromoform and dibromochloromethane absorption in rats following a 
single gavage dose. Both compounds were rapidly absorbed with peak plasma levels occurring <1 hour 
postexposure.  Oral absorption constants of 0.412 and 0.55 per hour were reported for bromoforom and 
dibromochloromethane, respectively.  A nonlinear relationship between dose (0.25 and 0.50 mmol/kg; 
63 and 126 mg/kg bromoform and 52 and 104 mg/kg dibromochloromethane) and areas under the blood 
concentration versus time curves (AUCs) were found, suggesting metabolism saturation.  The AUCs (20– 
360 minutes postexposure) for 63 and 126 mg/kg bromoform were 48.6 and 190.4 µM/hour; for 52 and 
104 mg/kg dibromochlormethane, the AUCs (20–360 minutes) were 31.2 and 85.6 µM/hour. When 
bromoform and dibromochloromethane were administered along with chloroform and dichlorobromo­
methane (0.25 mmol/kg of each trihalomethane), the AUC was significantly higher than when 
administered singly. 
Mink et al. (1986) found that 60–90% of the bromoform and dibromochloromethane administered in a 
mixture of trihalomethanes in corn oil to rats (100 mg trihalomethane/kg) or mice (150 mg trihalo­
methane/kg) were recovered in expired air, urine, or in internal organs.  This indicates that gastrointestinal 
absorption was at least 60–90% complete.  This is consistent with the ready gastrointestinal absorption 
observed for other halomethanes such as chloroform (Agency for Toxic Substances and Disease Registry 
1997).  As noted by Withey et al. (1983), the rate of halocarbon uptake from the gastrointestinal tract may 
be slower when compounds are given in oil than when they are given in water.   
3.4.1.3 Dermal Exposure  
No studies were located regarding dermal absorption of bromoform.  A single study was found to 
quantitatively demonstrate dermal absorption of dibromochloromethane in human volunteers exposed for  
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60 minutes to tap water having a temperature similar to that of bathing water (Prah et al. 2002).  The 
sealed exposure apparatus was designed to permit the exposure of a single hand and lower arm by 
immersion while preventing an inhalation exposure.  The mean tap water concentration of dibromochloro­
methane was 1.4 ng/mL.  Dibromochloromethane levels in the blood increased constantly from the start 
to 5 minutes after the end of the exposure.  At 15 minutes after cessation of exposure, blood levels 
appeared to fall slightly slower than the rate of appearance.  These data have limited use since rates of 
dermal absorption or appearance in the blood were not reported. 
As discussed under Inhalation Exposure, showering, which involves both inhalation and dermal exposure 
with water contaminated with trihalomethanes, can result in significantly elevated blood bromoform and 
dibromochloromethane levels.  Xu et al. (2002) reported dermal absorption coefficients of 0.21 and 
0.20 cm/hour for aqueous solutions of bromoform and dibromochloromethane, respectively.  These 
values were determined in vitro using excess breast skin tissues at two temperature settings (20 and 
25 °C). 
3.4.2 Distribution  
Several studies have estimated the tissue:air partition coefficients for bromoform and dibromochloro­
methane in humans and rats; these values are summarized in Table 3-7.  In vitro data, suggest that 
hemoglobin is the primary ligand for bromoform, and presumably dibromochloromethane, in the blood 
(Béliveau and Krishnan 2000b). 
3.4.2.1 Inhalation Exposure 
No studies were located regarding the distribution of bromoform or dibromochloromethane in humans or 
animals following inhalation exposure.  However, adverse effects involving several organs (liver, kidney, 
central nervous system) indicate distribution to these sites. 
3.4.2.2 Oral Exposure  
The distribution of bromoform and dibromochloromethane in tissues following oral exposure has not 
been thoroughly investigated.  Analysis of bromoform levels in the organs of a child who died after an 
accidental overdose revealed concentrations of 10–40 mg/kg tissue in intestine, liver, kidney, and brain, 
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with somewhat higher levels in lung (90 mg/kg) and stomach (130 mg/kg) (Roth 1904, as cited in von 
Oettingen 1955).  This suggests that bromoform is distributed fairly evenly from the stomach to other 
tissues. 
In animals, Mink et al. (1986) found that only about 1–2% of a single oral dose of 14C-labeled dibromo­
chloromethane or bromoform as part of a trihalomethane mixture was retained in the soft tissues of rats 
8 hours after dosing.  The tissues which contained measurable amounts of the radiolabel were the brain, 
kidney, liver, lungs, muscle, pancreas, stomach (excluding contents), thymus, and urinary bladder.  The 
relative amount of radiolabel in each tissue was not mentioned.  Similar results were noted in mice, 
except that blood also contained a significant fraction of the total dose (10% in the case of bromoform).  
The chemical form of the material in the tissues (parent, metabolite, or adduct) was not reported.  The 
form in blood also was not determined, but studies by Anders et al. (1978) suggest that some or all may 
have been carbon monoxide bound to hemoglobin (see Section 3.4.3). 
3.4.2.3 Dermal Exposure  
No studies were located regarding the distribution of bromoform or dibromochloromethane in humans or 
animals following dermal exposure. 
3.4.3 Metabolism 
The metabolism of bromoform, dibromochloromethane, and other trihalomethanes has been investigated 
by Anders and colleagues (Ahmed et al. 1977; Anders et al. 1978; Stevens and Anders 1979, 1981).  The 
main reactions, which are not believed to be route-dependent, are shown in Figure 3-3.  The first step in 
the metabolism of trihalomethanes is oxidation by the cytochrome P-450 mixed function oxidase system 
of liver. This has been demonstrated in vitro using isolated rat liver microsomes (Ahmed et al. 1977), and 
in vivo, where the rate of metabolism is increased by cytochrome P-450 inducers (phenobarbital) and 
decreased by cytochrome P-450 inhibitors (SKF-525A) (Anders et al. 1978).  The product of this reaction 
is presumed to be trihalomethanol, which then decomposes by loss of hydrogen and halide ions to yield 
the dihalocarbonyl.  Although this intermediate has not been isolated, its formation has been inferred by 
the detection of 2-oxothiazolidine-4-carboxylic acid (OZT) in an in vitro microsomal system metabolizing 
bromoform in the presence of cysteine (Stevens and Anders 1979).  The dihalocarbonyl molecule (an  
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*Adapted from Stevens and Anders 1981 
X = halogen atom (chlorine, bromine); R = cellular nucleophile (protein, nucleic acid); GSH = reduced glutathione; 
GSSG = oxidized glutathione; OZT = oxothiazolidine carboxylic acid 
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Figure 3-3. Proposed Pathway of Trihalomethane Metabolism in Rats* 
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analogue of phosgene) is highly reactive, and may undergo a number of reactions, including:  (a) direct 
reaction with cellular nucleophiles to yield covalent adducts; (b) reaction with two moles of glutathione 
(GSH) to yield carbon monoxide and oxidized glutathione (GSSG); and (c) hydrolysis to yield CO2. The 
amount of trihalomethane metabolized by each of these pathways has not been studied in detail, but it 
appears that conversion to CO2 is the main route.  However, this depends on the species, the trihalo­
methane being metabolized, and metabolic conditions (cellular glutathione levels).  Mink et al. (1986) 
found that mice oxidized 72% of an oral dose of dibromochloromethane and 40% of an oral dose of 
bromoform to CO2. In contrast, rats oxidized only 18% of dibromochloromethane and 4% of bromoform 
to CO2. The fraction of the dose converted to carbon monoxide has not been quantified, but dramatically 
increased levels of carboxyhemoglobin have been reported following oral exposure of rats to bromoform 
(Anders et al. 1978; Stevens and Anders 1981).  Mink et al. (1986) reported that about 10% of a dose of 
bromoform was present in blood in mice; the form of the label was not investigated, but it may have been 
carboxyhemoglobin. 
Metabolism of trihalomethanes by cytochrome P-450 can also lead to the production of highly reactive 
trihalomethyl free radicals, especially under hypoxic conditions (O'Brien 1988). Radical formation from 
bromoform has been observed both in isolated hepatocytes incubated with bromoform in vitro and in the 
liver of rats exposed to bromoform in vivo (Tomasi et al. 1985).  Although it has not been studied, it 
seems likely that this pathway would also generate trihalomethyl radicals from dibromochloromethane.  
While metabolism to free radicals is a minor pathway in the sense that only a small fraction of the total 
dose is converted, it might be an important component of the toxic and carcinogenic mechanism of 
dibromochloromethane and bromoform.  Figure 3-4 shows how free radical generation can lead to an 
autocatalytic peroxidation of polyunsaturated fatty acids (PLJFAs) in cellular phospholipids (O'Brien 
1988). Peroxidation of cellular lipids has been observed in rat kidney slices incubated with bromoform in 
vitro, although lipid peroxidation was not detectable in liver slices (Fraga et al. 1987).  Lipid peroxidation 
is considered to be a likely cause of cell injury for other halogenated compounds such as carbon tetra­
chloride (Agency for Toxicological Substances and Disease Registry 1994), but the significance of this 
pathway in the toxicity of dibromochloromethane and bromoform remains to be determined. 
Development of the general metabolic scheme for trihalomethanes shown in Figure 3-3 relied primarily 
on the use of chloroform and bromoform as model substrates.  However, some metabolic data specific to 
dibromochloromethane are available from a series of experiments conducted in rats by Pankow et al. 
(1997). Increased levels of the metabolites bromide (in plasma) and carbon monoxide (as detected by 
cytochrome P-450 
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*Adapted from O’Brien 1988 
X = halogen atom (chlorine, bromine, iodine); PUFA = polyunsaturated fatty acid 
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formation of carboxyhemoglobin in blood) and dependence of their rate of production on hepatic GSH 
concentration in rats treated with dibromochloromethane are consistent with the metabolic scheme for the 
oxidative pathway shown in Figure 3-3.  Observation of increased hepatic levels of GSSG in dosed rats 
by Pankow et al. (1997) is also consistent with the proposed scheme.  The observation of (1) partial 
inhibition of bromide and carboxyhemoglobin production in dosed rats co-administered diethyldithio­
carbamate (a potent inhibitor of P-450 isoform CYP2E1) and (2) stimulation of production in rats 
pretreated with isoniazid (a potent inducer of CYP2E1) indicates that cytochrome P-450 isoform 
CYP2E1 is at least partially responsible for oxidative metabolism of dibromochloromethane.  
Pretreatment with phenobarbital (an inducer of CYP2B1/2 in the rat) increased the concentration of 
bromide in plasma, suggesting that CYP2B1/2, as well as CYP2E1, catalyzes metabolism of 
dibromochloromethane in the rat. 
Recent studies suggest that brominated trihalomethanes, including bromoform and dibromochloro­
methane, may be metabolized by one or more pathways dependent on glutathione conjugation catalyzed 
by glutathione S-transferase (De Marini et al. 1997; Pegram et al. 1977) in addition to the oxidative and 
reductive pathways described above.  Transfection of Salmonella typhimurium test strain TA1535 with 
the gene for rat glutathione S-transferase theta 1-1 increased the mutagenicity of bromoform and 
dibromochloromethane (by 95- and 85-fold, respectively) in reverse mutation assays when compared to 
mutagencity in TA1535 transfected with a nonfunctional form of the gene (De Marini et al. 1997).  The 
mutational spectra and site specificity for bromoform, dibromochloromethane, and bromodichloro­
methane (a structurally-related brominated trihalomethane) were closely similar, suggesting bioactivation 
of all three compounds via common metabolic intermediates.  The mutagenic metabolites were not 
identified in this study, but S-(1-halomethyl)glutathione, S-(1,1-dihalomethyl) glutathione, or their further 
metabolites were presumed on the basis of data reported for other halomethanes to be capable of reacting 
with DNA to produce the observed mutations (De Marini et al. 1997). 
The formation of reactive metabolites by conjugation of bromoform or dibromochloromethane via 
glutathione S-transferase theta-mediated pathways has not been examined in mammalian test systems.  
However, the metabolism of bromodichloromethane via glutathione conjugation has been investigated in 
vitro using cytosols prepared from human, rat, and mouse liver (Ross and Pegram 2003).  Conjugation of 
bromodichloromethane with glutathione in mouse liver cytosol was time- and protein-dependent, was not 
affected by an inhibitor of alpha-, mu-, and pi-class glutathione S-transferases, and was correlated with 
activity toward 1,2-epoxy-3-(4'-nitrophenoxy)propane (a substrate specific for theta-class glutathione 
S-transferases). Conjugation activity toward bromodichloromethane in hepatic cytosols isolated from 
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different species followed the rank order mouse, followed by rat, then human.  The initial conjugate 
formed was S-chloromethyl glutathione.  This compound was unstable and degraded to multiple 
metabolites including S-hydroxymethyl glutathione, S-formyl glutathione, and formic acid.  These data 
demonstrate that glutathione conjugation of bromodichloromethane occurs in mammalian liver cytosols 
and is likely catalyzed by glutathione S-transferase theta.  These findings are significant because 
production of reactive glutathione conjugates from bromodichloromethane may result in formation of 
DNA adducts and thus cause genotoxicity.  Because there is structural similarity among the brominated 
trihalomethanes and evidence for common pathways of bioactivation (De Marini et al. 1997), the findings 
of Ross and Pegram (2003) support the idea that glutathione conjugation of bromoform and dibromo­
chloromethane leading to formation of reactive metabolites also occurs in the liver of rodents and 
humans. 
Comparison of catalytic efficiencies for recombinant rat CYP2E1 and glutathione S-transferase theta 1-1 
using bromodichloromethane as a substrate (data on bromoform or dibromochloromethane are not 
available) suggest that glutathione conjugation is likely to be a quantitatively minor hepatic pathway in 
vivo (Ross and Pegram 2003).  Although metabolism via this pathway may be minor from the standpoint 
that only a small fraction of the total dose is converted, it might be an important component of the 
mechanism for dibromochloromethane and/or bromoform toxicity in extrahepatic tissues where 
GSTT1-1 is expressed in conjunction with lower levels of CYP2E1. 
3.4.4 Elimination and Excretion 
3.4.4.1 Inhalation Exposure 
No studies were located regarding excretion of bromoform or dibromochloromethane by humans or 
animals following inhalation exposure. 
3.4.4.2 Oral Exposure  
In rats and mice given a single oral dose of 14C-labeled bromoform or dibromochloromethane as part of a 
trihalomethane mixture (100 mg/kg in rats and 150 mg/kg in mice), excretion occurred primarily by 
exhalation of bromoform or dibromochloromethane or of CO2 (Mink et al. 1986).  In mice, 39.68 and 
71.58% of the administered radiolabelled bromoform and dibromochloromethane, respectively, were 
exhaled as CO2 and 7.18 and 12.31% as unmetabolized compound, respectively.  In contrast, 4.3 and 
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18.2% of bromoform and dibromochloromethane were exhaled as CO2 in rats and 66.9 and 48.1% of 
parent compound.  Only 1–5% of the dose was excreted in urine (the chemical form in urine was not 
determined).  The elimination half-times of bromoform and dibromochloromethane were 0.8 and 
1.2 hours, respectively, in rats at 8 or 2.5 hours, respectively, in mice. 
3.4.4.3 Dermal Exposure  
No studies were located regarding excretion of bromoform or dibromochloromethane by humans or 
animals following dermal exposure. 
3.4.5 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models  
Physiologically based pharmacokinetic (PBPK) models use mathematical descriptions of the uptake and 
disposition of chemical substances to quantitatively describe the relationships among critical biological 
processes (Krishnan et al. 1994).  PBPK models are also called biologically based tissue dosimetry 
models.  PBPK models are increasingly used in risk assessments, primarily to predict the concentration of 
potentially toxic moieties of a chemical that will be delivered to any given target tissue following various 
combinations of route, dose level, and test species (Clewell and Andersen 1985).  Physiologically based 
pharmacodynamic (PBPD) models use mathematical descriptions of the dose-response function to 
quantitatively describe the relationship between target tissue dose and toxic end points.   
PBPK/PD models refine our understanding of complex quantitative dose behaviors by helping to 
delineate and characterize the relationships between: (1) the external/exposure concentration and target 
tissue dose of the toxic moiety, and (2) the target tissue dose and observed responses (Andersen et al. 
1987; Andersen and Krishnan 1994).  These models are biologically and mechanistically based and can 
be used to extrapolate the pharmacokinetic behavior of chemical substances from high to low dose, from 
route to route, between species, and between subpopulations within a species.  The biological basis of 
PBPK models results in more meaningful extrapolations than those generated with the more conventional 
use of uncertainty factors. 
The PBPK model for a chemical substance is developed in four interconnected steps:  (1) model 
representation, (2) model parametrization, (3) model simulation, and (4) model validation (Krishnan and 
Andersen 1994).  In the early 1990s, validated PBPK models were developed for a number of 
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toxicologically important chemical substances, both volatile and nonvolatile (Krishnan and Andersen 
1994; Leung 1993).  PBPK models for a particular substance require estimates of the chemical substance-
specific physicochemical parameters, and species-specific physiological and biological parameters.  The 
numerical estimates of these model parameters are incorporated within a set of differential and algebraic 
equations that describe the pharmacokinetic processes.  Solving these differential and algebraic equations 
provides the predictions of tissue dose.  Computers then provide process simulations based on these 
solutions. 
The structure and mathematical expressions used in PBPK models significantly simplify the true 
complexities of biological systems.  If the uptake and disposition of the chemical substance(s) are 
adequately described, however, this simplification is desirable because data are often unavailable for 
many biological processes.  A simplified scheme reduces the magnitude of cumulative uncertainty.  The 
adequacy of the model is, therefore, of great importance, and model validation is essential to the use of 
PBPK models in risk assessment. 
PBPK models improve the pharmacokinetic extrapolations used in risk assessments that identify the 
maximal (i.e., the safe) levels for human exposure to chemical substances (Andersen and Krishnan 1994).  
PBPK models provide a scientifically sound means to predict the target tissue dose of chemicals in 
humans who are exposed to environmental levels (for example, levels that might occur at hazardous waste 
sites) based on the results of studies where doses were higher or were administered in different species.  
Figure 3-5 shows a conceptualized representation of a PBPK model. 
PBPK models have not been developed for bromoform or dibromochloromethane.  da Silva et al. (1999) 
developed a model to simulate the venous blood concentration of each trihalomethane after simultaneous 
exposure to the four trihalomethanes.  This model, which simulates competitive inhibition of hepatic 
metabolism, is discussed in Section 3.9.  Although da Silva et al. (1999) also described models in rats 
following single administration of bromoform or dibromochloromethane, these models involved 
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Figure 3-5. Conceptual Representation of a Physiologically Based 

Pharmacokinetic (PBPK) Model for a  

Hypothetical Chemical Substance 

Source: adapted from Krishnan et al. 1994 
Note: This is a conceptual representation of a physiologically based pharmacokinetic (PBPK) model for a 
hypothetical chemical substance.  The chemical substance is shown to be absorbed via the skin, by inhalation, or by 
ingestion, metabolized in the liver, and excreted in the urine or by exhalation. 
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3.5 MECHANISMS OF ACTION  
3.5.1 Pharmacokinetic Mechanisms 
Bromoform and dibromochloromethane can be absorbed by inhalation (Graham 1915; Merzbach 1928), 
ingestion (Backer et al. 2000; Mink et al. 1986), and dermal (Backer et al. 2000; Xu et al. 2002) routes of 
exposure. In humans and laboratory animals, bromoform and dibromochloromethane are generally 
absorbed quickly (Backer et al. 2000).  Although bromoform and dibromochloromethane are lipophilic, 
they do not appear to accumulate in adipose tissue (Stanley 1986).  Bromoform and dibromochloro­
methane are thought to be metabolized by at least two route-independent pathways:  oxidation by 
cytochrome P-450 mixed function oxidase system (Ahmed et al. 1977; Anders et al. 1978) and 
conjugation via glutathione S-transferase (DeMarini et al. 1997; Pegram et al. 1977).  Bromoform and 
dibromochloromethane are primarily excreted via exhalation as the parent compound or carbon dioxide 
(Mink et al. 1986). 
3.5.2 Mechanisms of Toxicity 
The mechanisms by which bromoform and dibromochloromethane cause damage in target tissues is not 
fully understood, but there is strong evidence that metabolism to reactive intermediates is a prerequisite 
for toxicity. Subsequent interaction of the reactive intermediates with key cellular molecules leads to 
impaired function and/or cell death. 
Several mechanisms for cell injury by trihalomethanes have been proposed based on the combined 
experimental database for chloroform and the brominated trihalomethanes.  These include:  (1) oxidative 
metabolism by CYP2E1 to produce dihalocarbonyls, which deplete glutathione content, and alkylate 
cellular macromolecules to produce necrosis; (2) reductive dehalogenation under conditions of low 
physiological oxygen tension to produce highly reactive dihalomethyl free radicals that covalently bind to 
proteins or lipids; and (3) glutathione-dependent metabolism to DNA-reactive intermediates, which 
results in adduct formation and mutation.  Toxicity of bromoform and dibromochloromethane may result 
from metabolism by one or more of these pathways.  Bromine is generally a better leaving group than 
chlorine, suggesting that the degree of bromine substitution will influence the rate of metabolism among 
chlorinated and brominated trihalomethanes and the flux through specific pathways. 
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Although mechanistic data on bromoform and dibromochloromethane are lacking, the requirement for 
metabolism of these compounds to toxic intermediates is supported by studies of chloroform and 
bromodichloromethane.  In a representative study, Ilett et al. (1973) observed covalent binding of 
radiolabeled material to proteins in the liver and kidney following administration of [14C]chloroform to 
mice. The amount of binding was correlated with the extent of renal and hepatic necrosis both in normal 
animals and in male mice pretreated with an inhibitor or inducer of microsomal enzymes.  Autoradio­
grams showed that the bound radioactivity was located mainly in necrotic lesions.  In other studies, 
Brown et al.(1974) reported that pretreatment of rats with phenobarbital (a cytochrome P-450 inducer) 
resulted in increased formation of covalent adducts and increased hepatic toxicity following chloroform 
exposure. Pohl et al. (1980) reported that the level of covalent binding correlated directly with injury to 
the liver tissue and concluded that phosgene was the metabolite responsible for the covalent binding to 
liver macromolecules.  Tyson et al. (1983) confirmed that covalent binding to proteins in rats was more 
prevalent in areas of necrosis than in less damaged areas.  More recently, Constan et al. (1999) evaluated 
toxicity in male B6C3F1, SV/129 wild-type (CYP2E1 +/+), and SV/129 null (CYP2E1 -/-) mice exposed 
to chloroform by inhalation.  Parallel groups of control and treated mice (B6C3F1 and wild-type SV/129) 
were also treated with an irreversible cytochrome P-450 inhibitor. Extensive hepatic and renal necrosis 
occurred in B6C3F1 and SV/129 mice exposed to chloroform.  Chloroform-exposed animals that received 
the inhibitor were completely protected against hepatic and renal toxicity and pathological changes were 
absent in null mice, demonstrating that metabolism is necessary for toxicity. 
The data linking metabolism of brominated trihalomethanes to toxicity are less extensive than those for 
chloroform.  No data were located specifically for bromoform or dibromochloromethane.  Pretreatment of 
female rats and mice with inhibitors of CYP2E1 metabolism reduced the acute renal and hepatic toxicity 
of bromodichloromethane (Thornton-Manning et al. 1994).  Depletion of glutathione by pretreatment of 
male F344 rats with butathione sulfoximine (BSO) increased the incidence and severity of hepatic and 
renal lesions (Gao et al. 1996). Addition of glutathione to hepatic microsomal and S9 preparations and 
renal microsomes under aerobic conditions decreased covalent binding of [14C]bromodichloromethane to 
proteins. Addition of glutathione to hepatic or renal microsomes under anaerobic conditions decreased 
binding of [14C]bromodichloromethane to lipids (Gao et al. 1996).  These data demonstrate a protective 
role of glutathione that is consistent with metabolism of bromodichloromethane to one or more reactive 
species. 
Studies in animals indicate that bromoform and dibromochloromethane have carcinogenic potential (NTP 
1985, 1989a).  The mechanism of action for tumor induction by these chemicals is unknown and may 
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involve contributions from more than one of the proposed pathways described above.  Pathway 1 
(oxidative metabolism to dihalocarbonyl) may not be directly genotoxic, but may lead to increased risk of 
cancer as a result of cytotoxicity and subsequent regenerative hyperplasia, as observed for chloroform 
(ILSI 1997).  Pathways 2 (reductive metabolism) and 3 (glutathione-dependent metabolism) may lead to 
direct DNA damage in vivo.  The relative contribution of these pathways to the carcinogenic potential of 
bromoform and dibromochloromethane has not been determined. 
Three studies have examined cytotoxicity and regenerative hyperplasia in the liver of female B6C3F1 
mice (Coffin et al. 2000; Melnick et al. 1998) or the kidney of male F344 rats (Potter et al. 1996) 
following exposure to bromoform or dibromochloromethane.  These studies are of limited use for 
understanding the mechanism of bromoform carcinogenesis because they do not address cytotoxicity or 
regeneration in the large intestine, the target tissue for tumor induction.  Dibromochloromethane induced 
cytotoxicity and cell proliferation in the liver of female B6C3F1 mice, but the LOAEL values reported by 
Melnick et al. (1998) and Coffin et al. (2000) were inconsistent (400 vs. 100 mg/kg/day). Therefore, a 
threshold for induction of cellular proliferation cannot be clearly identified for comparison with the liver 
tumor incidence data in female B6C3F1 mice (NTP 1985).  The reason for the discrepancy between 
studies is unknown, but might be related to the use of different techniques or different time points for 
measurement of labeling index (a method for estimating cell proliferation).  These data do not allow a 
conclusion regarding the role of cytotoxicity and regenerative cell proliferation in the development of 
hepatic tumors in mice exposed to dibromochloromethane.  Melnick et al. (1998) modeled dose response 
data for cell proliferation and serum enzyme activity (as a composite) and for tumor induction in the liver 
of B6C3F1 mice using an empirical Hill equation model.  The dose-response curves for these processes 
had different shapes, suggesting that they were not causally associated. 
Positive results for mutagenicity and cytogenetic damage have been observed in some standard assays 
(see Section 3.3), suggesting that some metabolites of bromoform and dibromochloromethane interact 
directly with DNA.  Reductive metabolism (Melnick et al. 1998) and glutathione conjugation of 
brominated trihalomethanes have been proposed as a source of DNA reactive intermediates (De Marini et 
al. 1997; Ross and Pegram 2003), but the available data are too limited to fully evaluate the contribution 
of these pathways to the genotoxicity and carcinogenicity of bromoform and dibromochloromethane.  
Studies of bromodichloromethane metabolism in hepatic cytosols prepared from rat, mouse, and liver 
microsomes suggest that metabolism of brominated trihalomethanes via a glutathione-dependent pathway 
is likely to be a minor pathway in the liver (Ross and Pegram 2003).  It is unknown whether the small 
amounts formed in the liver are toxicologically significant.  It is possible that glutathione-dependent 
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pathways are of greater toxicological significance in extrahepatic tissues where concentrations of 
CYP2E1 are lower, such as the distal large intestine (Ross and Pegram 2003).   
3.5.3 Animal-to-Human Extrapolations 
Most of the available data on the toxicity and toxicokinetic properties of bromoform and dibromochloro­
methane come from studies in rats and mice.  There are very limited human data, and the only end point 
that has been examined is neurotoxicity; high doses of bromoform result in central nervous system 
depression in humans and laboratory animals.  Data from other trihalomethanes, particularly chloroform 
(Agency for Toxic Substances and Disease Registry 1997), suggest that the available laboratory animal 
toxicity and toxicokinetic data for bromoform and dibromochloromethane would also be applicable for 
humans.  A potential difference between species is quantitative and qualitative differences in Phase I 
metabolism of trihalomethanes.  In rats, trihalomethanes are substrates of cytochrome P-450 enzyme 
isoforms CYP2E1, CYP2B1, CY2B2, and CYP1A2 (Allis et al. 2001; Pankow et al. 1997). CYP2E1 and 
CPY1A2 are also expressed in human tissues; however, the relevance of metabolism by CYP2B1/2 to 
human health is presently uncertain, since these isoforms have not been reported in human adult or fetal 
tissues (Juchau et al. 1998; Nelson et al. 1996).  CYP2B6 is the only active member of the CYP2B 
subfamily in man, although the CYP2B7 gene has also been found in the genome (Czerwinski et al. 
1994). 
3.6 TOXICITIES MEDIATED THROUGH THE NEUROENDOCRINE AXIS  
Recently, attention has focused on the potential hazardous effects of certain chemicals on the endocrine 
system because of the ability of these chemicals to mimic or block endogenous hormones.  Chemicals 
with this type of activity are most commonly referred to as endocrine disruptors. However, appropriate 
terminology to describe such effects remains controversial.  The terminology endocrine disruptors, 
initially used by Colborn and Clement (1992), was also used in 1996 when Congress mandated the EPA 
to develop a screening program for “...certain substances [which] may have an effect produced by a 
naturally occurring estrogen, or other such endocrine effect[s]...”.  To meet this mandate, EPA convened a 
panel called the Endocrine Disruptors Screening and Testing Advisory Committee (EDSTAC), and in 
1998, the EDSTAC completed its deliberations and made recommendations to EPA concerning endocrine 
disruptors. In 1999, the National Academy of Sciences released a report that referred to these same types 
of chemicals as hormonally active agents. The terminology endocrine modulators has also been used to 
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convey the fact that effects caused by such chemicals may not necessarily be adverse.  Many scientists 
agree that chemicals with the ability to disrupt or modulate the endocrine system are a potential threat to 
the health of humans, aquatic animals, and wildlife.  However, others think that endocrine-active 
chemicals do not pose a significant health risk, particularly in view of the fact that hormone mimics exist 
in the natural environment.  Examples of natural hormone mimics are the isoflavinoid phytoestrogens 
(Adlercreutz 1995; Livingston 1978; Mayr et al. 1992).  These chemicals are derived from plants and are 
similar in structure and action to endogenous estrogen.  Although the public health significance and 
descriptive terminology of substances capable of affecting the endocrine system remains controversial, 
scientists agree that these chemicals may affect the synthesis, secretion, transport, binding, action, or 
elimination of natural hormones in the body responsible for maintaining homeostasis, reproduction, 
development, and/or behavior (EPA 1997).  Stated differently, such compounds may cause toxicities that 
are mediated through the neuroendocrine axis.  As a result, these chemicals may play a role in altering, 
for example, metabolic, sexual, immune, and neurobehavioral function.  Such chemicals are also thought 
to be involved in inducing breast, testicular, and prostate cancers, as well as endometriosis (Berger 1994; 
Giwercman et al. 1993; Hoel et al. 1992). 
No in vitro studies were located regarding endocrine disruption of bromoform and dibromochloro­
methane. 
There is little evidence to suggest that bromoform or dibromochloromethane has the potential to distrupt 
the normal functioning of the neuroendocrine axis.  There are some suggestive data that these chemicals 
have the potential to alter reproductive hormone levels.  An ecological study found significant 
correlations between bromoform and dibromochloromethane concentrations in drinking water and 
alterations in menstrual cycle length (Windham et al. 2003); however, the women were exposed to a 
number of other potentially toxic compounds in the drinking water and the data are inadequate for 
establishing causality.  In rats administered 310–380 mg/kg/day bromoform or dibromochloromethane, 
significant decreases in serum testosterone levels were observed (Potter 1996). 
3.7 CHILDREN’S SUSCEPTIBILITY  
This section discusses potential health effects from exposures during the period from conception to 
maturity at 18 years of age in humans, when all biological systems will have fully developed.  Potential 
effects on offspring resulting from exposures of parental germ cells are considered, as well as any indirect 
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effects on the fetus and neonate resulting from maternal exposure during gestation and lactation.  
Relevant animal and in vitro models are also discussed. 
Children are not small adults.  They differ from adults in their exposures and may differ in their 
susceptibility to hazardous chemicals.  Children’s unique physiology and behavior can influence the 
extent of their exposure.  Exposures of children are discussed in Section 6.6, Exposures of Children. 
Children sometimes differ from adults in their susceptibility to hazardous chemicals, but whether there is 
a difference depends on the chemical (Guzelian et al. 1992; NRC 1993).  Children may be more or less 
susceptible than adults to health effects, and the relationship may change with developmental age 
(Guzelian et al. 1992; NRC 1993).  Vulnerability often depends on developmental stage.  There are 
critical periods of structural and functional development during both prenatal and postnatal life and a 
particular structure or function will be most sensitive to disruption during its critical period(s).  Damage 
may not be evident until a later stage of development.  There are often differences in pharmacokinetics 
and metabolism between children and adults.  For example, absorption may be different in neonates 
because of the immaturity of their gastrointestinal tract and their larger skin surface area in proportion to 
body weight (Morselli et al. 1980; NRC 1993); the gastrointestinal absorption of lead is greatest in infants 
and young children (Ziegler et al. 1978).  Distribution of xenobiotics may be different; for example, 
infants have a larger proportion of their bodies as extracellular water and their brains and livers are 
proportionately larger (Altman and Dittmer 1974; Fomon 1966; Fomon et al. 1982; Owen and Brozek 
1966; Widdowson and Dickerson 1964).  The infant also has an immature blood-brain barrier (Adinolfi 
1985; Johanson 1980) and probably an immature blood-testis barrier (Setchell and Waites 1975).  Many 
xenobiotic metabolizing enzymes have distinctive developmental patterns.  At various stages of growth 
and development, levels of particular enzymes may be higher or lower than those of adults, and 
sometimes unique enzymes may exist at particular developmental stages (Komori et al. 1990; Leeder and 
Kearns 1997; NRC 1993; Vieira et al. 1996).  Whether differences in xenobiotic metabolism make the 
child more or less susceptible also depends on whether the relevant enzymes are involved in activation of 
the parent compound to its toxic form or in detoxification.  There may also be differences in excretion, 
particularly in newborns who all have a low glomerular filtration rate and have not developed efficient 
tubular secretion and resorption capacities (Altman and Dittmer 1974; NRC 1993; West et al. 1948).  
Children and adults may differ in their capacity to repair damage from chemical insults.  Children also 
have a longer remaining lifetime in which to express damage from chemicals; this potential is particularly 
relevant to cancer. 
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Certain characteristics of the developing human may increase exposure or susceptibility, whereas others 
may decrease susceptibility to the same chemical.  For example, although infants breathe more air per 
kilogram of body weight than adults breathe, this difference might be somewhat counterbalanced by their 
alveoli being less developed, which results in a disproportionately smaller surface area for alveolar 
absorption (NRC 1993). 
There are limited data on the toxicity of bromoform and dibromochloromethane.  In the early 1900s, 
bromoform was used as a sedative for the treatment of whooping cough (Benson 1907; Burton-Fanning 
1901; Dwelle 1903; Stokes 1900; von Oettingen 1955).  Sedation was observed at the prescribed dosage; 
higher doses often resulted in central nervous system depression.  Central nervous system depression has 
also been observed in adult animals following oral exposure to bromoform (Bowman et al. 1978; NTP 
1989a) or dibromochloromethane (Bowman et al. 1978; NTP 1985).  There is no indication that children 
are more susceptible than adults to this effect.   
Animal data provide strong evidence that the liver is the critical target of bromoform and dibromochloro­
methane toxicity (Aida et al. 1992; Coffin et al. 2000; Condie et al. 1983; NTP 1985, 1989a; Tobe et al. 
1982). These animal studies were conducted in adults and no animal studies using juveniles were located.  
The available data suggest that the hepatotoxicity of bromoform and dibromochloromethane is due to 
tissue damage from reactive intermediates that are generated during metabolism.  In rats, trihalomethanes 
are substrates for several cytochrome P-450 enzyme isoforms, including CYP2E1, CYP2B1, CYP2B2, 
and CYP1A2 (Allis et al. 2001; Pankow et al. 1997) in Phase I reactions and glutathione S-transferase 
theta (GSTT) (DeMarini et al. 1997; Pegram et al. 1987; Ross and Pegram 2003) in Phase II reactions.  
As discussed in EPA (2001a), CYP2E1 levels increase rapidly during the first 24 hours after birth and 
levels in children between 1 and 10 years of age are similar to those in adults.  Similarly, GSTT levels in 
children older than 1 year are similar to adults.  These data provide some suggestive evidence that 
exposure during early childhood would result in the formation of similar reactive intermediates and 
metabolites as in adults. 
The potential of bromoform and dibromochloromethane to induce developmental effects cannot be 
conclusively established from the existing database.  A significant alteration in the occurrence of 
sternebra aberrations were observed in the offspring of rats administered 200 mg/kg/day bromoform in 
corn oil during gestation (Ruddick et al. 1983).  A similar exposure to dibromochloromethane did not 
result in any significant alterations.  Similarly, no developmental alterations were observed in mouse 
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offspring exposed to 685 mg/kg/day dibromochloromethane in drinking water for several generations 
(Borzelleca and Carchman 1982).   
There are no specific biomarkers of exposure or effect for bromoform or dibromochloromethane that have 
been validated in children or adults exposed as children.  No studies were located regarding interactions 
of bromoform or dibromochloromethane with other chemicals in children.  Additionally, there are no 
pediatric-specific methods of reducing peak absorption or reducing body burden following exposure to 
bromoform or dibromochloromethane.  In the absence of these data, it is assumed that there are no age-
related differences in biomarkers, interactions, or mitigation of effects. 
3.8 BIOMARKERS OF EXPOSURE AND EFFECT 
Biomarkers are broadly defined as indicators signaling events in biologic systems or samples. They have 
been classified as markers of exposure, markers of effect, and markers of susceptibility (NAS/NRC 
1989). 
Due to a nascent understanding of the use and interpretation of biomarkers, implementation of biomarkers 
as tools of exposure in the general population is very limited.  A biomarker of exposure is a xenobiotic 
substance or its metabolite(s) or the product of an interaction between a xenobiotic agent and some target 
molecule(s) or cell(s) that is measured within a compartment of an organism (NAS/NRC 1989).  The 
preferred biomarkers of exposure are generally the substance itself or substance-specific metabolites in 
readily obtainable body fluid(s) or excreta.  However, several factors can confound the use and 
interpretation of biomarkers of exposure.  The body burden of a substance may be the result of exposures 
from more than one source.  The substance being measured may be a metabolite of another xenobiotic 
substance (e.g., high urinary levels of phenol can result from exposure to several different aromatic 
compounds).  Depending on the properties of the substance (e.g., biologic half-life) and environmental 
conditions (e.g., duration and route of exposure), the substance and all of its metabolites may have left the 
body by the time samples can be taken.  It may be difficult to identify individuals exposed to hazardous 
substances that are commonly found in body tissues and fluids (e.g., essential mineral nutrients such as 
copper, zinc, and selenium).  Biomarkers of exposure to bromoform and dibromochloromethane are 
discussed in Section 3.8.1. 
Biomarkers of effect are defined as any measurable biochemical, physiologic, or other alteration within an 
organism that, depending on magnitude, can be recognized as an established or potential health 
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impairment or disease (NAS/NRC 1989).  This definition encompasses biochemical or cellular signals of 
tissue dysfunction (e.g., increased liver enzyme activity or pathologic changes in female genital epithelial 
cells), as well as physiologic signs of dysfunction such as increased blood pressure or decreased lung 
capacity.  Note that these markers are not often substance specific.  They also may not be directly 
adverse, but can indicate potential health impairment (e.g., DNA adducts).  Biomarkers of effects caused 
by bromoform and dibromochloromethane are discussed in Section 3.8.2. 
A biomarker of susceptibility is an indicator of an inherent or acquired limitation of an organism's ability 
to respond to the challenge of exposure to a specific xenobiotic substance.  It can be an intrinsic genetic or 
other characteristic or a preexisting disease that results in an increase in absorbed dose, a decrease in the 
biologically effective dose, or a target tissue response.  If biomarkers of susceptibility exist, they are 
discussed in Section 3.10 “Populations that are Unusually Susceptible.” 
3.8.1 	 Biomarkers Used to Identify or Quantify Exposure to Bromoform and 
Dibromochloromethane 
The most straightforward means of identifying exposure to bromoform or dibromochloromethane in a 
person is measurement of parent compound in blood or expired air. Sensitive and specific gas 
chromatographic-mass spectrophotometric methods available for this purpose are described in 
Section 7.1. Quantification of exposure is complicated by the relatively rapid clearance rate of these 
compounds from the body, both by exhalation and metabolic breakdown.  Data are not available on 
clearance rates in humans, but in animals, clearance of parent is nearly complete within 8 hours (see 
Section 3.4.4). Consequently, this approach is best suited for detecting recent exposures (within 1– 
2 days). 
No data are available on blood or breath levels of bromoform or dibromochloromethane in acutely 
exposed individuals.  However, studies involving exposure to trihalomethanes in water have found 
elevated alveolar air levels of dibromochloromethane following a 1-hour exposure to volatilized 
trihalomethanes from swimming pool water (Aggazzotti et al. 1998) and elevated blood bromoform and 
dibromochloromethane levels following a 10-minute shower or 10-minute bath (Backer et al. 2000). 
Background concentrations in people not exposed to bromoform or dibromochloromethane except 
through chlorinated drinking water are about 0.6 ppb (Antoine et al. 1986), while levels in expired breath 
are undetectable (Wallace et al. 1986a, 1986b).  In a study of blood trihalomethane concentrations in 
women living in areas with trihalomethane in tap water (Miles et al. 2002), a simple linear relationship 
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between blood levels and tap water levels of trihalomethanes was not found.  For bromoform and 
dibromochloromethane, no significant correlations were found between tap water levels of these 
compounds and blood levels before showering.  After showering, a significant correlation between 
bromoform levels in the tap water and blood levels were found; however, the correlation coefficient 
(0.450) is relatively low, suggesting that a number of variables affected blood bromoform levels.  
Although bromoform and dibromochloromethane are lipophilic, they do not appear to accumulate in 
adipose tissue (Stanley 1986), so measurement of parent levels in this tissue is not likely to be valuable as 
a biomarker of exposure.  
The principal metabolites of bromoform and dibromochloromethane are CO2, CO, Cl-, and Br-. None of 
these metabolites are sufficiently specific to be useful as a biomarker of exposure.  It is suspected that 
reactive intermediates formed during metabolism may produce covalent adducts with proteins or other 
cellular macromolecules (see Section 3.4.3), but these putative adducts have not been identified nor has 
any means for their quantification been developed. 
3.8.2 	 Biomarkers Used to Characterize Effects Caused by Bromoform and 
Dibromochloromethane 
There are limited data on the toxicity of bromoform and dibromochloromethane in humans.  Exposure to 
bromoform can result in sedation; it is likely that the same is true for dibromochloromethane.  However, 
generalized central nervous system depression is too nonspecific to be useful as a biomarker of effects 
from bromoform or dibromochloromethane exposure.  Studies in animals indicate the liver and the 
kidneys are also affected, resulting in fatty liver, increased serum enzyme levels, and nephrosis.  Effects 
on liver and kidney can be evaluated using a variety of laboratory and clinical tests (CDC/ATSDR 1990), 
but these are also too nonspecific to be valuable in recognizing early effects caused by low level exposure 
to these two chemicals. 
3.9 INTERACTIONS WITH OTHER CHEMICALS  
It is well-known that exposure to alcohols, ketones, and a variety of other substances can dramatically 
increase the acute toxicity of halomethanes such as carbon tetrachloride (Agency for Toxic Substances 
and Disease Registry 1994) and chloroform (Agency for Toxic Substances and Disease Registry 1997).  
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Several studies have been performed to determine if the toxic effects of bromoform and dibromochloro­
methane are similarly affected by these agents.  
Hewitt et al. (1983) found that pretreatment of rats with a single oral dose of acetone resulted in a l0– 
40-fold potentiation of the hepatotoxic effects of a single oral dose of dibromochloromethane given 
18 hours later.  Similarly, pretreatment of rats for one to three days with chlordecone resulted in a 7– 
60-fold potentiation of the hepatotoxic effects of a single oral dose of dibromochloromethane (Plaa and 
Hewitt 1982a, 1982b). In contrast, chlordecone pretreatment had relatively little potentiating effect on the 
hepatotoxicity of bromoform (Agarwal and Mehendale 1983; Plaa and Hewitt 1982a).  
The mechanism by which chemicals such as acetone and chlordecone potentiate halomethane toxicity is 
not known, but it is generally considered that at least some of the effect is due to stimulation of metabolic 
pathways that yield toxic intermediates.  If so, the findings above support the hypothesis that the toxicity 
of dibromochloromethane is mediated at least in part by metabolic generation of reactive intermediates, 
but that metabolism is relatively less important in bromoform toxicity.  
Harris et al. (1982) found that exposure of rats to a combination of bromoform and carbon tetrachloride 
resulted in more liver injury (judged by release of hepatic enzymes into serum) than would be predicted 
by the effects of each chemical acting alone.  The mechanism of this interaction is not certain, but may be 
related to dihalocarbonyl formation and lipid peroxidation (Harris et al. 1982). 
A PBPK model has been developed by da Silva et al. (1999) that examined the influence of exposure to a 
mixture of trihalomethanes (bromoform, dibromochloromethane, dichlorobromomethane, and chloro­
form) on the kinetics of individual compounds.  When all four trihalomethanes were administered 
together (1.0 mmol/kg), the area under the blood concentration versus time curve was significantly higher 
as compared to the AUC after administration of a single compound (0.25 mmol/kg).  For bromoform and 
dibromochloromethane, the AUCs after the single 0.25 mmol/kg dose were 48.6 and 31.2 µM/hour and 
after the 1.0 mmol/kg mixture of trihalomethanes, the AUCs were 127.3 and 128.6 µM/hour. These data 
suggest that there is metabolic interation between the trihalomethanes; likely competitive inhibition of 
hepatic metabolism. 
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3.10 POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE 
A susceptible population will exhibit a different or enhanced response to bromoform or 
dibromochloromethane than will most persons exposed to the same level of bromoform or 
dibromochloromethane in the environment.  Reasons may include genetic makeup, age, health and 
nutritional status, and exposure to other toxic substances (e.g., cigarette smoke).  These parameters result 
in reduced detoxification or excretion of bromoform or dibromochloromethane, or compromised function 
of organs affected by bromoform or dibromochloromethane.  Populations who are at greater risk due to 
their unusually high exposure to bromoform or dibromochloromethane are discussed in Section 6.7, 
Populations with Potentially High Exposures. 
Studies of bromoform and dibromochloromethane toxicity in animals suggest that there may be some 
quantitative and qualitative differences in susceptibility between sexes and between species (see 
Section 3.2). The mechanistic basis for these differences is not known, but one likely factor is sex and 
species-dependent differences in metabolism (see Section 3.4.3).  Thus, it is reasonable to assume that 
differences in susceptibility could exist between humans as a function of sex, age, or other metabolism-
influencing factors.  Studies in animals (discussed in Section 3.9) also suggest that humans exposed to 
alcohols, ketones, or other drugs (e.g., barbiturates, anticoagulants) that influence halomethane 
metabolism might be more susceptible to the toxic effect of dibromochloromethane and perhaps 
bromoform as well.  Persons with existing renal or hepatic disease might also be more susceptible, since 
these organs are adversely affected by exposure to bromoform and dibromochloromethane. The elderly 
may represent an unusually suseptible population because they may have age-related deficiencies of liver 
and kidney function.  They may also be frequently exposed to metabolism-influencing medications.  
3.11 METHODS FOR REDUCING TOXIC EFFECTS  
This section will describe clinical practice and research concerning methods for reducing toxic effects of 
exposure to bromoform or dibromochloromethane.  However, because some of the treatments discussed 
may be experimental and unproven, this section should not be used as a guide for treatment of exposures 
to bromoform or dibromochloromethane.  When specific exposures have occurred, poison control centers 
and medical toxicologists should be consulted for medical advice.  The following texts provide specific 
information about treatment following exposures to bromoform or dibromochloromethane:   
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Haddad LM, Shannon MW, Winchester JF, eds.  1998.  Clinimal management of poisoning and drug 
overdose. Philadelphia, PA:  W.B. Saunders Co., 913-939, 992-1000. 
Viccellio P, ed. 1998.  Emergency toxicology.  Philadelphia, PA:  Lippincott-Raven Publishers, 925-932. 
3.11.1 Reducing Peak Absorption Following Exposure  
Human exposure to bromoform or dibromochloromethane may occur by inhalation, ingestion, or dermal 
contact. General recommendations for reducing absorption of these chemicals include removing the 
exposed individual from the contaminated area and removing the contaminated clothing.  If the eyes and 
skin were exposed, they should be flushed with water.  In order to reduce absorption of ingested 
bromoform and dibromochloromethane, emesis may be considered unless the patient is comatose, is 
convulsing, or has lost the gag reflex. Controversy exists concerning use of emesis because of the rapid 
onset of central nervous system depression, the risk of aspiration of stomach contents into the lungs, and 
the relative ineffectiveness of this method.  In comatose patients with absent gag reflexes, an endotracheal 
intubation may be performed in advance to reduce the risk of aspiration pneumonia.  Gastric lavage may 
also be used. 
3.11.2 Reducing Body Burden  
Trihalomethanes levels in human blood have a short half-life of approximately 0.5 hours (Lynberg et al. 
2001).  Bromoform or dibromochloromethane were not stored to any appreciable extent in the rat and 
were mostly metabolized to CO2 (see Section 3.4).  The elimination half-life of bromoform was reported 
to be 0.8 hours in the rat and 8 hours in the mouse (Mink et al. 1986).  The half-lives of dibromochloro­
methane were 1.2 and 2.5 hours in rats and mice, respectively (Mink et al. 1986).  Despite an expected 
relatively fast clearance of from the body, toxic effects may develop in exposed individuals.  No method 
is commonly practiced to enhance the elimination of the absorbed dose of bromoform or dibromochloro­
methane. 
3.11.3 Interfering with the Mechanism of Action for Toxic Effects  
The primary targets of bromoform and dibromochloromethane are the liver, kidneys, and central nervous 
system.  It is believed that the mechanism of bromoform and dibromochloromethane toxicity to the liver 
and kidneys involves metabolism to reactive intermediates.  No methods for interfering with the 
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mechanism of action have been developed for these compounds.  Studies using two other trihalomethanes 
(chloroform and dichlorobromomethane) provide suggestive evidence that administration of agents which 
inhibit cytochrome P-450 decreases hepatotoxicity. Co-administration of chloroform and 1-aminobenzo­
triazole (an irreversible cytochrome P-450 inhibitor) (Constan et al. 1999) or dibromochloromethane and 
a CYP2E1 inhibitor (Thornton-Manning et al. 1994) resulted a reduction of acute hepatic and renal 
toxicity. 
3.12 ADEQUACY OF THE DATABASE 
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the 
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether 
adequate information on the health effects of bromoform or dibromochloromethane is available.  Where 
adequate information is not available, ATSDR, in conjunction with the National Toxicology Program 
(NTP), is required to assure the initiation of a program of research designed to determine the health 
effects (and techniques for developing methods to determine such health effects) of bromoform or 
dibromochloromethane. 
The following categories of possible data needs have been identified by a joint team of scientists from 
ATSDR, NTP, and EPA. They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment.  This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled.  In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed. 
3.12.1 Existing Information on Health Effects of Bromoform and Dibromochloromethane 
The existing data on health effects of inhalation, oral, and dermal exposure of humans and animals to 
bromoform and dibromochloromethane are summarized in Figures 3-6 and 3-7, respectively. The 
purpose of this figure is to illustrate the existing information concerning the health effects of bromoform 
or dibromochloromethane.  Each dot in the figure indicates that one or more studies provide information 
associated with that particular effect.  The dot does not necessarily imply anything about the quality of the 
study or studies, nor should missing information in this figure be interpreted as a “data need”.  A data 
need, as defined in ATSDR’s Decision Guide for Identifying Substance-Specific Data Needs Related to 
Toxicological Profiles (Agency for Toxic Substances and Disease Registry 1989), is substance-specific  
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information necessary to conduct comprehensive public health assessments.  Generally, ATSDR defines a 
data gap more broadly as any substance-specific information missing from the scientific literature. 
As shown in Figure 3-6, there are limited data on the toxicity of bromoform following inhalation 
exposure. No human data were located and laboratory animal studies are limited to lethality studies, 
which found central nervous system depression, and acute and intermediate duration studies, which are 
only available as abstracts.  Human data on the oral toxicity of bromoform are limited to reports of 
children taking bromoform for the treatment of whooping cough; effects are limited to death and central 
nervous system depression and the exposure levels are poorly characterized.  A number of laboratory 
animal studies have examined the oral toxicity of bromoform, and data are available for all end points.  
However, in many cases, the available data for a particular end point are limited to a single study or use a 
route of administration (e.g., gavage) that may not be relevant to human environmental exposure to 
bromoform.  The dermal toxicity of bromoform has not been studied in humans or animals.   
As shown in Figure 3-7, there are no human toxicity data for dibromochloromethane following inhalation, 
oral, or dermal exposure. Additionally, there are no laboratory animal data on dibromochloromethane 
following inhalation or dermal exposure.  For the oral route of exposure, data are available for all end 
points. As noted for bromoform, information on a particular end point comes from a single study, and 
most studies used a gavage in oil administration route, which may not be relevant for human 
environmental exposure to dibromochloromethane.   
3.12.2 Identification of Data Needs 
Acute-Duration Exposure.    The available data on the acute toxicity of bromoform in humans are 
limited to reports of children prescribed bromoform for the treatment of whooping cough.  Following 
ingestion, the children were said to sleep undisturbed through the night, suggestive of sedation (Dwelle 
1903); accidental overdoses resulted in symptoms of central nervous system depression (Benson 1907; 
Burton-Fanning 1901; Dwelle 1903; Stokes 1900; von Oettingen 1955).  No human data were located 
discussing human toxicity following inhalation or dermal exposure to bromoform or after inhalation, oral, 
or dermal exposure to dibromochloromethane.  Inhalation and oral exposure animal studies confirm that 
high oral doses of bromoform (Balster and Borzelleca 1982; Bowman et al. 1978; Graham 1915; 
Mertzbach 1928; NTP 1989a) or dibromochloromethane (Balster and Borzelleca 1982; NTP 1985) can 
result in central nervous system depression.  At lower doses, the liver and possibly the kidney appear to 
be the primary targets of toxicity for both compounds.  Nonlethal animal inhalation data are limited to a 
108 BROMOFORM AND DIBROMOCHLOROMETHANE 
3. HEALTH EFFECTS 
study published in Russian that found liver and kidney effects in rats (Dykan 1964).  The inhalation data 
are inadequate to define the threshold for these effects or identify the critical target of toxicity; additional 
inhalation studies that examine a wide range of end points and exposure concentrations would be useful 
for establishing the critical targets of toxicity of bromoform and dibromochloromethane following 
inhalation exposure and establishing concentration-response relationships.  There is a more extensive 
database following oral exposure, which allows for the derivation of acute-duration oral MRLs for 
bromoform and dibromochloromethane.  Following oral exposure to bromoform, increases in liver weight 
(Munson et al. 1982), centrilobular pallor (Condie et al. 1983), and hepatocellular vacuolization and/or 
swelling (Coffin et al. 2000) have been observed.  Other effects of bromoform observed in acute-duration 
animal studies include mesangial nephrosis (Condie et al. 1983), impaired humoral immune function 
(Munson et al. 1982), and developmental effects (Ruddick et al. 1983).  As with bromoform, the most 
sensitive effects of dibromochloromethane following acute oral exposure are liver and kidney damage; 
the liver effects consisted of mottled liver, hepatocellular vacuolization and/or swelling, and increases in 
SGPT and SGOT levels (Coffin et al. 2000; Condie et al. 1983; Munson et al. 1982; NTP 1985) and 
kidney effects included mesangial hyperplasia and darkened renal medullae (Condie et al. 1983; NTP 
1985). At higher doses, impaired humoral immunity (Munson et al. 1982), decreased body weight gain 
(NTP 1985; Potter et al. 1996), and decreased serum testosterone levels (Potter et al. 1996) were 
observed. 
No data are available in humans or animals following dermal exposure to bromoform or dibromochloro­
methane. Contact with concentrated solutions of these chemicals might be expected to produce effects 
similar to those following ingestion or inhalation, and might also result in skin or eye irritation.  Studies 
on this would be useful, although contact with concentrated bromoform or dibromochloromethane is 
considered extremely unlikely for members of the general population or residents near waste sites.  
Studies on the effects of dermal contact with lower levels of the compounds in water or soil would be 
valuable, since people might be exposed by these routes near waste sites. 
Intermediate-Duration Exposure.    No human data are available on the intermediate-duration 
toxicity of bromoform or dibromochloromethane following inhalation, oral, or dermal exposure.  Animal 
data are limited to a study reporting liver and kidney effects in rats exposed to bromoform for 2 months 
(Dykan 1962); however, this study is currently only available as an abstract.  No intermediate-duration 
animal inhalation exposure data are available for dibromochloromethane.  Further studies on the 
intermediate-duration inhalation toxicity of these compounds would be valuable in assessing human 
health risks from airborne exposures near waste sites, although available data suggest that exposures in air 
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near such sites are likely to be low.  The available intermediate-duration oral exposure animal studies 
strongly identify the liver as the most sensitive target for bromoform and dibromochloromethane.  
Hepatocellular vacuolization and/or swelling have been observed at the lowest adverse effect levels (Aida 
et al. 1992; Daniel et al. 1990; NTP 1985, 1989a).  Other effects observed in animals exposed to higher 
doses of bromoform include lethargy (NTP 1989a), impaired performance on neurobehavioral tests 
(Balster and Borzelleca 1982), and decreased body weight gain (Aida et al. 1992).  Exposure to higher 
doses of dibromochloromethane also resulted in kidney damage (tubular degeneration and nephropathy) 
(Daniel et al. 1990; NTP 1985), impaired performance on neurobehavioral tests (Balster and Borzelleca 
1982), and impaired fertility (Borzelleca and Carchman 1982).  These animal data were considered 
adequate for derivation of an intermediate MRL for bromoform.  An MRL was not derived for 
dibromochloromethane because the resultant MRL would be higher than the MRL for acute duration 
exposure. Additional studies using a number of dose levels would provide additional information on the 
threshold of hepatic toxicity and possible allow for the derivation of an intermediate-duration MRL for 
dibromochloromethane.  There are no data on dermal exposure, and studies on intermediate-duration 
dermal exposure to the compounds in water or soil would be useful in evaluating human health risk at 
waste sites 
Chronic-Duration Exposure and Cancer.    No human studies examining the chronic toxicity of 
bromoform or dibromochloromethane were located, although a number of studies examining health 
outcomes in areas with elevated trihalomethanes in tap water have been located.  Chronic animal 
inhalation data are not available for either chemical, and would be useful, especially for 
dibromochloromethane, since it is significantly more volatile (vapor pressure=76 mmHg) than 
bromoform (vapor pressure=5 mmHg).  Chronic-duration studies that identify the critical targets of 
toxicity and establish concentration-response relationships would be useful for deriving chronic-duration 
inhalation MRLs for bromoform and dibromochloromethane.  In the absence of such data, extrapolation 
of observations from the oral route might be possible using appropriate toxicokinetic models.  The 
chronic oral toxicity of bromoform (NTP 1989a; Tobe et al. 1982) and dibromochloromethane (NTP 
1985; Tobe et al. 1982) has been investigated in several studies, and the data are sufficient to identify 
hepatotoxicity as the most sensitive end point and to derive MRL values for both chemicals.  However, in 
both cases, chronic oral MRLs are based on LOAELs for hepatotoxicity, so further studies to define the 
NOAELs would be helpful in reducing uncertainty in the MRL calculations.  No data exist for dermal 
exposure, and further studies (focusing on exposure in water or soil) would be valuable.  
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The carcinogenic effects of chronic oral exposure to bromoform (NTP 1989a) and dibromochloromethane 
(NTP 1985) have been investigated in well designed studies in both rats and mice, and the data suggest 
that both chemicals have carcinogenic potential.  However, effects were limited or equivocal in some 
cases, so additional studies to strengthen the weight of evidence would be valuable.  Of particular interest 
would be studies of the carcinogenic effects when exposure is via drinking water rather than by gavage, 
since drinking water is the most likely route of human exposure, and exposure by gavage (especially 
using oil as a medium) may not be a good model for this.  Also of value would be studies on the 
mechanism of carcinogenicity and on the identity of carcinogenic metabolites.  For example, studies on 
methylene chloride and other volatile halocarbons indicate that metabolism via a glutathione pathway 
may be important in carcinogenicity (e.g., Anderson et al. 1987; Reitz et al. 1989).  Studies to determine 
if dibromochloromethane or bromoform are metabolized by a similar pathway would be helpful in 
evaluating carcinogenic mechanism and risk. 
Genotoxicity.    There have been a number of studies that indicate bromoform and dibromochloro­
methane are genotoxic, both in prokaryotic (LeCurieux et al. 1995; Roldan-Arjona and Pueyo 1993; 
Simmon and Tardiff 1978; Simmon et al. 1977; Varma et al. 1988) and eukaryotic (Benigni et al. 1993; 
Fujie et al. 1993; Landi et al. 1999; Matsuoka et al. 1996; McGregor et al. 1991; Morimoto and Koizumi 
1983; Nestman and Lee 1985; Sobti 1984; Sofuni et al. 1996) organisms.  However, a number of other 
studies have failed to detect significant genotoxic potential for these compounds (Maddock and Kelly 
1980; NTP 1985, 1989a).  The basis for this inconsistency is not entirely obvious, but might be related to 
the efficacy of the test system to activate the parent compound to genotoxic metabolites.  Several in vivo 
studies have also found genotoxic effects following exposure to bromoform (Fujie et al. 1990; Morimoto 
and Koizumi 1983; NTP 1989a) or dibromochloromethane (Fujie et al. 1990; Morimoto and Koizumi 
1983), although other studies have not found effects (Hayashi et al. 1988; Potter et al. 1996; Stocker et al. 
1996). Further studies to define conditions under which these compounds are and are not genotoxic in 
vitro and in vivo may help clarify both the mechanism of genotoxicity and the relevance of this to human 
health risk. Studies on the genotoxic effects of bromoform and dibromochloromethane on germ cells 
(sperm or ova) would also be valuable. 
Reproductive Toxicity. A number of ecological studies have examined the reproductive toxicity to 
women ingesting drinking water contaminated with trihalomethanes (Bove et al. 1992, 1995; Dodds et al. 
1999; Kramer et al. 1992; Mills et al. 1998; Nieuwenhuijsen et al. 2000; Savitz et al. 1995; Waller et al. 
1999). Three of these studies (Kramer et al. 1992; Waller et al. 1999; Windham et al. 2003) measured 
bromoform and dibromochloromethane levels; however, the contribution of the other trihalomethanes to 
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the observed effects cannot be determined from the existing data.  Collectively, the trihalomethane studies 
provide insufficient evidence to establish a causal relationship between exposure to trihalomethanes and 
adverse reproductive outcome.  Animal data are limited to several studies that examined reproductive 
tissues for histological alterations or examined reproductive function following oral exposure to either 
compound. No histological alterations were observed in reproductive tissues following chronic exposure 
to bromoform (NTP 1989a) or dibromochloromethane (NTP 1985).  No significant alterations in 
reproductive performance or fertility were observed in males or females exposed to bromoform (NTP 
1989b). For dibromochloromethane, one study found a marked reduction in fertility at a maternally toxic 
dose level (Borzelleca and Carchman 1982), but no effects on reproductive performance or fertility were 
observed at lower doses (NTP 1986). Multigeneration studies involving oral exposure to bromoform and 
dibromochloromethane would provide useful data on the reproductive potential of these chemicals.  
Based on the oral studies, it does not seem likely that effects would occur following inhalation or dermal 
exposure except at very high levels, but inhalation and dermal exposure studies to confirm this important 
point would be valuable.  
Developmental Toxicity.    Several ecological studies have examined the relationship between 
exposure to trihalomethanes in tap water and the birth outcomes (Dodds et al. 1999; Kramer et al. 1992; 
Savitz et al. 1995). The Kramer et al. (1992) study reported levels for individual trihalomethanes, but this 
study, as well as the other studies, does not provide sufficient evidence for establishing a relationship 
between trihalomethane exposure and adverse birth outcomes.  No other human studies were located for 
bromoform or dibromochloromethane. No inhalation or dermal exposure animal developmental toxicity 
studies were located.  There are limited data on the developmental toxicity of bromoform and dibromo­
chloromethane following oral exposure in animals.  A minor skeletal abnormality was observed in the 
offspring of rats exposed to bromoform during gestation (Ruddick et al. 1983). No developmental effects 
were observed in studies of rat and mouse offspring exposed to dibromochloromethane (Borzelleca and 
Carchman 1982; Ruddick et al. 1983). Additional oral studies on the developmental effects of both 
bromoform and dibromochloromethane in animals would be valuable to determine whether these skeletal 
abnormalities are produced consistently, and whether they lead to significant adverse effects in the 
neonate. If so, then similar studies by the inhalation and dermal routes would also be valuable to define 
safe inhalation levels for developmental effects. 
Immunotoxicity.    The immunotoxic effects of bromoform and dibromochloromethane have been 
investigated in one 14-day oral study (Munson et al. 1982).  That study indicated that both chemicals can 
lead to changes in several immune cell-types in mice.  Similar studies in other species would be valuable 
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in determining if this is a common response.  In addition, longer duration studies and tests of the 
functional consequence of these changes (e.g., resistance to infectious disease) would be especially 
valuable in assessing the biological significance of these effects.  If these studies indicate the immune 
system is a target, then similar studies by inhalation and dermal exposure routes would also be valuable. 
Neurotoxicity.    Numerous studies, both in humans and animals, reveal that central nervous system 
depression is a rapid effect following either oral or inhalation exposure to bromoform; more limited data 
indicate that dibromochloromethane also causes this effect.  While central nervous system depression 
appears to be reversible within a short time after exposure ceases, the possibility of permanent 
neurological damage from high doses has not been thoroughly studied.  Histological studies by NTP 
indicate that sub-depressant doses of bromoform (NTP 1989a) and dibromochloromethane (NTP 1985) 
do not lead to detectable histological changes in the brain, but similar data are not available following 
narcotizing doses. In addition to histological studies, functional studies capable of detecting lasting 
neurological changes would be valuable.  One study of this sort (Balster and Borzelleca 1982) indicates 
that both bromoform and dibromochloromethane can cause some behavioral changes (impaired motor 
performance, decreased exploratory behavior [bromoform only], and decreased response rate in tests of 
operant behavior) at high doses.  Further studies along these lines, perhaps employing more sensitive tests 
of electrophysiological or neurobehavioral changes, would be helpful in determining if this is an effect of 
concern to exposed humans. 
Epidemiological and Human Dosimetry Studies.    No epidemiological or human dosimetry 
studies are currently available for bromoform or dibromochloromethane.  Since only very small quantities 
of these chemicals are produced or used in this country (see Chapter 5), it does not seem likely that a 
sufficiently large subpopulation of exposed workers exists to serve as the basis for a meaningful 
epidemiological study.  Epidemiological studies of populations exposed to low levels of bromoform and 
dibromochloromethane in chlorinated drinking water cannot provide specific data on the human health 
risks of dibromochloromethane or bromoform, since chlorinated drinking water contains hundreds of 
different contaminants. 
Biomarkers of Exposure and Effect.     
Exposure.  The only known biomarker of exposure to bromoform or dibromochloromethane is the level 
of parent compound in blood or in expired air.  However, data on blood or breath levels in humans 
following acute exposure are lacking, due to the rarity of such events.  Since both bromoform and 
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dibromochloromethane are rapidly cleared from the body by exhalation or metabolism, measurements of 
parent compounds in blood or breath are likely to be useful only for a short time (1–2 days) after an 
exposure. Monitoring of humans continuously exposed to the trace levels normally present in chlorinated 
water reveal very low to nondetectable levels in blood or expired air.  The main metabolites of these 
compounds (CO2, CO, Cl-, Br-) are not sufficiently specific to be useful for biomonitoring of exposure.  
Identification of stable and specific biomarkers of exposure (e.g., halomethyl adducts) would be valuable 
in evaluating the exposure history of people around waste sites and other sources where above-average 
levels might be encountered.  
Effect. No specific biomarkers of bromoform- or dibromochloromethane-induced effect are known.  
Neurological, hepatic, and renal effects caused by these chemicals can be detected by standard clinical or 
biochemical tests, but abnormal function in these tissues can be produced by a number of common 
diseases in humans, so detection of abnormal function is not proof that the effect was caused by 
bromoform or dibromochloromethane.  Efforts to identify more specific and sensitive biomarkers of 
bromoform and dibromochloromethane-induced effects would be useful, especially biomarkers (e.g., 
specific DNA adducts) that might be predictive of carcinogenic risk. 
Absorption, Distribution, Metabolism, Excretion.    Limited data indicate that bromoform and 
dibromochloromethane are rapidly and efficiently taken up from the gastrointestinal tract, but further 
studies to confirm and refine available estimates would be valuable.  Toxicokinetic studies to date have 
generally employed exposure by gavage in corn oil, so studies involving exposure via an aqueous vehicle 
would be especially valuable.  No toxicokinetic data exist for inhalation exposure, so quantitative 
estimates of the inhalation absorption fraction, tissue distribution, and excretion rate would be beneficial.  
Also, data on dermal absorption would be helpful, especially from soil or from dilute aqueous solutions, 
since this is how humans are most likely to experience dermal contact near waste sites.  
The pathways of bromoform and dibromochloromethane metabolism have been investigated in several 
laboratories, but quantitative data on the amount of chemical passing through each pathway are limited, 
and the chemical identity of products appearing in urine has not been studied.  Of particular interest 
would be studies that seek to clarify the role of metabolism in toxicity, the mechanism by which 
metabolites and adducts lead to toxic effects, and the importance of protective mechanisms such as 
cellular antioxidants. This would include careful dose-response studies to determine if either activating or 
protective pathways are saturable. 
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Comparative Toxicokinetics.    Available toxicity data indicate that target tissues of bromoform and 
dibromochloromethane are similar in humans, rats, and mice.  Limited data suggest that effect levels are 
generally similar across species, but some distinctions are apparent.  Toxicokinetic studies have revealed 
differences between rats and mice regarding metabolic patterns and clearance rates and these might 
underlie the differences in toxicity between tissues, sexes, and species.  Additional comparative studies in 
animals, with special emphasis on differences in metabolism, would be useful in understanding these 
differences, and in improving inter-species extrapolation.  In addition, in vitro studies of metabolism by 
human liver cells would be valuable in determining which animal species has the most similar pattern of 
metabolism and is the most appropriate model for human toxicity.  Data from studies of this sort could 
then be used to support physiologically-based toxicokinetic models. 
Methods for Reducing Toxic Effects.    Further research is needed to determine strategies designed 
to selectively inhibit the specific P-450 isozymes involved in the metabolism of bromoform or 
dibromochloromethane to reactive intermediates, and thus reduce the toxic effects.  Because bromoform 
or dibromochloromethane are thought to be metabolized by glutathione conjugation (DeMarini et al. 
1997; Pegram et al. 1977; Ross and Pegram 2003), further research is needed to determine if 
administration of sulfhydryl compounds, such as L-cysteine, reduced GSH or N-acetylcysteine, as 
glutathione surrogates might provide protection against nephrotoxicity or hepatotoxicity induced due to 
depleted glutathione stores.  Research on using dietary supplements for mitigating adverse effects of 
chronic exposure to bromoform or dibromochloromethane would be helpful, especially in the case of 
chronic exposure from chlorinated drinking water.  
Children’s Susceptibility. Data needs relating to both prenatal and childhood exposures, and 
developmental effects expressed either prenatally or during childhood, are discussed in detail in the 
Developmental Toxicity subsection above. 
The available human data for bromoform are mostly from case reports of accidental orally-administered 
overdose in children.  No data exist on the toxicity of dibromochloromethane following oral 
administration in children, or of bromoform or dibromochloromethane following inhalation or dermal 
exposure in children.  The developmental effects of oral exposure to bromoform and dibromochloro­
methane have not been extensively investigated, but limited data suggest that these chemicals have 
relatively low toxicity on the developing fetus (Borzelleca and Carchman 1982; Ruddick et al. 1983).  
However, these studies did not examine neurodevelopmental end points that may be a sensitive target.  
Additional animal studies assessing the neurodevelopmental toxicity of bromoform and dibromochloro­
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methane would be useful.  Toxicokinetic studies examining how aging can influence absorption rates 
would be useful in assessing children’s susceptibility to the toxicity of bromoform or dibromochloro­
methane. 
Child health data needs relating to exposure are discussed in Section 6.8.1, Identification of Data Needs:  
Exposures of Children. 
3.12.3 Ongoing Studies 
No ongoing studies on the health effects of bromoform or dibromochloromethane were listed in the 
Federal Research in Progress database (FEDRIP 2004). 
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4.1 CHEMICAL IDENTITY  
Information regarding the chemical identity of bromoform and dibromochloromethane is located in 
Table 4-1. 
4.2 PHYSICAL AND CHEMICAL PROPERTIES  
Information regarding the physical and chemical properties of bromoform and dibromochloromethane is 
located in Table 4-2. 
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Table 4-1. Chemical Identity of Bromoform and Dibromochloromethane 
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CAS = Chemical Abstracts Service; DOT/UN/NA/IMCO = Department of Transportation/United Nations/North 
 
America/International Maritime Dangerous Goods Code; EPA = Environmental Protection Agency;
 
HSDB = Hazardous Substances Data Bank; NCI = National Cancer Institute; NIOSH = National Institute for 
 
Occupational Safety and Health; OHM/TADS = Oil and Hazardous Materials/Technical Assistance Data System; 
 
RTECS = Registry of Toxic Effects of Chemical Substances
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Property Bromoform Dibromochloromethane Reference 
Molecular weight 252.73 208.28 O’Neil et al. 2001 
Color Colorless Colorless to pale yellow Verschueren 2001 
Physical state Liquid Liquid Verschueren 2001 
Melting point 8.0 °C -20 °C Lide 2000 
Boiling point 149.1 °C 120 °C Lide 2000 
Density at 20 °C 2.899 2.451 Lide 2000 
Odor Sweet, similar to No data Verschueren 2001 
chloroform 
Taste Similar to chloroform No data Lewis 1997 
Odor threshold: 
Water 0.51 mg/L No data Amoore and Hautala 1983
 Air 13.45 mg/m3 No data Amoore and Hautala 1983 
Solubility: 
 Water 3.10x103 mg/L (25 °C) 2.7x103 mg/L (20 °C) Horvath 1982; Heikes 
1987 
Organic solvents Miscible in ethanol, Soluble in ethanol, ether, Lide 2000 
benzene, petroleum acetone 
ether, acetone, oils 
Corrosivity Will attack some forms of No data HSDB 2004a 
plastics, rubber, and 
coatings. 
Partition coefficients: 
 Log octanol/water 2.4 2.16 CITI 1992; Sangster 1994
 Log Koc 2.06 1.92 Mabey et al. 1982 
Vapor pressure at 20 °C 5 mmHg 76 mmHg Mabey et al. 1982 
Vapor density 8.7 (air=1) No data IARC 1991a, 1991b 
Henry’s law constant 5.6x10-4 atm-m3/mol 9.9x10-4 atm-m3/mol Mabey et al. 1982 
Surface tension 41.53 dynes/cm No data Lewis 1997 
Heat of vaporization 46.05 KJ/mol (25 °C) No data Lide 2000 
Autoignition No data No data 
temperature 
Flashpoint No data No data 
Flammability limits Non-flammable Non-flammable HSDB 2004a, 2004b 
Conversion factor 1 ppm = 10.34 mg/m3 1 ppm = 8.52 mg/m3 IARC 1999a, 1999b 
1 mg/m3 = 0.097 ppm 1 mg/m3 = 0.12 ppm 
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5.1 PRODUCTION 
Bromoform may be prepared from acetone and sodium hypobromite, by treating chloroform with 
aluminum bromide, or by electrolysis of potassium bromide in ethyl alcohol (HSDB 2004a; Stenger 
1978). 
Bromoform is currently produced by Geoliquids, Inc., Prospect Heights, Illinois and Sigma-Aldrich Fine 
Chemicals (SRI 2004).  Bromoform was produced formerly by Dow Chemical Company, Midland, 
Michigan. In 1975, production of bromoform in the United States was estimated to be <500 metric tons 
(<1 million pounds) and the 1977 production was estimated at 50–500 metric tons (100,000–1 million 
pounds) (NTP 1989a; Orrell and Mackie 1988; Perwak et al. 1980).  The production volume of 
bromoform reported by manufacturers in 1990, 1994, and 1998 was within the range of 10,000– 
500,000 pounds (5–230 metric tons) (IUR 2002).  Production volume data were not listed for reporting 
year 2002. 
Dibromochloromethane can be prepared by the addition of dibromochloroacetone to 5N sodium 
hydroxide (IARC 1991b).  It can also be prepared by reaction of a mixture of chloroform and bromoform 
with triethylbenzylammonium chloride and sodium hydroxide (IARC 1991a).  Available information 
indicates that dibromochloromethane is no longer produced commercially in the United States (SRI 
2004). 
Both bromoform and dibromochloromethane are inadvertently generated during water chlorination when 
chlorine reacts with endogenous organic materials such as humic and fulvic acid (Rook 1977).  When 
chlorine is added to water, hypochlorous acid is formed (Wallace 1997).  Hypochlorous acid reacts with 
humic or fulvic acids in the water to produce chloroform or it can oxidize any bromide ion that is present 
to form hypobromous acid, which leads to the formation of bromoform, dibromochloromethane, or 
bromodichloromethane.  It is estimated that 17 kkg of bromoform and 204 kkg of dibromochloromethane 
were generated in this way in 1978 (Perwak et al. 1980).  According to a model generated by Clark et al. 
(1996), higher bromide to chloride ratios promote the bromine substitution reaction over the chlorine 
substitution reaction with organic matter in chlorinated water.  At higher bromide concentrations, levels 
of chloroform decreased, while levels of bromoform increased.  Dibromochloromethane was found to 
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increase to a maximum level for bromide concentrations of 2.5 mg/L and then decline with increasing 
bromide concentration (Clark et al. 1996). 
Table 5-1 summarizes information on companies that reported the production, import, or use of 
bromoform for the Toxics Release Inventory in 2002 (TRI02 2004).  The TRI data should be used with 
caution since only certain types of facilities are required to report.  This is not an exhaustive list. 
5.2 IMPORT/EXPORT 
Orrell and Mackie (1988) estimated that 6–9 kkg of bromoform were imported by Freeman Industries in 
the late 1980s.  No current information was located on the import of bromoform and dibromochloro­
methane, but it is likely that little, if any, is imported. 
5.3 USE 
Bromoform is used in geological assaying as a heavy liquid for mineral ore separations based on 
differences in specific gravity (Verschueren 2001).  It is used in the electronics industry in quality 
assurance programs (Orrell and Mackie 1988).  Bromoform has been used as a catalyst, initiator, or 
sensitizer in polymer reactions and in the vulcanization of rubber (HSDB 2004a).  As a solvent, 
bromoform has been used for waxes, greases, and oils as well as for liquid-solvent extractions and nuclear 
magnetic resonance (NMR) studies (Lewis 1997; NTP 1989a).  Former uses of bromoform include a fire-
resistant chemical ingredient, a gauge fluid ingredient, an intermediate in chemical syntheses, and a 
sedative and antitussive agent (HSDB 2004a; Perwak et al. 1980). 
Dibromochloromethane is used in laboratory quantities only and there is no current commercial use for 
this compound (Perwak et al. 1980).  Dibromochloromethane was used formerly as a chemical 
intermediate in the production of fire extinguishing agents, aerosol propellants, refrigerants, and 
pesticides (IARC 1991b). 
5.4 DISPOSAL 
Because bromoform and dibromochloromethane are listed as hazardous substances, land disposal of 
wastes containing these compounds is controlled by a number of federal regulations (see Chapter 8).   
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Table 5-1. Facilities that Produce, Process, or Use Bromoform 
Number of Minimum amount on site Maximum amount 
Statea facilities in poundsb on site in poundsb Activities and usesc 
AR 5 0 
 999,999  1, 2, 4, 9, 12, 13 

CA 1 100 
 999 12 

LA 2 0 
 999 1, 5, 13 

MS 1 0 
 99 12 

NE 1 10,000 
 99,999 12 

OH 1 1,000 
 9,999 12 

TX 2 1,000 
 999,999 12 

Source: TRI02 2004 (Data are from 2002) 
aPost office state abbreviations used 
bAmounts on site reported by facilities in each state 
cActivities/Uses: 
1. Produce 6. Impurity 11. Chemical Processing Aid 
2. Import 7. Reactant 12. Manufacturing Aid  
3. Onsite use/processing 8. Formulation Component 13. Ancillary/Other Uses 
4. Sale/Distribution 9. Article Component 14. Process Impurity 
5. Byproduct 10. Repackaging 
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Wastes containing dibromochloromethane or bromoform may be incinerated by rotary kiln, liquid 
injection, or fluidized bed methods.  CERCLA reportable quantities for bromoform and dibromochloro­
methane released to the environment are those quantities ≥100 pounds or 45.4 kg. 
The amount of bromoform and dibromochloromethane released or disposed of through industrial and/or 
laboratory use of these chemicals is not known, but is considered to be insignificant compared to the 
amount inadvertently generated by water chlorination processes (EPA 1987c; HSDB 2004a; Perwak et al. 
1980). 
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6.1 OVERVIEW 
Bromoform has been identified in at least 140 sites while dibromochloromethane has been identified in at 
least 174 sites of the 1,662 hazardous waste sites that have been proposed for inclusion on the EPA 
National Priorities List (NPL) (HazDat 2005).  However, the number of sites evaluated for bromoform 
and dibromochloromethane is not known.  The frequency of these sites can be seen in Figures 6-1 and 
6-2, respectively.  Of these sites, 137 of the 140 bromoform sites are located within the United States, 1 is 
located in the Virgin Islands (not shown), and 2 are located in the Commonwealth of Puerto Rico (not 
shown). For dibromochloromethane, 172 of the 174 sites are located within the United States, 1 is 
located in the Virgin Islands, and 1 is located in the Commonwealth of Puerto Rico. 
The principal route of human exposure to dibromochloromethane and bromoform is from the 
consumption of chlorinated drinking water.  These chemicals are thought to form in the water as by-
products from the reaction of chlorine with dissolved organic matter and bromide ions.  Dibromochloro­
methane and bromoform concentrations in water are quite variable, but average levels are usually 
<5 µg/L. 
Most dibromochloromethane and bromoform tend to volatilize from water when exposed to the air.  The 
fate of these chemicals in air has not been investigated, but it is likely they are relatively stable, with half-
lives of about 1–2 months.  Most measurements of the concentration of these chemicals in air indicate that 
levels are quite low (<10 ppt). 
Neither chemical is strongly adsorbed from water by soil materials, and it is likely that both readily 
migrate in groundwater. Neither chemical appears to be easily biodegradable under aerobic conditions, 
but they may readily biodegrade under anaerobic conditions.  
6.2 RELEASES TO THE ENVIRONMENT 
The TRI data should be used with caution because only certain types of facilities are required to report 
(EPA 1997). This is not an exhaustive list.  Manufacturing and processing facilities are required to report  
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information to the Toxics Release Inventory only if they employ 10 or more full-time employees; if their 
facility is classified under Standard Industrial Classification (SIC) codes 20–39; and if their facility 
produces, imports, or processes ≥25,000 pounds of any TRI chemical or otherwise uses >10,000 pounds 
of a TRI chemical in a calendar year (EPA 1997). 
Bromoform and dibromochloromethane have been identified in a variety of environmental media (air, 
surface water, groundwater, soil, and sediment) collected at 140 and 174 of the 1,662 NPL hazardous 
waste sites, respectively (HazDat 2005). 
6.2.1 Air 
Estimated releases of 12 pounds (0.01 metric tons) of bromoform to the atmosphere from 3 domestic 
manufacturing and processing facilities in 2002, accounted for about 3% of the estimated total 
environmental releases (TRI02 2004).  These releases are summarized in Table 6-1. 
Bromoform has been identified in air samples collected at 7 of the 140 NPL hazardous waste sites where 
it was detected in some environmental media (HazDat 2005).  Dibromochloromethane has been identified 
in air samples collected at 1 of the 174 NPL hazardous waste sites where it was detected in some 
environmental media. 
The average concentration of dibromochloromethane in uncontrolled emissions from 40 medical waste 
incinerators in the United States and Canada was 0.96 µg/kg waste (Walker and Cooper 1992).  The 
average concentration in controlled emissions was 536 µg/kg waste. 
Quack and Wallace (2003) estimated that the annual global flux of bromoform of 3–22 Gmol/year with 
the main source being sea-to-air emissions from macroalgal and planktonic bromoform production.  
Estimated anthropogenic emission rates for bromoform are 34 Mmol/year from coastal power plants, 
4 Mmol/year from inland nuclear power plants, 280 Mmol/year from coastal fossil fuel plants, 
14 Mmol/year from inland fossil fuel plants, 2 Mmol/year from desalination power plants, 12 Mmol/year 
from water disinfection processes giving a total of 346 Mmol/year from all anthropogenic sources (Quack 
and Wallace 2003).  Emissions of bromoform from a commercial rice paddy in Houston, Texas were 
reported to range from 0.012 to 0.032 µg/m2/hour with a median emission rate of 0.021 µg/m2/hour 
(Redeker et al. 2003).  The mean annual concentrations of bromoform in air extracted from deep firn air  
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Reported amounts released in pounds per yearb 
Total release 
Statec RFd Aire Waterf UIg Landh Otheri On-sitej Off-sitek On- and off-site 
AR 1 7 0 0 0 0 7 0 7 
LA 1 0 456 0 0 0 456 0 456 
NE 1 5 0 0 0 0 5 0 5 
Total 3 12 456 0 0 0 468 0 468 
Source: TRI02 2004 (Data are from 2002) 
aThe TRI data should be used with caution since only certain types of facilities are required to report.  This is not an 

exhaustive list.  Data are rounded to nearest whole number. 

bData in TRI are maximum amounts released by each facility. 

cPost office state abbreviations are used. 

dNumber of reporting facilities. 

eThe sum of fugitive and point source releases are included in releases to air by a given facility. 

fSurface water discharges, waste water treatment-(metals only), and publicly owned treatment works (POTWs)
 
(metal and metal compounds).
 
gClass I wells, Class II-V wells, and underground injection. 
 
hResource Conservation and Recovery Act (RCRA) subtitle C landfills; other on-site landfills, land treatment, surface 
 
impoundments, other land disposal, other landfills. 
 




jThe sum of all releases of the chemical to air, land, water, and underground injection wells. 
 
kTotal amount of chemical transferred off-site, including to POTWs. 
 
RF = reporting facilities; UI = underground injection 
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were 1.35 and 0.20 ppt at two Antarctic locations (Sturges et al. 2001).  Mean annual concentrations of 
dibromochloromethane were 0.20 and 0.14 ppt. 
No other studies were located regarding the amount of bromoform and dibromochloromethane released 
into the atmosphere from laboratories, chemical plants, or chemical waste sites.  However, since neither 
compound is produced or used in large quantities (Perwak et al. 1980), atmospheric emissions from these 
sources are probably small. 
6.2.2 Water 
Estimated releases of 456 pounds (0.21 metric tons) of bromoform to surface water and publicly owned 
treatment works from three domestic manufacturing and processing facilities in 2002, accounted for about 
97% of the estimated total environmental releases (TRI02 2004).  These releases are summarized in 
Table 6-1. 
Bromoform has been identified in surface water samples and groundwater samples collected at 14 and 
103 of the 140 hazardous waste sites, respectively, where it was detected in some environmental media.  
Dibromochloromethane has been identified in surface water samples and groundwater samples collected 
at 15 and 146 of the 174 hazardous waste sites, respectively, where it was detected in some environmental 
media (HazDat 2005). 
The principal anthropogenic source of bromoform and dibromochloromethane in the environment is 
chlorination of water containing organic materials (Bellar et al. 1974; EPA 1980a; Peters et al. 1994; 
Rook 1977; Rodriguez et al. 2004; Symons et al. 1975, 1993).  It has been estimated that the total 
amounts of bromoform and dibromochloromethane generated by chlorinating U.S. drinking water in 
1978 were 17 and 204 kkg, respectively (Perwak et al. 1980).  Bromoform and dibromochloromethane 
were detected in the distribution systems of three water treatment plants that each use different methods 
of water chlorination (LeBel et al. 1997).  Mean monthly concentrations of dibromochloromethane were 
0.2 µg/L in samples from the chlorine-chloramine treatment plant, 0.3 µg/L in samples from the chlorine-
chlorine treatment plant, and 0.1 µg/L in samples from the ozone-chlorine treatment plant.  Mean monthly 
bromoform concentrations were <0.1 µg/L in samples from all three plants. 
Unlike the chlorination of low-bromide fresh water where chloroform is the trihalomethane produced in 
the largest amounts, bromoform is the trihalomethane usually produced in the largest amounts during the 
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chlorination of sea water or high-bromide fresh water (Khalanski 2003; Richardson et al. 2003).  The 
concentrations of bromoform in the chlorinated cooling water at three European marine power stations on 
the English Channel were 25.16, 11.4, and 18.23 µg/L (Khalanski 2003).  Richardson et al. (2003) 
measured bromoform concentrations of 23.3, 57, 59, 44, and 55 µg/L in high-bromide water from the Sea 
of Galilee in Israel after a pre-chlorination step during the months of December, May, September, 
November, and July, respectively.  Concentrations of dibromochloromethanein these samples were 
reported only for the months of May, September, and July (9.39, 1.9, and 3.7 µg/L, respectively). 
Ozonation of water containing bromide ion has also been shown to be a source of bromoform in the 
environment (Glaze et al. 1989; Huang et al. 2003).  Bromoform levels were 1.4, 3.7, and 2.1 mg/L in 
California State Project Water samples after ozonation at the Los Angeles Aqueduct Filtration Plant in 
1987 at ozone doses of 1.0, 2.0, and 4.0 mg/L, respectively (Glaze et al. 1989).  Huang et al. (2004) 
reported that bromoform generation is greater in waters with higher organic matter content.   
Release of dibromochloromethane and bromoform into groundwater has been shown to occur as a 
consequence of the yearly aquifer storage and recovery (ASR) in the Las Vegas Valley.  As an example, it 
is estimated that up to 16.3x106 m3 water was injected into the underlying aquifer during the winter 
months of 1995–1996, when demand for water by neighboring Las Vegas was low (Thomas et al. 2000).  
Because the recharge water is chlorinated before injection, byproducts of this disinfection process are 
introduced into the groundwater at concentrations measured during the 1995–1996 ASR recharge seasons 
of 18 µg/L for dibromochloromethane and 2.6 µg/L for bromoform in the recharge water.  During the 
water recovery phase beginning in the spring of 1996, initial concentrations of dibromochloromethane 
and bromoform in water recovered from one recharge well (#14) in the spring of 1996 were below 
detection limits (0.5 µg/L) but were much higher, 15 and 2.4 µg/L, respectively, in a second well (#51).  
Dibromochloromethane and bromoform levels in water recovered from the second well fell during the 
remaining spring and summer months decreasing to concentrations of 1.5 and 0.6 µg/L, respectively, in 
September of 1996.  The differences in the concentrations of dibromochloromethane and bromoform 
between wells 14 and 51, and the decrease in concentrations observed in water recovered from well 
51 during the spring and summer recovery months of 1996, were attributed to both dilution of the 
recharge water in the aquifer with natural water from the surrounding aquifer basin and biotransformation 
of the trihalomethanes within the aquifer.    
Dibromochloromethane and bromoform may also occur as a consequence of chlorinating industrial waste 
waters (Perry et al. 1979).  Staples et al. (1985) reported that bromoform was detected in 60 of 
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1,346 samples of industrial waste effluent, at a median concentration of <5 µg/L, and dibromochloro­
methane was detected in 84 of 1,298 samples at a median concentration of <2.4 µg/L. These values are 
not significantly higher than those for typical chlorinated water (see Section 5.4.2), suggesting that 
industrial discharge may not be a major source of release. 
Bromoform and dibromochloromethane were detected in New York City municipal waste water samples 
taken from 1989 to 1993 (Stubin et al. 1996).  Influent concentrations ranged from 7 to 40 µg/L for 
bromoform with a frequency of detection of 4% and 9 µg/L for dibromochloromethane with a frequency 
of detection of 1%.  Effluent concentrations ranged from 3 to 11 µg/L for bromoform with a frequency of 
detection of 11% and from 2 to 15 µg/L for dibromochloromethane with a frequency of detection of 8%.  
Moschandreas et al. (1997) studied samples from 14 New York City waste water pollution control plants 
to determine the organic compound concentrations in the waste water at each of the plants.  Bromoform 
was detected with concentrations of 0.4–10 µg/L in raw influent samples, 2.0–9.0 µg/L in primary 
influent samples, 1.0–10 µg/L in primary effluent samples, 0.3–11 µg/L in aeration tank samples, 0.4– 
12 µg/L in superficial of return activated sludge samples, and 0.2–12 µg/L in plant effluent samples.  
Only the plant effluent concentration range (0.3–5.0 µg/L) was reported for dibromochloromethane. 
Although most raw water samples collected from different points of the Great Lakes in 1990 contained 
trihalomethanes at concentrations <2 µg/L, mean concentrations in treated water samples from four of the 
six locations were above 25 µg/L (Henshaw et al. 1993). The low trihalomethane concentrations of the 
other two locations are attributed to the use of alternative methods of water treatment such as ammonia 
addition and potassium permanganate disinfection. 
The average concentration of dibromochloromethane in sewage treatment effluents in England and Wales 
in 1995 was 0.2007 µg/L with a frequency of detection of 30.4% (Stangroom et al. 1998a).  The average 
concentration of dibromochloromethane in trade effluents in England and Wales in 1995 was 7.91 µg/L 
with a frequency of detection of 63%. 
Mean dibromochloromethane concentrations were determined to be 2 ng/L in water and sediment samples 
taken from the anoxic fjord Idefjorden between Norway and Sweden near the city of Halden, Norway 
(Abrahamsson and Klick 1989).  Dibromochloromethane was detected in effluent water from a nearby 
paper pulp mill. 
133 BROMOFORM AND DIBROMOCHLOROMETHANE 
6. POTENTIAL FOR HUMAN EXPOSURE 
Class et al. (1986) observed trace levels of dibromochloromethane and bromoform and other halogenated 
methanes in sea water (0.1–6 ng/L) and in the air (0.1–20 ppt) at several locations in the Atlantic.  Other 
studies have reported atmospheric bromoform concentration ranges of 1.0–22.7 pptv off the coast of 
Galway, Ireland, 0.7–8.0 pptv off the coast of northwestern Tasmania, 0.28–2.9 pptv in the West Pacific 
Islands, 0.32–7.1 pptv in the Asian Seas, and 1.0–37.4 pptv off the Antarctic Peninsula (Carpenter et al. 
1999, 2003).  Dibromochloromethane was also detected off the coasts of Galway, Ireland and 
northwestern Tasmania with atmospheric concentrations of 0.13–1.8 and 0.1–1.4 pptv, respectively.  The 
presence of these compounds can be attributed to biosynthesis and release of bromochloromethanes by 
macroalgae (Carpenter et al. 1999; Class et al. 1986; Gschwend et al. 1985; Marshall et al. 2003; Quack 
and Wallace 2003).  Gschwend et al. (1985) estimated that marine algae could be a major global source of 
volatile organobromides.  More recently, Carpenter and Liss (2000) estimated that macroalgae produce 
around 70% of the world’s bromoform, which is greater than what was previously estimated due to 
updated seaweed biomass estimates.  However, Class et al. (1986) states that this source accounts for 
<1% of the anthropogenic burden of total organohalogens in the atmosphere.  
6.2.3 Soil 
There were no releases to the ground either through soil or underground injection from three domestic 
manufacturing and processing facilities in 2002 (TRI02 2004).  This information is summarized in 
Table 6-1. 
Bromoform has been identified in soil and sediment samples collected at 26 and 3 of the 140 NPL 
hazardous waste sites, respectively, where it was detected in some environmental media.  Dibromochloro­
methane has been identified in soil and sediment samples collected at 21 and 4 of the 174 NPL hazardous 
waste sites, respectively, where it was detected in some environmental media (HazDat 2005). 
Soils and other unconsolidated surficial materials may become contaminated with bromoform and 
dibromochloromethane by chemical spills, the landfilling of halomethane-containing solid wastes, or the 
discharge of chlorinated water. However, no data were located to suggest that land releases are a 
significant source of the chemicals in the environment. 
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6.3 ENVIRONMENTAL FATE 
6.3.1 Transport and Partitioning 
Bromoform and dibromochloromethane are slightly volatile liquids, and tend to exist primarily as vapors 
in the atmosphere.  The vapor pressure of bromoform is 0.007 atm at 20 °C (Mabey et al. 1982), and the 
vapor pressure of dibromochloromethane at 20 °C is approximately 0.1 atm (Mabey et al. 1982).  The 
half-time of evaporation from flowing, aerated water (e.g., rivers and streams) has been estimated to 
range from 1 to 581 hours for bromoform and from 0.7 to 398 hours for dibromochloromethane (Kaczmar 
et al. 1984; Mackay et al. 1982).  
Both dibromochloromethane and bromoform are moderately soluble in water (Callahan et al. 1979; 
Heikes 1987), and so each may be removed from the air by being dissolved into clouds or raindrops.  
Estimates of the Henry's law constant (H) (the tendency of a chemical to partition between its vapor phase 
and water) for bromoform range from 4.3 to 5.6x10-4 atm-m3/mole, and from 8.7 to 9.9x10-4 atm-m3/mole 
for dibromochloromethane (Mabey et al. 1982; Mackay and Shiu 1981; Munz and Roberts 1987; 
Nicholson et al. 1984).  The magnitude of these values suggest that the two halomethanes will tend to 
partition to both water and air. 
It is not known if either compound can be adsorbed by airborne particulate matter that is subject to 
atmospheric dispersion, gravitational settling, or wash-out by rain.  Particle adsorption is probably not an 
important transport mechanism because these chemicals occur at such low concentrations in the 
atmosphere. 
Bromoform and dibromochloromethane have a minor tendency to be adsorbed by soils and sediments.  
Calculated and measured values of Koc (the organic carbon/water partition coefficient, an index of the 
relative mobility of a material in water-soil systems) for bromoform range from 62 to 126 (Hassett et al. 
1983; Hutzler et al. 1986; Mabey et al. 1982).  These relatively low values imply that bromoform will 
exhibit only a minor affinity for soil materials and will tend to be highly mobile (Roy and Griffin 1985).  
This low tendency for adsorption to soil has been confirmed in laboratory studies by Curtis et al. (1986) 
and in field studies by Roberts et al. (1986). 
A similar Koc value of 57 has been estimated for dibromochloromethane, based on its measured water 
solubility (Heikes 1987). No studies were located on the adsorption of dibromochloromethane by soils or 
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soil materials, but it is likely that dibromochloromethane will have properties generally similar to those of 
bromoform. 
Bromoform and dibromochloromethane may be slightly bioconcentrated by aquatic organisms.  The 
octanol/water partition coefficient (Kow) (an index of the partitioning of a compound between octanol and 
water) is approximately 240 for bromoform and 170 for dibromochloromethane (Mabey et al. 1982).  The 
magnitudes of these values suggest that the chemicals will tend to partition to fat tissues of aquatic 
organisms. No studies were located regarding the bioconcentration factor (BCF) for dibromochloro­
methane or bromoform, but based on measured BCFs for similar compounds (Kenaga 1980), the BCF of 
dibromochloromethane and bromoform may be on the order of 2–10.  It is not known if these chemicals 
can be transferred through food chains to higher trophic levels, but this seems unlikely to be of major 
concern. 
The percent removal of dibromochloromethane measured at the outlet of a waste-water-dependent 
constructed wetland near Phoenix, Arizona was 86.5% (Keefe et al. 2004).  The authors concluded that 
volatilization was the primary removal mechanism.  
6.3.2 Transformation and Degradation  
6.3.2.1 Air 
Based on the behavior of similar compounds, it seems likely that bromoform and dibromochloromethane 
may be degraded by photooxidative interactions with atmospheric OH radicals.  Radding et al. (1977) 
proposed that the atmospheric half-life of bromoform and dibromochloromethane is approximately 1– 
2 months, but this has not been confirmed by direct experimental measurements. 
6.3.2.2 Water 
Both dibromochloromethane and bromoform are relatively stable in water, with estimated hydrolytic rate 
constants of 3.2x10-11 sec-1 and 8x10-11 sec-1 (Mabey and Mill 1978).  These rate constants correspond to 
hydrolytic half-lives of 686 and 274 years for bromoform and dibromochloromethane, respectively.  
No information was located on oxidation or photolysis of these chemicals in water, but it is not expected 
that either is a significant degradative pathway. 
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It has been found that dibromochloromethane and bromoform undergo only limited biodegradation (10– 
25%) under aerobic conditions, although the rate may increase somewhat after microbial adaptation 
(Bouwer et al. 1981; Tabak et al. 1981a).  Bromoform, at initial concentrations ranging from 132 to 
177 µg/L, underwent >99% reduction in a continuous-flow biofilm column seeded with primary settled 
sewage with 1.5 hours packed-bed detention time (Cobb and Bouwer 1991).  Under anaerobic conditions, 
dibromochloromethane and bromoform have been found to be readily biodegraded in the presence of 
methane-producing bacteria (Bouwer and McCarty 1983a; Bouwer et al. 1981), and under denitrifying 
and sulfate-reducing conditions in batch and column experiments (Bouwer and McCarty 1983b; Bouwer 
and Wright 1986).  There is also some field evidence that trihalomethanes degrade in anaerobic 
groundwater (Bouwer et al. 1981), with half-lives estimated to be between 21 and 42 days (Bouwer and 
McCarty 1984).  Increased degradation rates were observed for bromoform and dibromochloromethane 
under conditions similar to those found inside ferrogenic aquifers, especially at higher pH (Kenneke et al. 
2003; Pecher et al. 2002). Bouwer and Wright (1986) reported that one degradation product of 
bromoform was dibromomethane, but there was no additional information on the identity or fate of 
environmental degradation by-products.  Bromoform was not degraded in enriched sea water cultures 
taken from beds of the giant kelp, M. pyrifera off the coast of California after 40 days (Goodwin et al. 
1997). 
The concentration of bromoform decreased from 58 µg/L to <1 µg/L in water stored in an aquifer 7 days 
after recharge with chlorinated water (Nicholson et al. 2002).  The concentration of dibromochloro­
methane decreased from 46 to 3 µg/L 28 days after recharge.  The authors stated that the main attenuation 
processes were most likely adsorption and degradation under methanogenic conditions.  McQuarrie and 
Carlson (2003) suggest that aquifer storage may be a potential method for the removal of disinfection 
byproducts such as bromoform and dibromochloromethane from treated water.  
6.3.2.3 Sediment and Soil 
No studies were located regarding the biodegradation of dibromochloromethane or bromoform in soil.  It 
is expected that observations regarding biodegradation rates in aerobic and anaerobic aqueous media 
(above) will be generally applicable to degradation rates in moist soils. 
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6.3.2.4 Other Media  
No information was located on the transformation and degradation of bromoform or dibromochloro­
methane in other media. 
6.4 LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT  
Reliable evaluation of the potential for human exposure to bromoform and dibromochloromethane 
depends in part on the reliability of supporting analytical data from environmental samples and biological 
specimens. Concentrations of bromoform and dibromochloromethane in unpolluted atmospheres and in 
pristine surface waters are often so low as to be near the limits of current analytical methods.  In 
reviewing data on bromoform and dibromochloromethane levels monitored or estimated in the 
environment, it should also be noted that the amount of chemical identified analytically is not necessarily 
equivalent to the amount that is bioavailable.  The analytical methods available for monitoring 
bromoform and dibromochloromethane in a variety of environmental media are detailed in Chapter 7. 
6.4.1 Air 
Dibromochloromethane and bromoform are usually found in air only at very low concentrations.  
Brodinsky and Singh (1983) tabulated data on dibromochloromethane and bromoform levels in ambient 
air from five urban locations across the United States.  For dibromochloromethane, 63 of 89 samples were 
below the detection limit, the mean value was 3.8 ppt (32 ng/m3), and the highest value was 27 ppt 
(230 ng/m3). For bromoform, 60 of 78 samples were below the detection limit, the mean value was 
3.6 ppt (37 ng/m3) and the highest value was 71 ppt (730 ng/m3). Forty-six air samples collected near 
four chemical plants in Arkansas contained a mean bromoform concentration of 0.9 ppt (9 ng/m3) 
(Pellizzari 1978). The mean dibromochloromethane concentration was 0.08 ppt (0.8 ng/m3), but 54 of 
56 measurements were <0.05 ppt (0.5 ng/m3). 
Fischer et al. (2000) found a nearly constant mixing ratio of bromoform at 0.5 parts per trillion by volume 
(pptv) in the marine troposphere of the Atlantic across 30 °W longitude.  In the coastal region of South 
America, bromoform concentrations were 2.4 pptv. A high concentration of bromoform (2.0 pptv) was 
found in an air sample taken near Cape Verde Island.  Air mixing ratios for bromoform in samples taken 
above the waters of the equatorial Pacific during the third joint Soviet-American Gases and Aerosols 
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(SAGA 3) experiment ranged from 0.68 to 3.28 pptv using the charcoal or Tenax adsorption method and 
from 0.5 to 6.7 pptv using the canister collection method (Atlas et al. 1993).  Air mixing ratios for 
dibromochloromethane ranged from 0.09 to 0.49 pptv using the charcoal or Tenax adsorption method.  
Dibromochloromethane was not measured with the canister collection method.  The mean concentration 
of bromoform in ambient air samples collected in the Arctic Circle was 5.1 ppt (53 ng/m3) (Berg et al. 
1984). 
During the Urban Air Toxics Monitoring Program, concentrations of bromoform and dibromochloro­
methane at 13 air monitoring sites located in Vermont, New Jersey, Louisiana, and Texas were <1 parts 
per billion by volume (ppbv) (no detection limit given) (Mohamed et al. 2002).  Bromoform was not 
detected in air samples from three permanent sites in Arizona (Tucson, Payson, and Casa Grande) during 
the Arizona Hazardous Air Pollutants Monitoring Program, though the detection limit was not specified 
(Zielinska et al. 1998).  Bromoform was detected at a fourth permanent site in Phoenix with a maximum 
concentration of 0.02 ppbv, although the average bromoform concentration at this site was below the 
detection limit.  Bromoform was not detected (detection limit unspecified) in air samples collected from 
13 semi-rural to urban locations in Maine, Massachusetts, New Jersey, Pennsylvania, Ohio, Illinois, 
Louisiana, and California (Pankow et al. 2003).  However, dibromochloromethane was detected at 
Kettering, Ohio at a concentration of 0.007 ppbV. This concentration was below the lowest daily 
standard of 0.057 ppbV.  Neither bromoform nor dibromochloromethane were detected (detection limit 
not specified) in air samples from 13 locations in Texas, Louisiana, New Jersey, and Vermont (Mohamed 
et al. 2002). 
The mean, minimum, and maximum concentrations of dibromochloromethane in air samples taken during 
the Southern California Ozone Study in 1997 were 0.02 ppbv (210 ng/m3), 0.04 ppbv (420 ng/m3), and 
0.01 ppbv (105 ng/m3), respectively at a residential/industrial site in Mexicali, Mexico (Zielinska et al. 
2001).  Dibromochloromethane was not detected at a residential site in Rosarito, Mexico (no detection 
limit given).  Dibromochloromethane was detected at 24 ppb (0.210 mg/m3) in Finnish industrial air 
samples medical industry preparing solutions and at 1.6 ppb (0.014 µg/m3) in suburban air from Turku, 
Finland (Kroneld 1989a, 1989b).  Dibromochloromethane was not detected in countryside air samples 
taken from the Islands of Inio at the southwest coast of Finland. Mean concentrations of bromoform 
detected in air samples collected at two locations in the city of Kaohsiung, Taiwan during the spring of 
2002 were 0.25 and 1.00 µg/m3 (Lai et al. 2004). 
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Bromoform was detected with an occurrence rate of 54% in indoor air samples taken from 26 houses, 
although actual concentrations were not given (Kostiainen 1995).  Air from 13 houses in Katusushika 
Ward, Tokyo, Japan were sampled during a survey of indoor pollution by volatile organohalogen 
compounds in February 1995 (Amagai et al. 1999).  Thirty houses were sampled in July 1995.  
Bromoform was detected in all 13 houses during the February survey.  In July, it was detected in 22 out 
of 30 houses.  Dibromochloromethane was detected in all houses during both the February and July 
surveys.  Mean concentrations of dibromochloromethane in February 1995 were 0.016 µg/m3 in outdoor 
air, 0.095 µg/m3 in living room air, 0.122 µg/m3 in kitchen air, 0.096 µg/m3 in bedroom air, and 
0.701 µg/m3 in bathroom air.  Mean concentrations of dibromochloromethane in July 1995 were 
0.007 ug/m3 in outdoor air, 0.050 µg/m3 in living room air, 0.065 µg/m3 in kitchen air, 0.042 µg/m3 in 
bedroom air, and 0.372 µg/m3 in bathroom air.  Mean concentrations of bromoform in February 
1995 were 0.009 ug/m3 in outdoor air, 0.016 µg/m3 in living room air, 0.018 µg/m3 in kitchen air, 
0.015 µg/m3 in bedroom air, and 0.091 µg/m3 in bathroom air.  Mean concentrations of bromoform in July 
1995 were 0.010 µg/m3 in outdoor air, 0.013 µg/m3 in living room air, 0.013 µg/m3 in kitchen air, 
0.012 µg/m3 in bedroom air, and 0.034 µg/m3 in bathroom air. 
Kerger et al. (2000) evaluated airborne concentrations of common trihalomethane compounds in 
bathrooms during showering and bathing in three urban homes supplied with chlorinated tap water.  
Samples were collected prior to, during, and after the water-use event for 16 shower and 7 bath events.  
The increases in average airborne concentration of dibromochloromethane were 0.5 µg/m3 per µg/L 
during showers and 0.15 µg/m3 per µg/L during baths. 
No studies were located regarding atmospheric concentrations of bromoform or dibromochloromethane in 
the workplace. Dibromochloromethane was detected in air samples at two hazardous waste sites, but the 
amounts were not quantified (LaRegina et al. 1986). 
6.4.2 Water 
Dibromochloromethane and bromoform are rarely measurable in nonchlorinated water (Cech et al. 1981; 
Staples et al. 1985; Varma et al. 1984), but both are very frequently found in chlorinated water.  The 
levels of bromoform and dibromochloromethane in finished (chlorinated) drinking water have been 
investigated in several studies (see Table 6-2).  Except for a few cases, the concentrations of bromoform 
and dibromochloromethane in drinking water were <100 µg/L, with mean concentrations generally 
<10 µg/L. 
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Symons et al. 1975 
Keith et al. 1976 
Brass et al. 1977 
ORVWSC 1979 
Glaze and Rawley 1979 
Smith et al. 1980 
Westrick et al. 1984 
Kelley et al. 1985 
Furlong and D’Itri 1986 
Wallace et al. 1986b 
Bellar et al. 1974 
Coleman et al. 1975 
Symons et al. 1975 
Keith et al. 1976 
Morris and Johnson 1976 
Brass et al. 1977 
ORVWSC 1979 
Glaze and Rawley 1979 
Smith et al. 1980 
Westrick et al. 1984 
Kelley et al. 1985 
Furlong and D’Itri 1986 
Wallace et al. 1986a 
Wallace et al. 1986b 
µg = microgram; L = liter; ND = not detected; NR = not reported 
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Bromoform and dibromochloromethane were detected in approximately 90% of samples from 5,320 wells 
in 21 states from 1985 to 1995 according to data collected by the United States Geological Survey 
(USGS) National Water-Quality Assessment Program, although actual concentrations were not given 
(Lapham et al. 2000).  Bromoform and dibromochloromethane were detected in 27 and 39 out of 
7,712 California drinking water wells, respectively, during monitoring studies conducted from 1984 to 
1990 (Lam et al. 1994).  Maximum concentrations were 78 µg/L for bromoform and 30 µg/L for 
dibromochloromethane.  Dibromochloromethane was detected in 5 out of 6 samples from 178 active 
public supply wells in the Los Angeles physiographic basin, California above the laboratory reporting 
limit of 0.18 µg/L in August through September 2000 (Shelton et al. 2001).  Bromoform was detected in 
four out of four samples above the laboratory reporting limit of 0.06 µg/L. Clark et al. (1994) collected 
drinking water samples from different points along the North Marin Water District, which serves the 
greater Novato area in California. Bromoform and dibromochloromethane were detected in the samples 
with concentrations ranging from 2.4 to 11.4 µg/L and from <0.1 to 7.5 µg/L, respectively.  The 
concentrations of bromoform and dibromochloromethane were below their detection limits of 0.06 and 
0.18 µg/L, respectively, in samples collected from 30 groundwater monitoring wells in Wichita, Kansas 
(USGS 2002).  The wells were located in areas of recent residential and commercial development. 
The State of California’s Water Quality Monitoring Database contains data for public drinking water 
systems that use either groundwater or surface water sources (Storm 1994).  Analysis of these data shows 
that bromoform was detected in 145 out of 11,765 samples (1.2%) and dibromochloromethane was 
detected in 171 out of 11,782 samples (1.5%). Mean concentrations in samples with detected dibromo­
chloromethane and bromoform were 8.95 and 7.63 µg/L, respectively.  Occurrence data from 
approximately 22,000 public water systems (source water:  88% groundwater and 12% surface water) 
from a cross-section of 24 states were selected from the Unregulated Contaminant Information System 
database (Round 1 monitoring data) (EPA 2001a).  Dibromochloromethane and bromoform were detected 
in these systems with 99th percentile values of 12.7 and 7.3 µg/L, respectively. Occurrence data from 
approximately 27,000 public water systems (source water:  89% groundwater and 11% surface water) 
from a cross-section of 22 states were selected from the Safe Drinking Water Information System 
database (Round 2 monitoring data).  Dibromochloromethane and bromoform were detected in these 
systems with 99th percentile values of 9.7 and 6.5 µg/L, respectively. 
It is usually found that halomethanes occur at higher concentrations in drinking water derived from 
surface sources than those from groundwater supplies because the former tends to contain more dissolved 
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organic matter (Bellar et al. 1974; Cech et al. 1981; Glaze and Rawley 1979; Page 1981).  The total 
trihalomethane content of finished water from a given facility can be extremely variable as a function of 
time (Arguello et al. 1979; Smith et al. 1980), with lower levels of halomethanes usually occurring during 
the winter. 
The mean concentration of dibromochloromethane was 0.74 µg/L in cold season samples from the 
Elizabethtown, New Jersey water distribution system (Chen and Weisel 1998).  Dibromochloromethane 
levels rose to 1.7 µg/L in warm season samples.  Bromoform was not found above the detection limit 
(0.10 µg/L) in cold season samples from the distribution system, but it was detected in warm season 
samples with a mean concentration of 0.27 µg/L. Summer concentration ranges in treated water 
immediately prior to distribution in a 1993 national Canadian survey conducted by Health Canada were 
<0.1–19.8 µg/L for dibromochloromethane and <0.1–4.2 µg/L for bromoform (Ritter et al. 2002).  Winter 
concentration ranges were <0.1–9.0 µg/L for dibromochloromethane and <0.1–3.3 µg/L for bromoform. 
Bromoform was detected in the influent, treated, and distribution stages from 47 municipal water 
treatment plants in Ontario, Canada at concentrations of 0.5, 0–7.0, and 0.2–8.5 µg/L, respectively.   
Dibromochloromethane was detected in samples from plant effluents of 35 Finnish waterworks with 
concentrations ranging from <0.05 to 3 µg/L (Nissinen et al. 2002).  One exception was a comparatively 
high concentration of 43 µg/L measured at one of the plants.  Bromoform concentrations were <0.05 µg/L 
in samples from all plants except for three (0.48, 0.31, and 27 µg/L). Concentrations of bromoform and 
dibromochloromethane in samples from two Finnish waterworks rose in the spring, changed little over 
summer and fall, and then dropped during winter.  Campillo et al. (2004) detected bromoform in tap water 
samples collected in Spanish cities at concentrations ranging from 1.8 to 24.7 µg/L (mean=13.5 µg/L). 
The concentrations of dibromochloromethane in these samples ranged from 2.0 to 66.5 µg/L 
(mean=30 µg/L). Mean concentrations of dibromochloromethane and bromoform were 0.5 µg/L and 
below the detection limit (0.3 µg/L), respectively, in tap water from the city of Cherepovets, Russia 
(Egorov et al. 2003).  Dibromochloromethane was detected in tap water samples collected from the 
19 districts of Hong Kong at concentrations ranging from 0.830 to 4.15 µg/L (Lee et al. 2004b).  
Bromoform was detected (detection limit 0.03 µg/L) in tap water samples from only 4 of the 19 districts 
at concentrations ranging from 0.040 to 0.920 µg/L. 
Bromoform and dibromochloromethane were detected in water samples from seven out of nine household 
residences in the Lower Rio Grande Valley during the spring of 1993 with concentrations ranging from 
1.0 to 14.1 µg/L and from 3.3 to 17.3 µg/L, respectively (Berry et al. 1997).  These compounds were 
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detected in water samples from five out of nine residences in the same region during the summer of 
1993 with concentrations ranging from 1.6 to 31.7 µg/L and from 1.8 to 49.9 µg/L, respectively. 
In order to reduce trihalomethane and related disinfection byproduct concentrations in treated water, 
communities have begun employing treatment methods that remove disinfection byproduct precursors 
such as natural organic carbon from the water prior to chlorination (Dey et al. 2001; Peltier et al. 2002; 
Shetty and Chellam 2003; Weiss et al. 2003; Westerhoff et al. 2004).  Some processes employ a 
coagulation step to aid in filtration or adsorption (Dey et al. 2001; Drikas et al. 2003).  Disinfection 
byproduct removal was studied in the two trains of the Mery-sur-Oise treatment plant, which feeds the 
northern Parisian Suburbs (Peltier et al. 2002).  The newer train uses nanofiltration technology while the 
older train employs conventional treatment.  Trihalomethane concentrations in water treated by the 
nanofiltration train were 50% less than trihalomethane concentrations in water treated by the conventional 
train. Weiss et al. (2002, 2003) observed that levels of total organic carbon and dissolved organic carbon 
in water from the Ohio, Wabash, and Missouri Rivers were reduced by 35–67% after riverbank filtration.  
However, the brominated trihalomethane precursors were not removed as efficiently as the chlorinated 
trihalomethane precursors (<40% compared to 80%).  This was attributed to the increase in the bromide 
to total organic carbon ratio as the water traveled from the rivers to the collection wells. 
Trihalomethanes may also form in chlorinated swimming pools (Beech et al. 1980).  For fresh water 
pools, chloroform and dichlorobromomethane were usually the predominant THM species present, with 
dibromochloromethane and bromoform averaging 3–15 and 1–2 µg/L, respectively.  However, in saline 
pools (which have a higher bromide ion content than fresh water pools), bromoform was the major THM 
present (average concentration of 650 µ/L), with lower concentrations (5–27 µg/L) of dibromochloro­
methane, bromodichloromethane, and chloroform.  Concentrations of bromoform and dibromochloro­
methane were 1.8–2.9 and 3.5–17 µg/L, respectively, in samples taken from three chlorinated sandy 
bottom swimming areas in September (Mansour et al. 1999).  The concentrations of dibromochloro­
methane were below 40 µg/L in water samples from eight swimming pools in Nagpur, India (Thacker and 
Nitnaware 2003).  Bromoform was detected in samples from only one of the pools at a concentration 
below 10 µg/L. 
Dibromochloromethane and bromoform have also been detected in water near hazardous waste sites, 
although this is not common.  Data from the Contract Laboratory Program (CLP) Statistical Data Base 
(CLPSD 1988) indicated that bromoform was detected in surface water at 2 of 862 hazardous-waste sites; 
the median concentration was 7 µg/L. Dibromochloromethane was detected in only one sample 
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(45 µg/L). Bromoform was detected in groundwater samples collected at four sites; the median 
concentration was 26 µg/L. Based on monitoring data from 479 disposal site groundwater investigations 
that were conducted across the United States, bromoform was detected in groundwater samples from 
10 hazardous waste disposal sites and dibromochloromethane has been detected in groundwater samples 
from 8 hazardous waste disposal sites (Plumb 1991).  Actual concentrations of bromoform and 
dibromochloromethane were not given. 
In a random survey of 954 community water systems, bromoform and dibromochloromethane were 
detected (minimum reporting limit of 0.2 µg/L) in 3.4 and 5.5%, respectively, of source water samples 
(Delzer and Ivahnenko 2003).  Both bromoform and dibromochloromethane were detected more 
frequently in groundwater sources than surface water sources.  Concentrations of bromoform in 
groundwater ranged from 0.19 to 2.61 µg/L with a median value of 0.26 µg/L; in surface water, the 
concentrations ranged from 0.03 to 0.06 µg/L with a median value of 0.05 µg/L.  For dibromochloro­
methane, concentrations in groundwater ranged from 0.02 to 2.43 µg/L with a median value of 0.04 µg/L; 
in surface water, the concentrations ranged from 0.02 to 0.15 µg/L with a median value of 0.03 µg/L. In a 
study of over 21 cities throughout the United States conducted between 1991–1995, dibromochloro­
methane was detected (minimum reporting limit of 0.2 µg/L) in 3.4% of storm water and 0.5% of shallow 
groundwater samples (Lopes and Bender 1998).  The presence of dibromochloromethane in these samples 
was attributed to the irrigation of lawns, gardens, and parks with chlorinated water, the draining of 
swimming pools, and uses of chlorinated water that result in its introduction to storm water catchments.   
Dibromochloromethane has been detected at concentrations ranging from 1.1 to 36.3 ng/L in the Scheldt 
River estuary, Germany during May 1998; from 0.2 to 22.7 ng/L in Scheldt River estuary, Germany 
during October 1998; from below the detection limit to 39.0 ng/L in the Thames River estuary, England 
during February 1999; from below the detection limit to 7.7 ng/L in the Loire River estuary, France 
during  September 1998; and from below the detection limit to 9.8 ng/L in the Rhine River estuary, 
Germany during November 1997 (Christof et al. 2002). Bromoform and dibromochloromethane were 
detected in water samples from the Southampton Water estuary at concentrations of 10–2,597 and 10– 
2,200 ng/L, respectively (Bianchi et al. 1991). 
Bromoform was not found above a detection limit of 0.08 µ/L in 644 samples from 46 surface water 
locations, including sea, estuarine, river, and industrial effluent, throughout Portugal (Martinez et al. 
2002).  Concentrations of bromoform in the Belaya River, Russia were <0.0001 mg/L above an industrial 
zone and <0.0004 mg/L below the industrial zone (Safarova et al. 2004).  The concentration of 
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bromoform in the waste water flowing into this river was measured as 0.0021 mg/L.  The concentrations 
of bromoform and dibromochloromethane in finished water from the city of Hanoi, Vietnam ranged from 
1.2 to 8.5 µg/L (average, 6.6 µg/L) and from 0.3 to 22.3 µg/L (average, 6.3 µg/L), respectively, in high 
bromide finished water and from <0.2 to 3.7 µg/L (average, 0.5 µg/L) and from <0.2 to 3.8 µg/L (average, 
1.8 µg/L), respectively, in low bromide finished water (Duong et al. 2003).  In high bromide finished 
water that also had high ammonia content, dibromochloromethane was detected at concentrations ranging 
from <0.2 to 3.7 µg/L (average, 0.3 µg/L), while the concentration of bromoform was <0.2 µg/L. 
Bromoform and dibromochloromethane have been detected in the Marta River, Italy at concentrations of 
2.39–3.35 and 0.04–0.11 µg/L, respectively (Russo et al. 2003).  The concentrations of bromoform and 
dibromochloromethane in the Tiber River, Italy were 0.82–1.82 and <16–0.11 µg/L, respectively. 
6.4.3 Sediment and Soil 
Staples et al. (1985) reported that bromoform was not detected in any of 353 sediment samples analyzed.  
No data were available for dibromochloromethane.  Data from the Contract Laboratory Program Statistic 
Data Base (CLPSD 1988) indicated dibromochloromethane and bromoform were detected in soils in only 
2 of 862 hazardous waste sites; the median concentrations were 17 µg/kg (bromoform) and 15 µg/kg 
(dibromochloromethane).  Bromoform and dibromochloromethane were detected in sediment samples 
from the Southampton Water estuary at concentrations ranging from 75 to 62,609 and from 150 to 
27,350 ng/kg, respectively (Bianchi et al. 1991).  During a monitoring study of volatile halogenated 
organic compounds in the Klosterhede State Forest District in Jutland, Denmark, bromoform was the only 
brominated compound detected in soil air samples and only in the upper soil layer with a concentration of 
0.25 ng/L (Laturnus et al. 2000b). 
6.4.4 Other Environmental Media 
The use of chlorinated water in the manufacture of commercially bottled drinks has raised concern over 
the presence of trihalomethanes in these drinks (McNeal et al. 1995).  Levels of dibromochloromethane in 
bottled water and in carbonated soft drinks ranged from 0.5 to 2 ng/g in a survey of soft drinks, juices, 
beers, bottled water, and canned foods purchased from Washington, DC markets in 1991–1992.  
Bromoform was not found in any of the samples above a detection limit of 0.1 ng/g.  Campillo et al. 
(2004) detected bromoform in pineapple juice, apple juice, and forest fruits juice at concentrations of 4.2, 
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3.5, and 2.5 µg/L, respectively.  Dibromochloromethane was found in pasteurized milk from a suburban 
area of Turku, Finland (Kroneld and Reunanen 1990). 
Neither bromoform nor dibromochloromethane were detected in oyster, clam, or sediment samples from 
the Ariho and Yoshingaga Rivers in Japan (Gotoh et al. 1992).  No detection limit was given.  The mean 
concentrations of bromoform and dibromochloromethane in daily dietary samples collected from 
housewives in Nogoya and Yokohama, Japan were 0.2–0.6 and <0.1–0.2 ng/g, respectively (Toyoda et al. 
1990). 
6.5 GENERAL POPULATION AND OCCUPATIONAL EXPOSURE  
Because of the variability of dibromochloromethane and bromoform concentrations in water and air, it is 
not possible to derive precise estimates of typical human exposure levels.  However, based on the typical 
ranges of dibromochloromethane and bromoform concentrations measured in water and air, it is likely 
that most individuals will be exposed to average doses of <1 µg/kg/day (Table 6-3), nearly all of which is 
from water.  Limited data suggest that exposure levels around chemical factories or waste sites are not 
likely to be much higher, but this can only be evaluated on a site-by-site basis.  
The range of dibromochloromethane concentrations in tap water, in blood samples before showering, and 
in blood samples after showering in Cobb County, Georgia were <1–4, 0.001–0.003, and 0.003– 
0.029 µg/L, respectively (Miles et al. 2002).  Concentrations in tap water, in blood samples before 
showering, and in blood samples after showering samples from Corpus Christi, Texas were 5–20, 0.002– 
0.031, and 0.011–>0.093 µg/L, respectively. Bromoform was detected in the Cobb County, Georgia 
samples at concentrations of <1 µg/L in tap water, 0.001–0.0052 µg/L in blood before showering, and 
0.0001–0.0059 µg/L in blood after showering.  Concentrations of dibromochloromethane in tap water, in 
blood samples before showering, and in blood samples after showering from Corpus Christi, Texas 
ranged from 2–17, 0.001–0.02, and 0.006–0.064 µg/L, respectively.  Breath samples of individuals taken 
within 5 minutes after a shower with high dibromochloromethane and bromoform water concentrations 
contained dibromochloromethane at a mean concentration of 4.8 µg/m3 and bromoform at a mean 
concentration of 2.3 µg/m3 (Weisel 1999). Breath samples taken 5–20 minutes after a shower with high 
water concentration contained dibromochloromethane at a mean concentration of 2.8 µg/m3 and 
bromoform at a mean concentration of 1.2 µg/m3. Breath samples taken >20 minutes after a shower with 
high water concentration contained dibromochloromethane at a mean concentration of 1 µg/m3 and 
bromoform at a mean concentration of 0.6 µg/m3. Breath samples from individuals after a shower with  
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 Exposure medium 
Parameter Water Air 
Typical concentration in medium 1–20 µg/L 0–0.1 µg/m3 
Assumed intake of medium by 70-kg adult 2 L/day 20 m3/day 
Assumed absorption fraction 1.0 0.5 
Estimated dose to 70-kg adult 0.03–0.6 µg/kg/day 0.0–0.01 µg/kg/day 
µg = microgram; kg = kilogram; L = liter; m3 = cubic meters 
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low water concentration contained dibromochloromethane with a mean concentration of 1 µg/m3 at 
different collection times and bromoform with a mean concentration of 0.6 µg/m3 at different collection 
times. 
Blood samples taken from 16 individuals in the Lower Rio Grande Valley during the spring of 1993 had a 
maximum dibromochloromethane concentration of 0.05 µg/L (38% frequency of detection) and a 
maximum bromoform concentration of 0.07 µg/L (19% frequency of detection) (Buckley et al. 1997).  
Blood samples taken during the Third National Health and Nutrition Examination Survey, which included 
over 1,000 individuals, had a maximum dibromochloromethane concentration of 0.024 µg/L (14.5% 
frequency of detection) and a maximum bromoform concentration of 0.034 µg/L (9.9% frequency of 
detection) (Buckley et al. 1997; Needham et al. 1995).  
Dibromochloromethane was found in human kidney and lung tissue at 0.6 and 0.06 µg/kg, respectively, in 
samples taken in the city of Turku, Finland in 1987 (Kroneld 1989a).  It was also detected in air samples 
from that region at a concentration of 0.31 mg/m3. Polkowska et al. (2003) studied the relationship 
between concentrations of volatile organic halogens in drinking water and the concentrations of these 
substances in the urine of individuals living in Gdansk-Sopot-Gdynia Tri City area of Poland.  
Concentrations of dibromochloromethane in drinking water from three locations were 0.015–0.159, 
0.912–1.125, and 0.953–0.987 µg/L with corresponding urine concentrations ranging from not detected to 
0.003 µg/L, from 0.001 to 0.012 µg/L, and from not detected to 0.005 µg/L, respectively.  Bromoform 
was only detected in drinking water from two locations at concentrations of 0.018–0.032 and 0.018– 
0.045 µg/L. It was not detected in any of the urine samples.  Detection limits were not provided in this 
study. 
The mean concentrations of bromoform and dibromochloromethane in daily dietary samples collected 
from housewives in Nogoya and Yokohama, Japan were 0.2–0.6 and <1–0.2 ng/g, respectively (Toyoda 
et al. 1990). Based on these concentrations, the mean daily dietary intakes for housewives in these cities 
were calculated to be 0.5–1.2 µg for bromoform and 0–0.5 µg for dibromochloromethane. 
Exposure to dibromochloromethane and bromoform may be above average for persons who swim in 
chlorinated swimming pools.  Beech (1980) estimated that the total dose for a 6-year-old boy who swam 
for 3 hours in a pool containing 500 µg/L of trihalomethanes could be as high as 2.8 mg (130 µg/kg). 
About 60% of this dose was attributed to dermal absorption, with about 30% resulting from inhalation.  In 
fresh water pools, only a small fraction of this would be dibromochloromethane or bromoform, but in a 
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salt water pool, a large fraction would be expected to be bromoform (Beech et al. 1980).  Aggazzotti et al. 
(1998) studied the exposure of competitive indoor swimmers to trihalomethanes. The mean 
concentrations of dibromochloromethane were 0.8 µg/L in the pool water, 5.2 µg/m3 in the pool air prior 
to swimming, and 11.4 µg/m3 in pool air during swimming.  The mean concentration of bromoform was 
0.1 µg/L in the pool water.  Bromoform was detected above 0.1 µg/m3 in only one air sample.  Mean 
concentrations of dibromochloromethane in the alveolar air sampled from five swimmers were 0.8 µg/m3 
before swimming and 1.4 µg/m3 after 1 hour of swimming.  Bromoform was not quantified in any of the 
alveolar air samples.  Calculated dibromochloromethane intakes for the five swimmers were 1.5– 
1.9 µg/hour before swimming and 14–22 µg/hour after 1 hour of swimming. 
Individuals who work at indoor pool facilities are expected to be at risk for occupational exposure to 
trihalomethanes (Fantuzzi et al. 2001).  Dibromochloromethane was detected in 24 out of 32 alveolar air 
samples collected from individuals who work at selected indoor swimming pools in Modena, Italy 
(Fantuzzi et al. 2001).  The mean concentration was 0.5 µg/m3. Bromoform was not detected in any of 
the alveolar air samples above the detection limit of 0.1 µg/m3. The authors reported that the 
concentration of trihalomethanes in the alveolar air of poolside attendants was double that in alveolar air 
collected from employees working in the engine room and reception area (25.1 vs. 14.8 µg/m3). Mean 
concentrations of dibromochloromethane measured in this study were 1.9 µg/L in pool water, 3.1 µg/m3 
in poolside ambient air, 1.5 µg/m3 in reception area ambient air, and 1.6 µg/m3 in engine room ambient 
air. The mean concentration of bromoform was 0.4 µg/L in pool water.  It was only detected in one 
ambient air sample (poolside) at a concentration of 0.8 µg/m3. 
6.6 EXPOSURES OF CHILDREN  
This section focuses on exposures from conception to maturity at 18 years in humans.  Differences from 
adults in susceptibility to hazardous substances are discussed in Section 3.7, Children’s Susceptibility. 
Children are not small adults.  A child’s exposure may differ from an adult’s exposure in many ways. 
Children drink more fluids, eat more food, breathe more air per kilogram of body weight, and have a 
larger skin surface in proportion to their body volume.  A child’s diet often differs from that of adults.  
The developing human’s source of nutrition changes with age:  from placental nourishment to breast milk 
or formula to the diet of older children who eat more of certain types of foods than adults.  A child’s 
behavior and lifestyle also influence exposure.  Children crawl on the floor, put things in their mouths, 
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sometimes eat inappropriate things (such as dirt or paint chips), and spend more time outdoors.  Children 
also are closer to the ground, and they do not use the judgment of adults to avoid hazards (NRC 1993). 
No information was located regarding the exposures of children to bromoform or dibromochloromethane.  
Exposures of children to bromoform and dibromochloromethane through inhalation are expected to vary 
depending on the length of time a child spends indoors and the concentrations of these compounds in 
indoor air.  The concentrations of bromoform and dibromochloromethane will depend on the source of 
household water, exchange rate of indoor and outdoor air, frequency and duration of showers, and 
emission rates of these compounds from other household sources (e.g., dishwasher, washing machines, 
etc.). Dermal exposures of children to bromoform and dibromochloromethane are expected to be lower 
than, or similar to, those found for adults, depending on frequency and duration of bathing or showering.  
However, the primary routes of exposure to bromoform and dibromochloromethane are expected to be 
through drinking water or consumption of beverage or food products that contain water that has been 
disinfected through chlorination.  It is expected that a child’s exposure to bromoform and dibromochloro­
methane will depend predominantly on the source and amount of drinking water consumed per day.  
Exposure of newborns and infants to bromoform and dibromochloromethane, whose diets are 
supplemented with human breast milk, cow’s milk, or infant formulas, is not known, since measurements 
of these compounds are not available in these media.  Swimming is expected to provide an additional 
source of exposure for children who spend time in chlorinated swimming pools (Beech et al. 1980). 
6.7 POPULATIONS WITH POTENTIALLY HIGH EXPOSURES  
The environmental medium most likely to be contaminated with bromoform and dibromochloromethane 
is chlorinated water. Therefore, any person who is in frequent contact with such water could have above 
average exposures. This includes individuals who drink large quantities of water, such as workers in hot 
climates, or individuals with swimming pools or saunas, where contact could occur by inhalation or by 
dermal contact.  Since bromoform and dibromochloromethane levels in water depend on the organic 
content of the source water before chlorination, individuals whose water source is high in organics are 
likely to have finished water with higher-than-average bromoform and dibromochloromethane levels. 
Workers in chemical production facilities or laboratories where bromoform and dibromochloromethane is 
made or used would also have potentially high exposures to the chemicals, most likely by inhalation or 
dermal exposure.  Persons living near hazardous-waste sites may have potentially high exposures to 
bromoform and dibromochloromethane, but this can only be evaluated on a case-by-case basis. 
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6.8 ADEQUACY OF THE DATABASE 
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the 
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether 
adequate information on the health effects of bromoform and dibromochloromethane is available.  Where 
adequate information is not available, ATSDR, in conjunction with the National Toxicology Program 
(NTP), is required to assure the initiation of a program of research designed to determine the health 
effects (and techniques for developing methods to determine such health effects) of bromoform and 
dibromochloromethane.  
The following categories of possible data needs have been identified by a joint team of scientists from 
ATSDR, NTP, and EPA. They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment.  This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled.  In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed.  
6.8.1 Identification of Data Needs 
Physical and Chemical Properties. The physical and chemical properties of dibromochloro­
methane and bromoform have been well studied, and reliable values for key parameters are available for 
use in environmental fate and transport models.  On this basis, it does not appear that further studies of 
the physical-chemical properties of dibromochloromethane and bromoform are essential.  
Production, Import/Export, Use, Release, and Disposal.    According to the Emergency 
Planning and Community Right-to-Know Act of 1986, 42 U.S.C. Section 11023, industries are required 
to submit substance release and off-site transfer information to the EPA.  The TRI, which contains this 
information for 2002, became available in May of 2004.  This database is updated yearly and should 
provide a list of industrial production facilities and emissions. 
Available data indicate that neither bromoform nor dibromochloromethane is produced or used in 
significant quantities in the United States. Nevertheless, a listing of laboratories or industries that use 
small amounts in research or testing would be valuable in identifying locations where the potential for 
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environmental releases or human exposure exists.  Also, information on the means of disposal of waste 
chemicals would be valuable in identifying environmental media likely to be affected at such sites.  
Federal regulations do restrict disposal of dibromochloromethane and bromoform to land or in industrial 
effluents. 
Environmental Fate. The fate of dibromochloromethane and bromoform in the environment has not 
been thoroughly studied, although the physical-chemical properties indicate that both are likely to 
partition to air and water. Volatilization rates have been calculated for flowing rivers and streams, but 
direct measurements of half-times of volatilization would be useful, both for surface waters and for 
household water (showers, baths, cooking, etc.).  Adsorption of these compounds to soils and sediments 
has been studied and does not appear to be a significant factor.  Consequently, transport in surface or 
groundwater are likely to be important.  Studies to confirm these expectations and provide more precise 
descriptions of the environmental behavior of these compounds would be valuable in assessing human 
exposure near specific sources of release. 
Degradation of dibromochloromethane and bromoform in air has not been studied, but is expected to 
occur by reaction with hydroxyl radicals.  Studies to measure the atmospheric half-times of these 
compounds would be valuable in estimating long-term trends in atmospheric levels, but such studies are 
probably not essential in estimating exposure near specific sources.  Neither chemical undergoes chemical 
degradation in water, but both are subject to microbial breakdown in water (especially anaerobic 
groundwater) or moist soils.  Further data on the rate of microbial degradation of dibromochloromethane 
and bromoform in water and soil would be valuable, with special attention to how these rates depend on 
environmental conditions (oxygen level, pH, etc.). 
Bioavailability from Environmental Media.    Both dibromochloromethane and bromoform are 
known to be absorbed following oral and inhalation exposure.  No data are available regarding dermal 
absorption, but it seems likely that uptake across the skin may occur.  No data were located regarding the 
relative bioavailability of dibromochloromethane and bromoform in water, soil or air.  Because of their 
physical and chemical properties, it is expected that the bioavailability of dibromochloromethane and 
bromoform are not significantly reduced by environmental media, but studies to substantiate this 
presumption would be helpful. 
Food Chain Bioaccumulation. There are few data on bioconcentration of dibromochloromethane 
or bromoform by plants or aquatic organisms, and no data were located on the bioaccumulation of 
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bromoform and dibromochloromethane in the food chain.  This lack of data may not be a major limitation 
because the general levels of the chemicals in water and soil appear to be quite low, and based on the Koc 
of these chemicals, there appears to be a low likelihood of food chain buildup. 
Exposure Levels in Environmental Media. Reliable monitoring data for the levels of bromoform 
and dibromochloromethane in contaminated media at hazardous waste sites are needed so that the 
information obtained on levels of bromoform and dibromochloromethane in the environment can be used 
in combination with the known body burden of bromoform and dibromochloromethane to assess the 
potential risk of adverse health effects in populations living in the vicinity of hazardous waste sites. 
There are several studies on the atmospheric concentrations of bromoform and dibromochloromethane in 
urban and rural environments, but many of the samples did not have detectable levels.  No data on levels 
in air near waste sites were located.  More research in this area using more sensitive analytical methods 
would be helpful, although it is anticipated that typical atmospheric levels will usually be low enough that 
air is not the principal route of exposure.  Data are available on dibromochloromethane and bromoform in 
a number of chlorinated drinking water systems, and these compounds have been detected in surface 
water and groundwater near a few hazardous waste sites.  Further studies on the levels of these 
compounds in water and soil around waste sites would be valuable in evaluating the risk to human health 
posed by these contaminants. 
Exposure Levels in Humans. There are no data on levels of dibromochloromethane or bromoform 
in blood, breath or other tissues from humans residing near waste sites.  Low levels of bromoform have 
been detected in blood of humans, presumably as the result of exposure through ingestion of chlorinated 
drinking water. Levels in expired breath and in adipose tissue appear to be too low to measure reliably 
for the general population. Direct measurement of typical human intake from water and air (especially 
indoor air) would be helpful in obtaining more accurate estimates of typical human dose levels.  Similar 
data on inhalation and dermal doses would be useful for bromoform and dibromochloromethane in and 
around swimming pools (especially indoor pools). 
This information is necessary for assessing the need to conduct health studies on these populations. 
Exposures of Children.  No formal studies of children’s inhalation, dermal, or oral exposures to 
bromoform and dibromochloromethane were located in the literature.  Based on the concentrations of 
bromoform and dibromochloromethane measured in indoor air and in drinking water that has been 
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disinfected by chlorination, studies are needed to assess the inhalation, dermal, and oral exposures of 
children to these and other disinfection by-products.  Data on inhalation and dermal doses would be 
useful for bromoform and dibromochloromethane in and around swimming pools (especially indoor 
pools). 
Child health data needs relating to susceptibility are discussed in Section 3.12.2, Identification of Data 
Needs: Children’s Susceptibility. 
Exposure Registries. No exposure registries for bromoform and dibromochloromethane were 
located. These compounds are not currently one of the compounds for which a sub-registry has been 
established in the National Exposure Registry. These compounds will be considered in the future when 
chemical selection is made for sub-registries to be established.  The information that is amassed in the 
National Exposure Registry facilitates the epidemiological research needed to assess adverse health 
outcomes that may be related to exposure to this substance. 
6.8.2 Ongoing Studies 
The Federal Research in Progress (FEDRIP 2004) database provides additional information obtainable 
from a few ongoing studies that may fill in some of the data needs identified in Section 6.8.1.  These 
studies are summarized in Table 6-4. 
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Table 6-4. Ongoing Studies on the Potential for Human Exposure to Bromoforma 
Investigator Affiliation Research description	 Sponsor 
Harrington, J;	 




University of Alaska 
Fairbanks Campus, 
Fairbanks, Alaska 
Development and testing of a radiation-transfer 
model for snow photochemistry. This will help 
quantify the extent of photochemical processing 
of trace compounds within snow and will help in 
interpreting ice core climate records and 
understanding atmospheric chemistry in snow-
covered regions.  The study will include 





Meyer GJ	 Johns Hopkins 
University, Baltimore, 
Maryland 
Development of new reductive and oxidative 
dehalogenation chemistries and the elucidation 
of their fundamental mechanisms; application of 
these new findings to the sensing, remediation, 




organohalide pollutants. The study will provide a 
pedagogical platform that informs and educates 
the next generation of environmental chemists. 
Saltzman E 	 University of 
California-Irvine 	 
The degradation of natural halogenated 
compounds in coastal seawater will be studied. 




for the uptake of atmospheric halocarbons by the 
oceans, the extent to which the oceans can 
buffer atmospheric halocarbon conc entrations, 
and the production rate for these gases in the 
surface oceans. 
aSource: CRIS 2003; FEDRIP 2003, 2004 
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The purpose of this chapter is to describe the analytical methods that are available for detecting, 
measuring, and/or monitoring bromoform and dibromochloromethane, its metabolites, and other 
biomarkers of exposure and effect to bromoform and dibromochloromethane.  The intent is not to provide 
an exhaustive list of analytical methods.  Rather, the intention is to identify well-established methods that 
are used as the standard methods of analysis.  Many of the analytical methods used for environmental 
samples are the methods approved by federal agencies and organizations such as EPA and the National 
Institute for Occupational Safety and Health (NIOSH).  Other methods presented in this chapter are those 
that are approved by groups such as the Association of Official Analytical Chemists (AOAC) and the 
American Public Health Association (APHA).  Additionally, analytical methods are included that modify 
previously used methods to obtain lower detection limits and/or to improve accuracy and precision. 
As is true for most volatile organic compounds, the preferred analytical technique for dibromochloro­
methane and bromoform is gas chromatography (GC) (Ashley et al. 1996; Djozan and Assadi 1995; 
Fishbein 1985). A number of devices are suitable for detection and quantification of dibromochloro­
methane and bromoform as they emerge from the GC, including flame ionization detection (GC/FID), 
halogen-sensitive detection (GC/HSD) or electron-capture detection (GC/ECD).  In general, HSD or ECD 
are preferable because of their high sensitivity for halogenated compounds. When absolute confidence in 
compound identity is required, mass spectrometry (GC/MS) is the method of choice. 
The most variable aspect of analyses of this sort is the sample preparation procedure used to separate 
dibromochloromethane and bromoform from the test medium in order to prepare a sample suitable for GC 
analysis.  As volatile organic compounds of relatively low water solubility, both dibromochloromethane 
and bromoform are easily lost from biological and environmental samples, so appropriate care must be 
exercised in handling and storing such samples for chemical analysis.  Brief summaries of the methods 
available for extraction and detection of these compounds in biological and environmental samples are 
provided below. 
7.1 BIOLOGICAL MATERIALS  
Separation of dibromochloromethane and bromoform from biological samples is most often achieved by 
headspace analysis, purge-and-trap collection, solvent extraction, or direct collection on adsorbent resins.  
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Headspace analysis offers speed, simplicity, and good reproducibility, but partitioning of the analyte 
between the headspace and the sample matrix is dependent upon the nature of the matrix and must be 
determined separately for each different kind of matrix (Walters 1986). 
Purge-and-trap collection is well suited to biological samples such as blood or urine that are readily 
soluble in water (Ashley et al. 1996; Peoples et al. 1979).  This method consists of bubbling an inert gas 
through a small volume of the sample and collecting the vapor in a trap packed with sorbent. The 
analytes are then removed from the trap by heating it and backflushing the analytes onto a gas 
chromatographic column.  The two materials most widely used for adsorption and thermal desorption of 
volatile organic compounds collected by the purge and trap technique are Carbotrap®, consisting of 
graphitized carbon black, and Tenax®, a porous polymer of 2,6-diphenyl-p-phenylene oxide (Fabbri et al. 
1987). 
For water-insoluble materials such as fat or other tissues, the most common separation procedure is 
extraction with an organic solvent such as diethyl ether (Zlatkis and Kim 1976).  Homogenization of 
tissue with the extractant and lysing of cells usually improves solvent extraction efficiency. 
Analytical methods for the determination of bromoform and dibromochloromethane in biological 
materials are summarized in Table 7-1.  
7.2 ENVIRONMENTAL SAMPLES 
Dibromochloromethane and bromoform may be isolated from environmental samples using the same 
methods and principles as those used for biological materials, followed by gas chromatographic analysis.  
The most convenient procedure for most liquid and solid samples is the purge-and-trap method.  Arthur et 
al. (1992) used solid phase micro extraction to separate volatile halogenated compounds from water 
samples.  The organic analytes partition between the water sample and the stationary phase coating of a 
fused silica fiber before they are thermally desorbed in a GC injector.  Djozan and Assadi (1995) 
introduced a gas stripping cryogenic trapping technique for separating volatile halogenated compounds 
from drinking water samples.  In this method, a purified gas passes through the water sample in a 
stripping column where it removes volatile compounds from a water sample.  The effluent from the 
column is dried, trapped in a cold trapping coil, and then released to the GC system by warming.  
Membrane inlet mass spectrometry (MIMS) is another technique for separating organohalogen 
compounds from drinking water (Bocchini et al. 1999).  With this method, volatile organic compounds 
Table 7-1. Analytical Methods for Determining Bromoform and 

Dibromochloromethane in Biological Materials 

Sample Accuracy 
Sample Analytical detection (percent 
matrix Preparation method method limit recovery) Reference 
Adipose Extraction, bulk lipid HRGC/MS 0.1 µg/g NR Mack and Stanley 
tissue removal, Florisil 1985 
fractionation 
Adipose Heated dynamic HRGC/MS 1 ng/g NR Stanley 1986 
tissue headspace purge-and- (DBCM) 
trap 2 ng/g (TBM) 
Adipose Purge from liquified fat GC/HSD <2 µg/L 83–107 (TBM) Peoples et al. 1979 
tissue at 115 °C, trap on 90–118 (DBCM) 
Tenax/silica gel, thermal 
desorption 
Blood Purge from blood onto GC/MS ≈0.1 ng/mL NR Antoine et al. 1986 
Tenax, thermal 
desorption onto column 
maintained at -20 °C 
Blood Extract with n-pentane HRGC/ECD 0.1 µg/L NR Kroneld 1985 
(DBCM) 
Blood Purge from blood at GC/MS 0.021µg/L 102–108 (TBM) Ashley et al. 1992 
30 °C, trap onto Tenax, (TBM) 
thermal desorption 
Blood Purge from blood at GC/MS 0.017µg/L 91–104 (DBCM) Ashley et al. 1992 
30 °C, trap onto Tenax, (DBCM) 
thermal desorption 
Blood, Macerate tissue in GC/MS 3 ng/mL NR Pellizzari et al. 1985b 
tissue water, warm blood or (blood) 
tissue, pass inert gas 6 ng/g (tissue) 
through, trap on Tenax, 
thermal desorption 
Blood Purge from water-serum GS/HSD <2 µg/L 79–100 (TBM) Peoples et al. 1979 
serum mixture containing 78–100 (DBCM) 
antifoam reagent at 
115 °C, trap on 
Tenax/silica gel, thermal 
desorption 
Breath Trap on Tenax, dry over GC/MS 1–5 µg/m3 92±15 (TBM) Wallace et al. 1986b 




µg = microgram; DBCM = dibromochloromethane; ECD = electron capture detector; g = gram; GC = gas 
chromatography; HRGC = high resolution gas chromatography; HSD = halide specific detector; L = liter; m3 = cubic 
meters; mg = milligram; mL = milliliter; MS = mass spectrometry; ng = nanogram; NR = not reported; 
TBM = bromoform 
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from the drinking water sample diffuse through a hollow-fiber membrane into a mass spectrometer.  The 
advantages of this method are that sample pre-treatment is not required, response times are fast, and trace 
analysis of the pollutants can be preformed on-line. Halocarbons can also be removed from water by 
adsorption on synthetic polymers contained in cartridges, followed by thermal desorption of the analyte 
(Pankow et al. 1988).  Among the products used for this purpose are Tenax-GC® and Tenax-TA®. A 
similar procedure is used for air, in which the air is passed through an adsorbent canister, followed by 
thermal desorption (Pankow et al. 1998).  
Analytical methods for the determination of dibromochloromethane and bromoform in environmental 
samples are given in Table 7-2. 
7.3 ADEQUACY OF THE DATABASE 
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the 
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether 
adequate information on the health effects of bromoform and dibromochloromethane is available.  Where 
adequate information is not available, ATSDR, in conjunction with the National Toxicology Program 
(NTP), is required to assure the initiation of a program of research designed to determine the health 
effects (and techniques for developing methods to determine such health effects) of bromoform and 
dibromochloromethane.  
The following categories of possible data needs have been identified by a joint team of scientists from 
ATSDR, NTP, and EPA. They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment.  This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled.  In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed.  
7.3.1 Identification of Data Needs 
Methods for Determining Biomarkers of Exposure and Effect.     
Exposure. Sensitive and specific methods exist for the determination of dibromochloromethane and 
bromoform in blood, expired air, and adipose tissue.  These methods are presumably sensitive enough to 
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Table 7-2. Analytical Methods for Determining Bromoform and 

Dibromochloromethane in Environmental Samples 

Sample Accuracy 
Sample Analytical detection (percent 
matrix Preparation method method limit recovery) Reference 
Drinking Solvent extraction with HRGC/ECD <0.5 µg/L NR Fayad and 
water pentane, direct injection of Iqbal 1985 
extract 
Drinking Gas stripping and cryogenic GC/FID 0.05 µg/L 75±7.7 Djozan and 
water trapping system (DBCM) (DBCM) Assadi 1995 
Drinking Adsorption to and diffusion MIMS 0.5 µg/L NR Bocchini et al. 
water through a polymeric hollow­ (TBM) 1999 
fiber membrane 
Drinking Adsorption to and diffusion MIMS 0.5 µg/L NR Bocchini et al. 
water through a polymeric hollow­ (DBCM) 1999 
fiber membrane 
Drinking Purge and trap, thermal GC/MS 0.1µg/L 89–90 (TBM) Eichelberger et 
water desorption al. 1990 
Drinking Purge and trap, thermal GC/MS 0.1µg/L 95–100 (TBM) Eichelberger et 
water desorption al. 1990 
Air Coconut shell charcoal GC/FID 10 µg/sample 14.0 (TBM) NIOSH 1994 
sorption, carbon disulfide (TBM) 
desorption 
Air Carbotrap/Carboxen filled GC/MS 0.02 ppbv 95–102 (TBM) Pankow et al. 
glass cartridge (TBM) 1998 
adsorption/thermal 
desorption 
Air Carbotrap/Carboxen filled GC/MS 0.04 ppbv 96–99 (DBCM) Pankow et al. 
glass cartridge (DBCM) 1998 
adsorption/thermal 
desorption 
Water Purge and trap GC/MS 10 µg/L NR EPA 1980b 
Water Purge and trap GC/HSD 0.20 µg/L 89±9 (TBM) EPA 1982a 
(TBM) 
0.09 µg/L 98±7 (DBCM) 
(DBCM) 
Water Purge and trap GC/MS 4.7 µg/L 105±16 (TBM) EPA 1982b 
(TBM) 
3.1 µg/L 104±14 
(DBCM) (DBCM) 
Water Purge and trap GC/HSD 0.5 µg/L 97 (DBCM) APHA 1985a 
101 (DBCM) 
Water Purge and trap GC/MS <2 µg/L 82 (TBM) APHA 1985b 
Water Solvent extraction GC/ECD 2 µg/L NR ASTM 1988 
(isooctane) 
Water Solid phase micro extraction GC/MS 4.7 µg/L Arthur et al. 
(TBM) 1992 
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Table 7-2. Analytical Methods for Determining Bromoform and 

Dibromochloromethane in Environmental Samples 

Sample Accuracy 
Sample Analytical detection (percent 
matrix Preparation method method limit recovery) Reference 
Water Solid phase micro extraction GC/MS 3.1 µg/L Arthur et al. 
(DBCM) 1992 
Contaminated Purge and trap GC/HSD 2 µg/kg (TBM) 96b (TBM) EPA 1986a 
soil 0.9 µg/kg 94b (DBCM) 
(DBCM) 
Wastes, Purge and trap GC/HSD 250 µg/kg 96b (TBM) EPA 1986a 
nonwater (TBM) 
miscible 113 µg/kg 94b (DBCM) 
(DBCM) 
Solid waste Purge and trap GC/MS 5 µg/kg 118b (TBM) EPA 1986b 
101b (DBCM) 
aValue refers to both DBCM and TBM unless noted otherwise. 
 




µg = microgram; DBCM = dibromochloromethane; ECD = electron capture detector; FID = flame ionization detector; 
 
g = gram; GC = gas chromatography; HRGC = high resolution gas chromatography; HSD = halide specific detector; 
 
kg = kilogram; L = liter; MS = mass spectrometry; NR = not reported; TBM = bromoform 
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measure levels in humans exposed to doses of the chemicals that produce sedation or cause injury to 
liveand kidney. However, data on this are lacking due to absence of cases.  The methods are also suitable 
for measuring background levels in the general population, although increased sensitivity would be useful 
for analysis of expired air and adipose tissue.  The major limitation to these methods is that only recent 
exposures can be detected, so work to identify and quantify a more stable biomarker of exposure (e.g., a 
halomethyl adduct) would be valuable. 
Effect. No chemical or biochemical biomarkers of effect are recognized, aside from nonspecific indices 
of hepatic or renal dysfunction, Efforts to identify a specific biomarker of effect (in particular, an effect 
such as alkylation of DNA that may be related to cancer risk) would be valuable in evaluating potential 
health risk to exposed humans.  
Methods for Determining Parent Compounds and Degradation Products in Environmental 
Media. Reliable and specific methods exist for measuring parent dibromochloromethane and 
bromoform in air, water, soil and solid wastes.  Humans could be exposed to these compounds by contact 
with any of these media, although ingestion of or dermal contact with contaminated water appears to be 
the most likely route near a chemical waste site.  Existing methods are readily able to detect concentration 
values in environmental media that are likely to lead to significant noncancer health effects, but might not 
be sensitive enough to measure levels that pose low levels of cancer risks.  However, since no chemical- 
specific cancer potency values are available for these components, this is not certain. 
7.3.2 Ongoing Studies 
No ongoing studies on analytical methods were identified in a search of the Federal Research in Progress  
database (FEDRIP 2004). 
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The international, national, and state regulations and guidelines regarding bromoform and dibromochloro-
methane in air, water, and other media are summarized in Table 8-1. 
An acute-duration oral MRL of 0.7 mg/kg/day has been derived for bromoform.  This MRL is based on a 
NOAEL of 72 mg/kg/day and a LOAEL of 145 mg/kg/day for centrilobular pallor in mice receiving 
gavage doses of bromoform for 14 days (Condie et al. 1983).  The MRL was derived by dividing the 
NOAEL by an uncertainty factor of 100 (10 for animal to human extrapolation and 10 for human 
variability).  
An intermediate-duration oral MRL of 0.2 mg/kg/day has been derived for bromoform.  This MRL is 
based on a NOAEL of 50 mg/kg for hepatocellular vacuolization in rats administered gavage doses of 
bromoform in corn oil 5 days/week for 13 weeks (NTP 1989a).  The MRL was derived by dividing the 
duration adjusted NOAEL of 18 mg/kg/day by an uncertainty factor of 100 (10 for animal to human 
extrapolation and 10 for human variability).   
A chronic-duration oral MRL of 0.02 mg/kg/day has been derived for bromoform.  This MRL is based on 
a LOAEL of 100 mg/kg for hepatocellular vacuolization in rats administered gavage doses of bromoform 
in corn oil 5 days/week for 2 years (NTP 1989a).  The MRL was derived by dividing the duration 
adjusted LOAEL of 71 mg/kg/day by an uncertainty factor of 300 (3 for use of a minimal LOAEL, 10 for 
animal to human extrapolation, and 10 for human variability) and a modifying factor of 10 to account for 
the identification of a lower LOAEL in a 13-week study (NTP 1989a).   
An acute-duration oral MRL of 0.1 mg/kg/day has been derived for dibromochloromethane. This MRL is 
based on a LOAEL of 37 mg/kg for hepatocellular vacuolization in mice administered gavage doses of 
dibromochloromethane in corn oil for 14 days (Condie et al. 1983).  The MRL was derived by dividing 
the LOAEL by an uncertainty factor of 300 (3 for use of a minimal LOAEL, 10 for animal to human 
extrapolation, and 10 for human variability). 
A chronic-duration oral MRL of 0.09 mg/kg/day has been derived for dibromochloromethane.  This MRL 
is based on a LOAEL of 40 mg/kg for fatty changes in the liver of rats administered gavage doses of 
dibromochloromethane in corn oil for 2 years (NTP 1985).  The MRL was derived by dividing the 
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duration-adjusted LOAEL of 28 mg/kg/day by an uncertainty factor of 300 (3 for use of a minimal 
LOAEL, 10 for animal to human extrapolation, and 10 for human variability). 
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Agency Description 	 Information Reference 
INTERNATIONAL 
Guidelines: 
















ACGIH TLV (8-hour TWA) 
 Bromoformb 
NIOSH REL (10-hour TWA)  
 Bromoformc 
IDLH 
OSHA PEL (8-hour TWA) for general 
industry 
 Bromoformd 
PEL (8-hour TWA) for construction 
industry 
 Bromoformd 




USC Hazardous air pollutant 

b. Water 
EPA Drinking water health advisories 
 Bromoform 
1-day (10-kg child) 




1-day (10-kg child) 
10-day (10-kg child) 
DWELe 
Lifetimeg 
10-4 Cancer riskf 
Effluent guidelines and standards; 
toxic pollutants pursuant to 
Section 307 (a)(1) of the Clean 
Water Act 












29 CFR 1910.1000, 
0.5 ppm Table Z-1 
OSHA 2003c 
29 CFR 1926.55, 
0.5 ppm Appendix A 
OSHA 2003b 
29 CFR 1915.1000 
0.5 ppm 
Bromoform USC 2003 










Bromoform EPA 2003c 
40 CFR 401.15 
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Agency Description 	 Information Reference 
NATIONAL (cont.) 
EPA National primary drinking water EPA 2003f 
regulations 40 CFR 141.12 
MCL for total trihalomethanesh 0.10 mg/L 
Pollutants of initial focus in the Bromoform and EPA 2003m 
Great Lakes Water Quality Initiative dibromochloromethane 40 CFR 132, Table 6 
c. 	Food 
FDA Bottled drinking water allowable 0.10 mg/L FDA 2003 
concentrations for total trihalo­ 21 CFR 165.110 
methanesi 
d. Other 
 ACGIH Carcinogenicity classification A3j ACGIH 2003
 EPA Carcinogenicity classification IRIS 2004a, 2004b 
 Bromoform 	 B2k 
Cl Dibromochloromethane 
RfC No data IRIS 2004a, 2004b 
RfD IRIS 2004a, 2004b 
 Bromoform 2.0x10-2 mg/kg/day 

 Dibromochloromethane 2.0x10-2 mg/kg/day 

Community right-to-know; release EPA 2003i 
report; effective date of reporting 40 CFR 372.65 
 Bromoform 01/01/87 
Identification and listing of EPA 2003d 
hazardous waste; hazardous waste 40 CFR 261, 
number Appendix VIII 
 Bromoform U225 
Land disposal restrictions; universal Waste Non-waste EPA 2003e 
treatment standards water water 40 CFR 268.48 
(mg/L) mg/kg) 
 Bromoform 0.63 15 
 Dibromochloromethane 0.57 15 
Municipal solid waste landfills; Suggested EPA 2003a 
hazardous constituents method PQL (µg/L) 40 CFR 258, 
 Bromoform 8010 2 Appendix II 
8021 15 
8260 5 
 Dibromochloromethane 8010 1 
8021 0.3 
8260 5 
Reportable quantity of hazardous EPA 2003b 
substance in accordance with 40 CFR 302.4 
Section 307 (a) of the Clean Water 
Act, Section 112 of RCRA, and 
Section 112 of the Clean Air Act 
 Bromoform 100 pounds 
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Agency Description 	 Information Reference 
NATIONAL (cont.) 
EPA Reportable quantity of hazardous EPA 2003b 
substance in accordance with 40 CFR 302.4 
Section 112 of RCRA 
 Dibromochloromethane 100 pounds 
Standards for the management of EPA 2003g 
specific hazardous waste and types 40 CFR 266, 
of hazardous waste management Appendix V 
facilities Risk specific doses 
 Bromoform 7.0x10-1 µg/m3 
Standards for owners or operators EPA 2003h 
of hazardous waste TSD facilities; 40 CFR 264, 
maximum concentration for Suggested Appendix IX 
groundwater protection method PQL (µg/L) 
 Bromoform 8010 2 
8240 5 
 Dibromochloromethane 8010 1 
8240 5 
TSCA; chemical information rules Effective Sunset EPA 2003k 
date date 40 CFR 712.30 
 Bromoform 03/11/94 05/10/94 
TSCA; health and safety data Effective Sunset EPA 2003j 
reporting date date 40 CFR 716.120 
 Bromoform 06/01/87 06/01/97 
 Dibromochloromethane 06/01/87 06/01/87 
TSCA; identification of specific EPA 2003l 
chemical substance and mixture 40 CFR 799.5055 
testing requirements for  
 Bromoform Hydrolysis testing 
STATE 
a. Air No data 
b. 	Water 
Arizona Drinking water guideline HSDB 2004a, 2004b 
 Bromoform 0.19 µg/L 
 Dibromochloromethane 0.19 µg/L 
Florida Drinking water guideline HSDB 2004a, 2004b 
 Bromoform 4.0 µg/L 
 Dibromochloromethane 1.0 µg/L 
Minnesota Drinking water guideline HSDB 2004a, 2004b 
 Bromoform 40 µg/L 
 Dibromochloromethane 10 µg/L 
New Hampshire Drinking water guideline HSDB 2004a 
 Bromoform 4.0 µg/L 
Wisconsin Drinking water guideline HSDB 2004a, 2004b 
 Bromoform 
 4.4 µg/L 
 Dibromochloromethane 
 60 µg/L 
170 BROMOFORM AND DIBROMOCHLOROMETHANE 
8. REGULATIONS AND ADVISORIES 




Agency Description Information Reference 
STATE (cont.) 
c. Food No data 
d. Other No data 
aGroup 3: not classifiable as to its carcinogenicity to humans 
bSkin notation: refers to the potential significant contribution to the overall exposure by the cutaneous route, including 
mucous membranes and the eyes, either by contact with vapors or, of probable greater significance, by direct skin 
contact with the substance. 
cSkin designation: indicates the potential for dermal absorption; skin exposure should be prevented as necessary 
through the use of good work practices and gloves, coveralls, goggles, and other appropriate equipment. 
dSkin designation 
eDWEL: a lifetime exposure concentration protection of adverse, non-cancer health effects, that assumes all of the 
exposure to a contaminant is from drinking water. 
f10-2 Cancer risk:  the concentration of a chemical in drinking water corresponding to an excess estimated lifetime 
cancer risk of 1 in 10,000. 
gLifetime: the concentration of a chemical in drinking water that is not expected to cause any adverse 
noncarcinogenic effects for a lifetime of exposure.  The Lifetime HA is based on exposure of a 70-kg adult 
consuming 2 L water/day.  
hTotal trihalomethanes (the sum of the concentrations of bromoform, dibromochloromethane, bromodichloro­
methane, and chloroform) applies to subpart H community water systems which serve a population of 10,000 people 
or more until December 31, 2001.  This level applies to community water systems that use only groundwater not 
under the direct influence of surface water and serves a population of 10,000 people or more until December 31, 
2003.  Compliance with the MCL for total trihalomethanes is calculated pursuant to 40 CFR 141.30.  After 
December 31, 2003, this section no longer applies. 
iTotal trihalomethanes: sum of the concentration in mg/L of the trihalomethane compounds (bromoform, 
 
dibromochloromethane, bromodichloromethane, and chloroform), rounded to two significant figures. 
 
jA3: confirmed animal carcinogen with unknown relevance to humans 
 
kB2: probable human carcinogen 
 
lC: possible human carcinogen 
ACGIH = American Conference of Governmental Industrial Hygienists; CFR = Code of Federal Regulations; 
DWEL = drinking water equivalent level; EPA = Environmental Protection Agency; FDA = Food and Drug 
Administration; HSDB = Hazardous Substances Data Bank; IARC = International Agency for Research on Cancer; 
IDLH = immediately dangerous to life or health; IRIS = Integrated Risk Information System; MCL = maximum 
contaminant level; NIOSH = National Institute for Occupational Safety and Health; OSHA = Occupational Safety and 
Health Administration; PEL = permissible exposure limit; PQL = practical quantitation level; RCRA = Resource 
Conservation and Recovery Act; REL = recommended exposure limit; RfC = inhalation reference concentration; 
RfD = oral reference dose; TLV = threshold limit values; TSCA = Toxic Substances Control Act; TSD = treatment, 
storage, and disposal; TWA = time-weighted average; USC = United States Code; WHO = World Health 
Organization 
_______________________ 
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Absorption—The taking up of liquids by solids, or of gases by solids or liquids. 
Acute Exposure—Exposure to a chemical for a duration of 14 days or less, as specified in the 
Toxicological Profiles. 
Adsorption—The adhesion in an extremely thin layer of molecules (as of gases, solutes, or liquids) to the 
surfaces of solid bodies or liquids with which they are in contact. 
Adsorption Coefficient (Koc)—The ratio of the amount of a chemical adsorbed per unit weight of 
organic carbon in the soil or sediment to the concentration of the chemical in solution at equilibrium. 
Adsorption Ratio (Kd)—The amount of a chemical adsorbed by sediment or soil (i.e., the solid phase) 
divided by the amount of chemical in the solution phase, which is in equilibrium with the solid phase, at a 
fixed solid/solution ratio. It is generally expressed in micrograms of chemical sorbed per gram of soil or 
sediment. 
Benchmark Dose (BMD)—Usually defined as the lower confidence limit on the dose that produces a 
specified magnitude of changes in a specified adverse response.  For example, a BMD10 would be the 
dose at the 95% lower confidence limit on a 10% response, and the benchmark response (BMR) would be 
10%.  The BMD is determined by modeling the dose response curve in the region of the dose response 
relationship where biologically observable data are feasible.    
Benchmark Dose Model—A statistical dose-response model applied to either experimental toxicological 
or epidemiological data to calculate a BMD. 
Bioconcentration Factor (BCF)—The quotient of the concentration of a chemical in aquatic organisms 
at a specific time or during a discrete time period of exposure divided by the concentration in the 
surrounding water at the same time or during the same period. 
Biomarkers—Broadly defined as indicators signaling events in biologic systems or samples. They have 
been classified as markers of exposure, markers of effect, and markers of susceptibility. 
Cancer Effect Level (CEL)—The lowest dose of chemical in a study, or group of studies, that produces 
significant increases in the incidence of cancer (or tumors) between the exposed population and its 
appropriate control. 
Carcinogen—A chemical capable of inducing cancer. 
Case-Control Study—A type of epidemiological study that examines the relationship between a 
particular outcome (disease or condition) and a variety of potential causative agents (such as toxic 
chemicals).  In a case-controlled study, a group of people with a specified and well-defined outcome is 
identified and compared to a similar group of people without outcome. 
Case Report—Describes a single individual with a particular disease or exposure.  These may suggest 
some potential topics for scientific research, but are not actual research studies. 
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Case Series—Describes the experience of a small number of individuals with the same disease or 
exposure. These may suggest potential topics for scientific research, but are not actual research studies. 
Ceiling Value—A concentration of a substance that should not be exceeded, even instantaneously. 
Chronic Exposure—Exposure to a chemical for 365 days or more, as specified in the Toxicological 
Profiles. 
Cohort Study—A type of epidemiological study of a specific group or groups of people who have had a 
common insult (e.g., exposure to an agent suspected of causing disease or a common disease) and are 
followed forward from exposure to outcome.  At least one exposed group is compared to one unexposed 
group. 
Cross-sectional Study—A type of epidemiological study of a group or groups of people that examines 
the relationship between exposure and outcome to a chemical or to chemicals at one point in time. 
Data Needs—Substance-specific informational needs that if met would reduce the uncertainties of human 
health assessment. 
Developmental Toxicity—The occurrence of adverse effects on the developing organism that may result 
from exposure to a chemical prior to conception (either parent), during prenatal development, or 
postnatally to the time of sexual maturation.  Adverse developmental effects may be detected at any point 
in the life span of the organism. 
Dose-Response Relationship—The quantitative relationship between the amount of exposure to a 
toxicant and the incidence of the adverse effects. 
Embryotoxicity and Fetotoxicity—Any toxic effect on the conceptus as a result of prenatal exposure to 
a chemical; the distinguishing feature between the two terms is the stage of development during which the 
insult occurs.  The terms, as used here, include malformations and variations, altered growth, and in utero 
death. 
Environmental Protection Agency (EPA) Health Advisory—An estimate of acceptable drinking water 
levels for a chemical substance based on health effects information.  A health advisory is not a legally 
enforceable federal standard, but serves as technical guidance to assist federal, state, and local officials. 
Epidemiology—Refers to the investigation of factors that determine the frequency and distribution of 
disease or other health-related conditions within a defined human population during a specified period.   
Genotoxicity—A specific adverse effect on the genome of living cells that, upon the duplication of 
affected cells, can be expressed as a mutagenic, clastogenic, or carcinogenic event because of specific 
alteration of the molecular structure of the genome. 
Half-life—A measure of rate for the time required to eliminate one half of a quantity of a chemical from 
the body or environmental media. 
Immediately Dangerous to Life or Health (IDLH)—The maximum environmental concentration of a 
contaminant from which one could escape within 30 minutes without any escape-impairing symptoms or 
irreversible health effects. 
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Immunologic Toxicity—The occurrence of adverse effects on the immune system that may result from 
exposure to environmental agents such as chemicals. 
Immunological Effects—Functional changes in the immune response. 
Incidence—The ratio of individuals in a population who develop a specified condition to the total 
number of individuals in that population who could have developed that condition in a specified time 
period. 
Intermediate Exposure—Exposure to a chemical for a duration of 15–364 days, as specified in the 
Toxicological Profiles. 
In Vitro—Isolated from the living organism and artificially maintained, as in a test tube. 
In Vivo—Occurring within the living organism. 
Lethal Concentration(LO) (LCLO)—The lowest concentration of a chemical in air that has been reported 
to have caused death in humans or animals. 
Lethal Concentration(50) (LC50)—A calculated concentration of a chemical in air to which exposure for 
a specific length of time is expected to cause death in 50% of a defined experimental animal population. 
Lethal Dose(LO) (LDLo)—The lowest dose of a chemical introduced by a route other than inhalation that 
has been reported to have caused death in humans or animals. 
Lethal Dose(50) (LD50)—The dose of a chemical that has been calculated to cause death in 50% of a 
defined experimental animal population. 
Lethal Time(50) (LT50)—A calculated period of time within which a specific concentration of a chemical 
is expected to cause death in 50% of a defined experimental animal population. 
Lowest-Observed-Adverse-Effect Level (LOAEL)—The lowest exposure level of chemical in a study, 
or group of studies, that produces statistically or biologically significant increases in frequency or severity 
of adverse effects between the exposed population and its appropriate control. 
Lymphoreticular Effects—Represent morphological effects involving lymphatic tissues such as the 
lymph nodes, spleen, and thymus. 
Malformations—Permanent structural changes that may adversely affect survival, development, or 
function. 
Minimal Risk Level (MRL)—An estimate of daily human exposure to a hazardous substance that is 
likely to be without an appreciable risk of adverse noncancer health effects over a specified route and 
duration of exposure. 
Modifying Factor (MF)—A value (greater than zero) that is applied to the derivation of a Minimal Risk 
Level (MRL) to reflect additional concerns about the database that are not covered by the uncertainty 
factors. The default value for a MF is 1. 
Morbidity—State of being diseased; morbidity rate is the incidence or prevalence of disease in a specific 
population. 
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Mortality—Death; mortality rate is a measure of the number of deaths in a population during a specified 
interval of time. 
Mutagen—A substance that causes mutations.  A mutation is a change in the DNA sequence of a cell’s 
DNA. Mutations can lead to birth defects, miscarriages, or cancer. 
Necropsy—The gross examination of the organs and tissues of a dead body to determine the cause of 
death or pathological conditions. 
Neurotoxicity—The occurrence of adverse effects on the nervous system following exposure to a 
chemical. 
No-Observed-Adverse-Effect Level (NOAEL)—The dose of a chemical at which there were no 
statistically or biologically significant increases in frequency or severity of adverse effects seen between 
the exposed population and its appropriate control.  Effects may be produced at this dose, but they are not 
considered to be adverse. 
Octanol-Water Partition Coefficient (Kow)—The equilibrium ratio of the concentrations of a chemical 
in n-octanol and water, in dilute solution. 
Odds Ratio (OR)—A means of measuring the association between an exposure (such as toxic substances 
and a disease or condition) that represents the best estimate of relative risk (risk as a ratio of the incidence 
among subjects exposed to a particular risk factor divided by the incidence among subjects who were not 
exposed to the risk factor). An OR of greater than 1 is considered to indicate greater risk of disease in the 
exposed group compared to the unexposed group. 
Organophosphate or Organophosphorus Compound—A phosphorus-containing organic compound 
and especially a pesticide that acts by inhibiting cholinesterase. 
Permissible Exposure Limit (PEL)—An Occupational Safety and Health Administration (OSHA) 
allowable exposure level in workplace air averaged over an 8-hour shift of a 40-hour workweek. 
Pesticide—General classification of chemicals specifically developed and produced for use in the control 
of agricultural and public health pests. 
Pharmacokinetics—The dynamic behavior of a material in the body, used to predict the fate 
(disposition) of an exogenous substance in an organism.  Utilizing computational techniques, it provides 
the means of studying the absorption, distribution, metabolism, and excretion of chemicals by the body. 
Pharmacokinetic Model—A set of equations that can be used to describe the time course of a parent 
chemical or metabolite in an animal system.  There are two types of pharmacokinetic models:  data-based 
and physiologically-based.  A data-based model divides the animal system into a series of compartments, 
which, in general, do not represent real, identifiable anatomic regions of the body, whereas the 
physiologically-based model compartments represent real anatomic regions of the body. 
Physiologically Based Pharmacodynamic (PBPD) Model—A type of physiologically based dose-
response model that quantitatively describes the relationship between target tissue dose and toxic end 
points. These models advance the importance of physiologically based models in that they clearly 
describe the biological effect (response) produced by the system following exposure to an exogenous 
substance. 
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Physiologically Based Pharmacokinetic (PBPK) Model—Comprised of a series of compartments 
representing organs or tissue groups with realistic weights and blood flows.  These models require a 
variety of physiological information:  tissue volumes, blood flow rates to tissues, cardiac output, alveolar 
ventilation rates, and possibly membrane permeabilities.  The models also utilize biochemical 
information, such as air/blood partition coefficients, and metabolic parameters.  PBPK models are also 
called biologically based tissue dosimetry models. 
Prevalence—The number of cases of a disease or condition in a population at one point in time.  
Prospective Study—A type of cohort study in which the pertinent observations are made on events 
occurring after the start of the study.  A group is followed over time. 
q1*—The upper-bound estimate of the low-dose slope of the dose-response curve as determined by the 
multistage procedure.  The q1* can be used to calculate an estimate of carcinogenic potency, the 
incremental excess cancer risk per unit of exposure (usually µg/L for water, mg/kg/day for food, and 
µg/m3 for air). 
Recommended Exposure Limit (REL)—A National Institute for Occupational Safety and Health 
(NIOSH) time-weighted average (TWA) concentration for up to a 10-hour workday during a 40-hour 
workweek. 
Reference Concentration (RfC)—An estimate (with uncertainty spanning perhaps an order of 
magnitude) of a continuous inhalation exposure to the human population (including sensitive subgroups) 
that is likely to be without an appreciable risk of deleterious noncancer health effects during a lifetime.  
The inhalation reference concentration is for continuous inhalation exposures and is appropriately 
expressed in units of mg/m3 or ppm. 
Reference Dose (RfD)—An estimate (with uncertainty spanning perhaps an order of magnitude) of the 
daily exposure of the human population to a potential hazard that is likely to be without risk of deleterious 
effects during a lifetime.  The RfD is operationally derived from the no-observed-adverse-effect level 
(NOAEL, from animal and human studies) by a consistent application of uncertainty factors that reflect 
various types of data used to estimate RfDs and an additional modifying factor, which is based on a 
professional judgment of the entire database on the chemical.  The RfDs are not applicable to 
nonthreshold effects such as cancer. 
Reportable Quantity (RQ)—The quantity of a hazardous substance that is considered reportable under 
the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA).  Reportable 
quantities are (1) 1 pound or greater or (2) for selected substances, an amount established by regulation 
either under CERCLA or under Section 311 of the Clean Water Act.  Quantities are measured over a 
24-hour period. 
Reproductive Toxicity—The occurrence of adverse effects on the reproductive system that may result 
from exposure to a chemical.  The toxicity may be directed to the reproductive organs and/or the related 
endocrine system.  The manifestation of such toxicity may be noted as alterations in sexual behavior, 
fertility, pregnancy outcomes, or modifications in other functions that are dependent on the integrity of 
this system. 
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Retrospective Study—A type of cohort study based on a group of persons known to have been exposed 
at some time in the past.  Data are collected from routinely recorded events, up to the time the study is 
undertaken. Retrospective studies are limited to causal factors that can be ascertained from existing 
records and/or examining survivors of the cohort. 
Risk—The possibility or chance that some adverse effect will result from a given exposure to a chemical. 
Risk Factor—An aspect of personal behavior or lifestyle, an environmental exposure, or an inborn or 
inherited characteristic that is associated with an increased occurrence of disease or other health-related 
event or condition. 
Risk Ratio—The ratio of the risk among persons with specific risk factors compared to the risk among 
persons without risk factors. A risk ratio greater than 1 indicates greater risk of disease in the exposed 
group compared to the unexposed group. 
Short-Term Exposure Limit (STEL)—The American Conference of Governmental Industrial 
Hygienists (ACGIH) maximum concentration to which workers can be exposed for up to 15 minutes 
continually. No more than four excursions are allowed per day, and there must be at least 60 minutes 
between exposure periods. The daily Threshold Limit Value-Time Weighted Average (TLV-TWA) may 
not be exceeded. 
Standardized Mortality Ratio (SMR)—A ratio of the observed number of deaths and the expected 
number of deaths in a specific standard population. 
Target Organ Toxicity—This term covers a broad range of adverse effects on target organs or 
physiological systems (e.g., renal, cardiovascular) extending from those arising through a single limited 
exposure to those assumed over a lifetime of exposure to a chemical. 
Teratogen—A chemical that causes structural defects that affect the development of an organism. 
Threshold Limit Value (TLV)—An American Conference of Governmental Industrial Hygienists 
(ACGIH) concentration of a substance to which most workers can be exposed without adverse effect.  
The TLV may be expressed as a Time Weighted Average (TWA), as a Short-Term Exposure Limit 
(STEL), or as a ceiling limit (CL). 
Time-Weighted Average (TWA)—An allowable exposure concentration averaged over a normal 8-hour 
workday or 40-hour workweek. 
Toxic Dose(50) (TD50)—A calculated dose of a chemical, introduced by a route other than inhalation, 
which is expected to cause a specific toxic effect in 50% of a defined experimental animal population. 
Toxicokinetic—The absorption, distribution, and elimination of toxic compounds in the living organism. 
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Uncertainty Factor (UF)—A factor used in operationally deriving the Minimal Risk Level (MRL) or 
Reference Dose (RfD) or Reference Concentration (RfC) from experimental data.  UFs are intended to 
account for (1) the variation in sensitivity among the members of the human population, (2) the 
uncertainty in extrapolating animal data to the case of human, (3) the uncertainty in extrapolating from 
data obtained in a study that is of less than lifetime exposure, and (4) the uncertainty in using lowest-
observed-adverse-effect level (LOAEL) data rather than no-observed-adverse-effect level (NOAEL) data. 
A default for each individual UF is 10; if complete certainty in data exists, a value of 1 can be used; 
however, a reduced UF of 3 may be used on a case-by-case basis, 3 being the approximate logarithmic 
average of 10 and 1. 
Xenobiotic—Any chemical that is foreign to the biological system. 
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The Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA) [42 U.S.C. 
9601 et seq.], as amended by the Superfund Amendments and Reauthorization Act (SARA) [Pub. L. 99– 
499], requires that the Agency for Toxic Substances and Disease Registry (ATSDR) develop jointly with 
the U.S. Environmental Protection Agency (EPA), in order of priority, a list of hazardous substances most 
commonly found at facilities on the CERCLA National Priorities List (NPL); prepare toxicological 
profiles for each substance included on the priority list of hazardous substances; and assure the initiation 
of a research program to fill identified data needs associated with the substances. 
The toxicological profiles include an examination, summary, and interpretation of available toxicological 
information and epidemiologic evaluations of a hazardous substance.  During the development of 
toxicological profiles, Minimal Risk Levels (MRLs) are derived when reliable and sufficient data exist to 
identify the target organ(s) of effect or the most sensitive health effect(s) for a specific duration for a 
given route of exposure. An MRL is an estimate of the daily human exposure to a hazardous substance 
that is likely to be without appreciable risk of adverse noncancer health effects over a specified duration 
of exposure. MRLs are based on noncancer health effects only and are not based on a consideration of 
cancer effects.  These substance-specific estimates, which are intended to serve as screening levels, are 
used by ATSDR health assessors to identify contaminants and potential health effects that may be of 
concern at hazardous waste sites.  It is important to note that MRLs are not intended to define clean-up or 
action levels. 
MRLs are derived for hazardous substances using the no-observed-adverse-effect level/uncertainty factor 
approach. They are below levels that might cause adverse health effects in the people most sensitive to 
such chemical-induced effects.  MRLs are derived for acute (1–14 days), intermediate (15–364 days), and 
chronic (365 days and longer) durations and for the oral and inhalation routes of exposure.  Currently, 
MRLs for the dermal route of exposure are not derived because ATSDR has not yet identified a method 
suitable for this route of exposure. MRLs are generally based on the most sensitive chemical-induced end 
point considered to be of relevance to humans.  Serious health effects (such as irreparable damage to the 
liver or kidneys, or birth defects) are not used as a basis for establishing MRLs.  Exposure to a level 
above the MRL does not mean that adverse health effects will occur. 
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MRLs are intended only to serve as a screening tool to help public health professionals decide where to 
look more closely.  They may also be viewed as a mechanism to identify those hazardous waste sites that 
are not expected to cause adverse health effects.  Most MRLs contain a degree of uncertainty because of 
the lack of precise toxicological information on the people who might be most sensitive (e.g., infants, 
elderly, nutritionally or immunologically compromised) to the effects of hazardous substances.  ATSDR 
uses a conservative (i.e., protective) approach to address this uncertainty consistent with the public health 
principle of prevention. Although human data are preferred, MRLs often must be based on animal studies 
because relevant human studies are lacking.  In the absence of evidence to the contrary, ATSDR assumes 
that humans are more sensitive to the effects of hazardous substance than animals and that certain persons 
may be particularly sensitive.  Thus, the resulting MRL may be as much as 100-fold below levels that 
have been shown to be nontoxic in laboratory animals. 
Proposed MRLs undergo a rigorous review process:  Health Effects/MRL Workgroup reviews within the 
Division of Toxicology, expert panel peer reviews, and agency-wide MRL Workgroup reviews, with 
participation from other federal agencies and comments from the public.  They are subject to change as 
new information becomes available concomitant with updating the toxicological profiles.  Thus, MRLs in 
the most recent toxicological profiles supersede previously published levels.  For additional information 
regarding MRLs, please contact the Division of Toxicology, Agency for Toxic Substances and Disease 
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MINIMAL RISK LEVEL (MRL) WORKSHEET 
Chemical Name: Bromoform 
CAS Number: 75-25-2 
Date:   August 2005 
Profile Status: Final Draft of Post-Public Comment Toxicological Profile  
Route: [ ] Inhalation  [X] Oral 
Duration: [X] Acute   [ ] Intermediate  [ ] Chronic 
Key to Figure: 13 
Species: Mice 
Minimal Risk Level: 0.7 [X] mg/kg/day  [ ] mg/m3 
Reference: Condie LW, Smallwood CL, Laurie RD.  1983.  Comparative renal and hepatotoxicity of 
halomethanes: Bromodichloromethane, bromoform, chloroform, dibromochloromethane and methylene 
chloride. Drug Chem Toxicol 6:563-578. 
Experimental design: 
Groups of 5–16 male CD-1 mice received daily gavage doses of 0, 72, 145, or 289 mg/kg/day  
bromoform in corn oil for 14 days.  Body weight was measured on days 1 and 14.  Blood was collected 
for clinical chemistry at study termination.  Renal cortical slices of kidney tissue were collected for 
measurement of para-aminohippurate (PAH) uptake, and samples of liver and kidney tissue were 
collected for histopathological examination.   
Effects noted in study and corresponding concentrations: 
No significant alterations in body weight gain were observed.  PAH uptake by kidney slices was 
decreased by 30% in the 289 mg/kg/day group; a significant increase in SGPT was also observed at this 
dose. Minimal to moderate liver and kidney histological alterations were observed.  Liver effects 
included centrilobular pallor at 145 and 289 mg/kg/day and focal inflammation at 289 mg/kg/day. 
Kidney effects consisted of epithelial hyperplasia at 289 mg/kg/day and mesangial nephrosis at 145 and 
289 mg/kg/day. 
Concentration and end point used for MRL derivation: 
The MRL is based on a NOAEL of 72 mg/kg/day and a LOAEL of 145 mg/kg/day for hepatice 
centrilobular pallor in mice.    
[ X ] NOAEL  [ ] LOAEL 
Uncertainty Factors used in MRL derivation: 
[X] 10 for extrapolation from animals to humans 
[X] 10 for human variability 
Was a conversion factor used from ppm in food or water to a mg/body weight dose?  No. 
If an inhalation study in animals, list conversion factors used in determining human equivalent 
concentration: NA 
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Was a conversion used from intermittent to continuous exposure? No. 
Other additional studies or pertinent information that lend support to this MRL: 
Several acute-duration studies support the identification of the liver as the most sensitive target of 
bromoform toxicity.  The observed effects include hepatocellular vacuolization and swelling (Chu et al. 
1982a; Coffin et al. 2000), centrilobular pallor (Condie et al. 1983), increased absolute and relative liver 
weights (Munson et al. 1982), alterations in serum chemistry enzymes such as SGPT (Munson et al. 
1982), and impaired liver function (Munson et al. 1982).  The highest NOAEL for liver effects is 
72 mg/kg/day in mice (Condie et al. 1983); in this study, centrilobular pallor (Condie et al. 1983), which 
was considered to be indicative of liver degeneration, was observed at 145 mg/kg/day.  At 
125 mg/kg/day, increases in liver weight were observed (Munson et al. 1982) and hepatocellular 
vacuolization and swelling were observed at 200 mg/kg (164 mg/kg/day) (Coffin et al. 2000). Other 
adverse effects that have been observed at similar or higher dose levels include mesangial nephrosis at 
145 mg/kg/day (NOAEL of 72 mg/kg/day) (Condie et al. 1983), impaired immune function at 
125 mg/kg/day (NOAEL of 50 mg/kg/day) (Munson et al. 1982), skeletal anomalies in the offspring of 
rats exposed to 200 mg/kg/day (NOAEL of 100 mg/kg/day) (Ruddick et al. 1983), and central nervous 
system depression at ≥600 mg/kg (Balster and Borzelleca 1982; Bowman et al. 1978; NTP 1989a).  
Although several adverse effects have been reported at 100–200 mg/kg/day, the liver was selected as the 
critical target because the adverse liver effects are consistently observed in animals following acute-, 
intermediate-, and chronic-duration exposure.   
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MINIMAL RISK LEVEL (MRL) WORKSHEET 
Chemical Name: Bromoform 
CAS Number: 75-25-2 
Date:   August 2005 
Profile Status: Final Draft of Post-Public Comment Toxicological Profile 
Route: [ ] Inhalation  [X] Oral 
Duration: [ ] Acute   [X] Intermediate  [ ] Chronic 
Key to Figure: 26 
Species: Rat 
Minimal Risk Level: 0.2 [X] mg/kg/day  [ ] mg/m3 
Reference: NTP. 1989a.  Toxicology and carcinogenesis studies of tribromomethane (bromoform) in 
F344/N rats and B6C3F1 mice (gavage studies).  National Toxicology Program.  Technical Report Series 
No. 350. Research Triangle Park, NC: U.S. Department of Health and Human Services.  
Experimental design: 
Groups of F344/N male and female F344/N rats (10/sex/group) received gavage doses of 0, 12, 25, 50, 
100, or 200 mg/kg bromoform in corn oil 5 days/week for 13 weeks.  The rats were observed twice per 
day and weighed weekly. At sacrifice, all animals were necropsied and tissues from the vehicle control 
and high dose groups were examined histologically.  
Effects noted in study and corresponding concentrations: 
None of the rats died before the end of the study.  Final mean body weights were similar in dosed and 
control groups.  Lethargy was observed in all male rats exposed to 100 or 200 mg/kg and in all females 
exposed to 200 mg/kg.  Hepatocellular vacuolization was observed in male rats (3/10, 6/10, 5/10, 8/10, 
8/10, and 10/10 in the 0, 12, 25, 50, 100, and 200 mg/kg groups, respectively); the response reached 
statistical significance (Fisher exact one-tailed p-value of 0.03) at 50 mg/kg/day.  Severity data were not 
reported for this lesion, but the study authors noted that vacuoles were more numerous in the 200 mg/kg 
group.  Corresponding hepatic effects were not observed in females.   
Concentration and end point used for MRL derivation: 
The MRL is based on a NOAEL of 25 mg/kg (duration-adjusted to 18 mg/kg/day) and a LOAEL of 
50 mg/kg (duration-adjusted to 36 mg/kg/day) for hepatic lesions (hepatocellular vacuolization). 
[X] NOAEL [ ] LOAEL 
Uncertainty Factors used in MRL derivation: 
[X] 10 for extrapolation from animals to humans 
[X] 10 for human variability 
Was a conversion factor used from ppm in food or water to a mg/body weight dose?  No. 
If an inhalation study in animals, list conversion factors used in determining human equivalent 
concentration: NA 
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Was a conversion used from intermittent to continuous exposure?  
The NOAEL was adjusted for intermittent exposure:  25 mg/kg x 5 days/7 days = 18 mg/kg/day  
Other additional studies or pertinent information that lend support to this MRL: 
A number of animal studies have identified the liver as the critical target of bromoform oral toxicity.  An 
intermediate-duration study in rats (Aida et al. 1992) supports the identification of 50 mg/kg as the critical 
dose. In this study, a LOAEL of 56.4 mg/kg/day was identified for hepatocellular vacuolization and 
swelling in rats exposed to bromoform in the diet for 1 month.  At a higher dose (207.5 mg/kg/day), a 
decrease in serum triglycerides and an increase in serum cholesterol levels were found; these findings are 
consistent with the liver histological alterations.  Mice appear to be less sensitive to the toxicity of 
bromoform than rats.  NOAEL and LOAEL values of 100 and 200 mg/kg (5 days/week) for 
hepatocellular vacuolization were identified in the intermediate-duration mouse NTP study (NTP 1989a). 
Melnick et al. (1998) found hydropic degeneration and increases in SGPT and sorbitol dehydrogenase 
levels in mice receiving gavage doses of 500 mg/kg, 5 days/week for 3 weeks.  Acute- and chronic-
duration studies have also identified the liver as the most sensitive target of toxicity.    
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MINIMAL RISK LEVEL (MRL) WORKSHEET 
Chemical Name: Bromoform 
CAS Number: 75-25-2 
Date:   September 2005 
Profile Status: Final Draft of Post-Public Comment Toxicological Profile 
Route: [ ] Inhalation  [X] Oral 
Duration: [ ] Acute   [ ] Intermediate  [X] Chronic 
Key to Figure: 38 
Species: Rat 
Minimal Risk Level: 0.02 [X] mg/kg/day  [ ] mg/m3 
Reference: NTP. 1989a.  Toxicology and carcinogenesis studies of tribromomethane (bromoform) in 
F344/N rats and B6C3F1 mice (gavage studies).  National Toxicology Program.  Technical Report Series 
No. 350. Research Triangle Park, NC: U.S. Department of Health and Human Services.  
Experimental design: 
Groups of male and female F344/N rats (50/sex/group) were administered via gavage 0, 100, or 
200 mg/kg bromoform in corn oil 5 days/week for 103 weeks.  Animals were observed for clinical signs 
throughout the study.  Body weights were measured weekly for 12 weeks and monthly thereafter.  At 
termination, all study animals were necropsied.  Full histopathological examination was performed on all 
control and high dose animals and on low dose males.  Selected tissues including esophagus, gross 
lesions, kidney, liver, lymph nodes, mammary gland, pancreas, pituitary gland, salivary glands, thyroid 
gland, trachea, and uterus were examined in low-dose females. 
Effects noted in study and corresponding concentrations: 
Significantly increased mortality was observed in male rats exposed to 200 mg/kg after week 91 (36–78% 
vs. 26–32%).  Survival was comparable to vehicle controls in males exposed to 100 mg/kg and in females 
exposed to 100 or 200 mg/kg.  Bromoform-related clinical signs included lethargy in both sexes and 
aggressiveness in males.  After 15 weeks, the difference between control body weights and body weights 
of males exposed to 200 mg/kg males was consistently ≥10%; terminal body weights were 21% lower 
than controls.  In the females exposed to 200 mg/kg, the difference in body weights was ≥10% after week 
41; terminal body weights were 25% lower than controls.  Body weights in the 100 mg/kg groups were 
typically within 10% of controls.  Bromoform-related hepatic lesions included fatty change (characterized 
as hepatocellular vacuolization) in 23/50, 49/50, and 50/50 males exposed to 0, 100, or 200 mg/kg, 
respectively, and 19/50, 39/49, and 46/50 females; chronic active inflammation (male:  0/50, 29/50, and 
23/50; female:  9/50, 8/49, and 27/50); and necrosis (male:  7/50, 3/50, and 20/50; female:  11/50, 3/49, 
and 2/50). Other lesions with significantly increased incidences included salivary gland duct squamous 
metaplasia at 100 and 200 mg/kg (males:  0/50, 15/50, and 31/48; females:  0/49, 10/49, and 16/50) and 
chronic active inflammation (male: 0/50, 14/50, and 22/48; female:  0/49, 9/49, and 18/50); ulcers of the 
forestomach in  males at 200 mg/kg (1/49, 5/50, and 10/50); chronic active inflammation in the lungs in 
males at 100 and 200 mg/kg (1/50, 7/50, and 15/50); squamous metaplasia in the prostate gland at 
200 mg/kg (2/49, 6/46, and 12/50); hyperplasia of the anterior lobe of the pituitary gland in males at 
100 mg/kg (9/48, 26/50, and 15/50); and spleen pigmentation in females at 200 mg/kg (7/49, 6/28, and 
29/50), which was characteristic of hemosiderin.  The occurrence of ulcers in the forestomach may have 
resulted from gavage bolus dose delivery.  Lesions observed in the lungs and salivary glands were 
reported to be consistent with infection by sialodacryloadenitis (SDA) virus.  However, since the 
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occurrence of these lesions was clearly dose-related, the study authors concluded that they were likely to 
represent a combination of viral and chemical-related effects.  
It should be noted that the study authors did not report statistical analysis data for nonneoplastic lesions.  
An independent statistical analysis was conducted; statistical significance was determined using a Fisher 
exact test, one tailed p<0.05). 
Concentration and end point used for MRL derivation: 
The MRL is based on a LOAEL of 100 mg/kg (duration-adjusted to 71 mg/kg/day) for histopathological 
changes (vacuolization) in the liver. 
[ ] NOAEL   [X] LOAEL 
Uncertainty Factors used in MRL derivation: 
[X] 	 3 for use of a minimal LOAEL 
[X] 	 10 for extrapolation from animals to humans 
[X] 	 10 for human variability 
Modifying Factors used in MRL derivation: 
[X] 	 10 to account for the identification of a lower LOAEL in the 13-week NTP (1989a) 
study. 
Was a conversion factor used from ppm in food or water to a mg/body weight dose?  No. 
If an inhalation study in animals, list conversion factors used in determining human equivalent 
concentration: NA 
Was a conversion used from intermittent to continuous exposure? Yes. 
The LOAEL was adjusted for intermittent exposure:  100 mg/kg x 5 days/7 days = 71 mg/kg/day 
Other additional studies or pertinent information that lend support to this MRL:  
Two studies have examined the chronic toxicity of bromoform (NTP 1989a; Tobe et al. 1982).  Both 
studies identified the liver as the most sensitive target of toxicity.  Both the NTP (1989a) rat and mouse 
studies identified LOAEL values of 100 mg/kg (5 days/week) for hepatocellular vacuolization.  The rat 
study was selected over the mouse study because the effects were observed in both sexes.  This study is 
supported by a 2-year dietary study conducted by Tobe et al. (1982).  Yellowing of the liver and increases 
in absolute and liver weights were observed in female rats exposed to 140 mg/kg/day; histological 
examinations were not conducted.  Alterations in several clinical chemistry parameters are also indicative 
of liver damage.  Increases in SGOT and SGPT and decreases in serum triglycerides and cholesterol were 
observed at 590–720 mg/kg/day.  A number of intermediate-duration studies (Aida et al. 1992; Chu et al. 
1982b; Melnick et al. 1998; NTP 1989a) support the identification of the liver as the critical target of 
bromoform toxicity.   
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MINIMAL RISK LEVEL (MRL) WORKSHEET 
Chemical Name: Dibromochloromethane 
CAS Number: 124-48-1 
Date:   August 2005 
Profile Status: Final Draft of Post-Public Comment Toxicological Profile 
Route: [ ] Inhalation  [X] Oral 
Duration: [X] Acute   [ ] Intermediate  [ ] Chronic 
Key to Figure: 16 
Species: Mouse 
Minimal Risk Level: 0.1 [X] mg/kg/day  [ ] mg/m3 
Reference: Condie LW, Smallwood CL, Laurie RD.  1983.  Comparative renal and hepatotoxicity of 
halomethanes: Bromodichloromethane, bromoform, chloroform, dibromochloromethane and methylene 
chloride. Drug Chem Toxicol 6:563-578. 
Experimental design: 
Groups of 5–16 male CD-1 mice received daily gavage doses of 0, 37, 74, or 147 mg/kg/day dibromo-
chloromethane in corn oil for 14 days.  Body weight was measured on days 1 and 14.  Blood was 
collected for clinical chemistry at study termination.  Renal cortical slices of kidney tissue were collected 
for measurement of para-aminohippurate uptake, and samples of liver and kidney tissue were 
histopathological examination.   
Effects noted in study and corresponding concentrations: 
No deaths or treatment-related clinical signs were reported.  No significant alterations in body weight gain 
were observed.  Para-aminohippurate uptake by kidney slices was decreased by approximately 30% in the 
147 mg/kg/day group; a significant increase in SGPT was also observed at this dose.  Minimal to 
moderate liver and kidney histological alterations were observed.  Liver effects included hepatocellular 
vacuolization at 37 mg/kg/day and higher (1/16, 3/5, 4/10, and 8/10 in the 0, 37, 74, and 147 mg/kg/day 
groups, respectively) and mitotic figures at 147 mg/kg/day (0/16, 0/5, 2/10, and 4/10).  Kidney effects 
consisted of mesangial hypertrophy was observed at 37 mg/kg/day and higher (0/16, 4/5, 7/10, and 7/10).   
Concentration and end point used for MRL derivation: 
The MRL is based on a LOAEL of 37 mg/kg/day for hepatocellular vacuolization (Condie et al. 1983).  
[ ] NOAEL   [X] LOAEL 
Uncertainty Factors used in MRL derivation: 
[X] 3 for use of a minimal LOAEL 
[X] 10 for extrapolation from animals to humans 
[X] 10 for human variability 
Was a conversion factor used from ppm in food or water to a mg/body weight dose? No. 
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If an inhalation study in animals, list conversion factors used in determining human equivalent 
concentration: NA 
Was a conversion used from intermittent to continuous exposure? No. 
Other additional studies or pertinent information that lend support to this MRL: 
There are numerous studies that support the identification of the liver as the critical target of 
dibromochloromethane toxicity.  Hepatocellular vacuolization and/or swelling were observed in mice 
exposed to 100 and 300 mg/kg (9 doses in an 11-day period) (Coffin et al. 2000), at ≥50 mg/kg in rats and 
mice exposed to dibromochloromethane for an intermediate duration (Aida et al. 1992; Daniel et al. 1990; 
NTP 1985) and in rats and mice exposed to ≥40 for 2 years (NTP 1985).  At higher doses, hepatocellular 
necrosis is observed (Aida et al. 1993; Daniel et al. 1990; NTP 1985) in rats and mice exposed to 
≥100 mg/kg for intermediate durations.  
The Condie et al. study (1983) also identified the 37 mg/kg/day dose as a LOAEL for kidney effects, 
mesangial cell hyperplasia.  Other animal studies have also found kidney lesions following oral exposure 
to dibromochloromethane.  Nephropathy, characterized by tubular cell degeneration and tubular cast 
formation was noted in 80% of male rats and 100% of female rats, but was not found in the controls or 
other dose groups exposed to dibromochloromethane in corn oil for 13 weeks (NTP 1985). The liver was 
selected as the critical target because the results of other studies suggest that it may be the more sensitive 
target of toxicity. 
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MINIMAL RISK LEVEL (MRL) WORKSHEET 
Chemical Name: Dibromochloromethane 
CAS Number: 124-48-1 
Date:   August 2005 
Profile Status: Final Draft of Post-Public Comment Toxicological Profile 
Route: [ ] Inhalation  [X] Oral 
Duration: [ ] Acute   [ ] Intermediate  [X] Chronic 
Key to Figure: 46 
Species: Rat 
Minimal Risk Level: 0.09 [X] mg/kg/day  [ ] mg/m3 
Reference: NTP. 1985.  Toxicology and carcinogenesis studies of dibromochloromethane in F344/N rats 
and B6C3F1 mice (gavage studies).  National Toxicology Program.  Technical Report Series No. 282. 
Research Triangle Park, NC:  U.S. Department of Health and Human Services. 
Experimental design: 
Groups of 50 male and 50 female F344/N rats received 0, 40, or 80 mg/kg gavage doses of 
dibromochloromethane in corn oil 5 days/week for 2 years.  Clinical signs were recorded weekly.  Body 
weights were recorded weekly for the first twelve weeks of the study and monthly thereafter.  Necropsy 
was performed on all animals.  Histopathological examination was conducted on tissues from all dose 
groups. 
Effects noted in study and corresponding concentrations: 
Survival was comparable in all study groups.  Body weight gain was within 10% of controls throughout 
the study.  In the liver, fatty change (male:  27/50, 47/50, and 49/50; female:  12/50, 23/50, and 50/50) 
and "ground glass" cytoplasmic changes (male:  8/50, 22/50, and 34/50; female:  0/50, 1/50, and 12/50) 
were observed. A dose-related increase in nephrosis was observed in female rats (7/50, 11/50, and 
14/50); however, the incidences in exposed rats was not statistically higher than in vehicle controls 
assessed using the Fisher exact test. 
It should be noted that the study authors did not report statistical analysis data for nonneoplastic lesions.  
An independent statistical analysis was conducted; statistical significance was determined using a Fisher 
exact test, one tailed p<0.05). 
Concentration and end point used for MRL derivation: 
The MRL is based on a LOAEL of 40 mg/kg (duration-adjusted to 28 mg/kg/day) for liver histopathology 
(fatty change) (NTP 1985). 
[ ] NOAEL   [X] LOAEL 
Uncertainty Factors used in MRL derivation: 
[X] 3 for use of a minimal LOAEL 
[X] 10 for extrapolation from animals to humans 
[X] 10 for human variability 
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Was a conversion factor used from ppm in food or water to a mg/body weight dose?  No. 
If an inhalation study in animals, list conversion factors used in determining human equivalent 
concentration: NA 
Was a conversion used from intermittent to continuous exposure? 
The LOAEL was adjusted for intermittent exposure:  40 mg/kg x 5 days/7 days = 28 mg/kg/day  
Other additional studies or pertinent information that lend support to this MRL: 
The identification of the liver as the critical target is supported by numerous acute-duration studies in rats 
and mice exposed to ≥37 mg/kg (Chu et al. 1982a; Coffin et al. 2000; Condie et al. 1983; Hewitt et al. 
1983; Munson et al. 198; NTP 1985), 50 mg/kg for intermediate durations (Aida et al. 1992; Daniel et al. 
1990; Melnick et al. 1998; NTP 1985), and 40 mg/kg for chronic durations (NTP 1985; Tobe et al. 1982).  
The identification of the LOAEL of 40 mg/kg for fatty changes in the liver is supported by the NTP 
(1985) mouse study and a rat study by Tobe et al. (1982).  Fatty metamorphosis was found in mice 
receiving gavage doses of 50 mg/kg, 5 days/week for 2 years (NTP 1985).  Necrosis was observed at 
100 mg/kg.  In the Tobe et al. (1982) study, groups of rats were exposed to dibromochloromethane in diet 
for 2 years.  No histological examinations were conducted; however, hypertrophy and yellowing of the 
liver was found at 85 mg/kg/day.  Alterations in a number of clinical chemistry parameters, which are 
indicative of liver damage, were also observed.  Decreases in serum triglycerides were observed at 
20 mg/kg/day and decreases in serum cholesterol were observed at 540 mg/kg/day. 
Agency Contact (Chemical Managers):  John Risher, Dennis Jones 
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Chapter 1 
Public Health Statement 
This chapter of the profile is a health effects summary written in non-technical language.  Its intended 
audience is the general public, especially people living in the vicinity of a hazardous waste site or 
chemical release.  If the Public Health Statement were removed from the rest of the document, it would 
still communicate to the lay public essential information about the chemical. 
The major headings in the Public Health Statement are useful to find specific topics of concern.  The 
topics are written in a question and answer format.  The answer to each question includes a sentence that 
will direct the reader to chapters in the profile that will provide more information on the given topic. 
Chapter 2 
Relevance to Public Health 
This chapter provides a health effects summary based on evaluations of existing toxicologic, 
epidemiologic, and toxicokinetic information.  This summary is designed to present interpretive, weight­
of-evidence discussions for human health end points by addressing the following questions: 
1.	 What effects are known to occur in humans? 
2. 	 What effects observed in animals are likely to be of concern to humans? 
3. 	 What exposure conditions are likely to be of concern to humans, especially around hazardous 
waste sites? 
The chapter covers end points in the same order that they appear within the Discussion of Health Effects 
by Route of Exposure section, by route (inhalation, oral, and dermal) and within route by effect.  Human 
data are presented first, then animal data.  Both are organized by duration (acute, intermediate, chronic).  
In vitro data and data from parenteral routes (intramuscular, intravenous, subcutaneous, etc.) are also 
considered in this chapter. 
The carcinogenic potential of the profiled substance is qualitatively evaluated, when appropriate, using 
existing toxicokinetic, genotoxic, and carcinogenic data.  ATSDR does not currently assess cancer 
potency or perform cancer risk assessments.  Minimal Risk Levels (MRLs) for noncancer end points (if 
derived) and the end points from which they were derived are indicated and discussed. 
Limitations to existing scientific literature that prevent a satisfactory evaluation of the relevance to public 
health are identified in the Chapter 3 Data Needs section. 
Interpretation of Minimal Risk Levels 
Where sufficient toxicologic information is available, ATSDR has derived MRLs for inhalation and oral 
routes of entry at each duration of exposure (acute, intermediate, and chronic).  These MRLs are not 
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meant to support regulatory action, but to acquaint health professionals with exposure levels at which 
adverse health effects are not expected to occur in humans. 
MRLs should help physicians and public health officials determine the safety of a community living near 
a chemical emission, given the concentration of a contaminant in air or the estimated daily dose in water.  
MRLs are based largely on toxicological studies in animals and on reports of human occupational 
exposure. 
MRL users should be familiar with the toxicologic information on which the number is based.  Chapter 2, 
"Relevance to Public Health," contains basic information known about the substance.  Other sections such 
as Chapter 3 Section 3.9, "Interactions with Other Substances,” and Section 3.10, "Populations that are 
Unusually Susceptible" provide important supplemental information. 
MRL users should also understand the MRL derivation methodology.  MRLs are derived using a 
modified version of the risk assessment methodology that the Environmental Protection Agency (EPA) 
provides (Barnes and Dourson 1988) to determine reference doses (RfDs) for lifetime exposure.   
To derive an MRL, ATSDR generally selects the most sensitive end point which, in its best judgement, 
represents the most sensitive human health effect for a given exposure route and duration.  ATSDR 
cannot make this judgement or derive an MRL unless information (quantitative or qualitative) is available 
for all potential systemic, neurological, and developmental effects.  If this information and reliable 
quantitative data on the chosen end point are available, ATSDR derives an MRL using the most sensitive 
species (when information from multiple species is available) with the highest no-observed-adverse-effect 
level (NOAEL) that does not exceed any adverse effect levels.  When a NOAEL is not available, a 
lowest-observed-adverse-effect level (LOAEL) can be used to derive an MRL, and an uncertainty factor 
(UF) of 10 must be employed.  Additional uncertainty factors of 10 must be used both for human 
variability to protect sensitive subpopulations (people who are most susceptible to the health effects 
caused by the substance) and for interspecies variability (extrapolation from animals to humans).  In 
deriving an MRL, these individual uncertainty factors are multiplied together.  The product is then 
divided into the inhalation concentration or oral dosage selected from the study. Uncertainty factors used 




Tables and Figures for Levels of Significant Exposure (LSE) 
Tables and figures are used to summarize health effects and illustrate graphically levels of exposure 
associated with those effects.  These levels cover health effects observed at increasing dose 
concentrations and durations, differences in response by species, MRLs to humans for noncancer end 
points, and EPA's estimated range associated with an upper- bound individual lifetime cancer risk of 1 in 
10,000 to 1 in 10,000,000. Use the LSE tables and figures for a quick review of the health effects and to 
locate data for a specific exposure scenario.  The LSE tables and figures should always be used in 
conjunction with the text.  All entries in these tables and figures represent studies that provide reliable, 
quantitative estimates of NOAELs, LOAELs, or Cancer Effect Levels (CELs). 
The legends presented below demonstrate the application of these tables and figures.  Representative 
examples of LSE Table 3-1 and Figure 3-1 are shown.  The numbers in the left column of the legends 
correspond to the numbers in the example table and figure. 
B-3 BROMOFORM AND DIBROMOCHLOROMETHANE 
APPENDIX B 
LEGEND 
See Sample LSE Table 3-1 (page B-6) 
(1) 	 Route of Exposure. One of the first considerations when reviewing the toxicity of a substance 
using these tables and figures should be the relevant and appropriate route of exposure.  Typically 
when sufficient data exist, three LSE tables and two LSE figures are presented in the document.  
The three LSE tables present data on the three principal routes of exposure, i.e., inhalation, oral, 
and dermal (LSE Tables 3-1, 3-2, and 3-3, respectively). LSE figures are limited to the inhalation 
(LSE Figure 3-1) and oral (LSE Figure 3-2) routes.  Not all substances will have data on each 
route of exposure and will not, therefore, have all five of the tables and figures. 
(2) 	Exposure Period. Three exposure periods—acute (less than 15 days), intermediate (15– 
364 days), and chronic (365 days or more)—are presented within each relevant route of exposure.  
In this example, an inhalation study of intermediate exposure duration is reported.  For quick 
reference to health effects occurring from a known length of exposure, locate the applicable 
exposure period within the LSE table and figure. 
(3) 	Health Effect. The major categories of health effects included in LSE tables and figures are 
death, systemic, immunological, neurological, developmental, reproductive, and cancer.  
NOAELs and LOAELs can be reported in the tables and figures for all effects but cancer.  
Systemic effects are further defined in the "System" column of the LSE table (see key number 
18). 
(4) 	 Key to Figure. Each key number in the LSE table links study information to one or more data 
points using the same key number in the corresponding LSE figure.  In this example, the study 
represented by key number 18 has been used to derive a NOAEL and a Less Serious LOAEL 
(also see the two "18r" data points in sample Figure 3-1). 
(5) 	Species. The test species, whether animal or human, are identified in this column.  Chapter 2, 
"Relevance to Public Health," covers the relevance of animal data to human toxicity and 
Section 3.4, "Toxicokinetics," contains any available information on comparative toxicokinetics.  
Although NOAELs and LOAELs are species specific, the levels are extrapolated to equivalent 
human doses to derive an MRL. 
(6) 	Exposure Frequency/Duration. The duration of the study and the weekly and daily exposure 
regimens are provided in this column.  This permits comparison of NOAELs and LOAELs from 
different studies. In this case (key number 18), rats were exposed to “Chemical x” via inhalation 
for 6 hours/day, 5 days/week, for 13 weeks.  For a more complete review of the dosing regimen, 
refer to the appropriate sections of the text or the original reference paper (i.e., Nitschke et al. 
1981). 
(7) 	System. This column further defines the systemic effects.  These systems include respiratory, 
cardiovascular, gastrointestinal, hematological, musculoskeletal, hepatic, renal, and 
dermal/ocular.  "Other" refers to any systemic effect (e.g., a decrease in body weight) not covered 
in these systems.  In the example of key number 18, one systemic effect (respiratory) was 
investigated. 
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(8) 	NOAEL. A NOAEL is the highest exposure level at which no harmful effects were seen in the 
organ system studied.  Key number 18 reports a NOAEL of 3 ppm for the respiratory system, 
which was used to derive an intermediate exposure, inhalation MRL of 0.005 ppm (see 
footnote "b"). 
(9) 	LOAEL. A LOAEL is the lowest dose used in the study that caused a harmful health effect. 
LOAELs have been classified into "Less Serious" and "Serious" effects.  These distinctions help 
readers identify the levels of exposure at which adverse health effects first appear and the 
gradation of effects with increasing dose.  A brief description of the specific end point used to 
quantify the adverse effect accompanies the LOAEL.  The respiratory effect reported in key 
number 18 (hyperplasia) is a Less Serious LOAEL of 10 ppm.  MRLs are not derived from 
Serious LOAELs. 
(10)	 Reference. The complete reference citation is given in Chapter 9 of the profile. 
(11)	 CEL. A CEL is the lowest exposure level associated with the onset of carcinogenesis in 
experimental or epidemiologic studies.  CELs are always considered serious effects.  The LSE 
tables and figures do not contain NOAELs for cancer, but the text may report doses not causing 
measurable cancer increases. 
(12)	 Footnotes. Explanations of abbreviations or reference notes for data in the LSE tables are found 
in the footnotes.  Footnote "b" indicates that the NOAEL of 3 ppm in key number 18 was used to 
derive an MRL of 0.005 ppm. 
LEGEND 
See Sample Figure 3-1 (page B-7) 
LSE figures graphically illustrate the data presented in the corresponding LSE tables.  Figures help the 
reader quickly compare health effects according to exposure concentrations for particular exposure 
periods. 
(13)	 Exposure Period. The same exposure periods appear as in the LSE table.  In this example, health 
effects observed within the acute and intermediate exposure periods are illustrated. 
(14) 	Health Effect. These are the categories of health effects for which reliable quantitative data 
exists. The same health effects appear in the LSE table. 
(15)	 Levels of Exposure. Concentrations or doses for each health effect in the LSE tables are 
graphically displayed in the LSE figures.  Exposure concentration or dose is measured on the log 
scale "y" axis.  Inhalation exposure is reported in mg/m3 or ppm and oral exposure is reported in 
mg/kg/day. 
(16) 	NOAEL. In this example, the open circle designated 18r identifies a NOAEL critical end point in 
the rat upon which an intermediate inhalation exposure MRL is based.  The key number 18 
corresponds to the entry in the LSE table.  The dashed descending arrow indicates the 
extrapolation from the exposure level of 3 ppm (see entry 18 in the table) to the MRL of 
0.005 ppm (see footnote "b" in the LSE table). 
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(17)	 CEL. Key number 38m is one of three studies for which CELs were derived.  The diamond 
symbol refers to a CEL for the test species-mouse.  The number 38 corresponds to the entry in the 
LSE table. 
(18) 	 Estimated Upper-Bound Human Cancer Risk Levels. This is the range associated with the upper-
bound for lifetime cancer risk of 1 in 10,000 to 1 in 10,000,000.  These risk levels are derived 
from the EPA's Human Health Assessment Group's upper-bound estimates of the slope of the 
cancer dose response curve at low dose levels (q1*). 




1 → 	 Table 3-1. Levels of Significant Exposure to [Chemical x] – Inhalation 
LOAEL (effect) Exposure 
Key to 	 frequency/ NOAEL Less serious Serious (ppm) 




→ INTERMEDIATE EXPOSURE 

1098765 
→ Systemic ↓ ↓ ↓ ↓ ↓ 	 ↓  
3b18 Rat 	 13 wk Resp 10 (hyperplasia) 




3  multiple Wong et al. 1982 
s) 
3  lung tumors, NTP 1982 
tumors) 
4  lung tumors, NTP 1982 
ngiosarcomas) 









































8 Rat 	 18 mo 20 (CEL,
5 d/wk organ
7 hr/d 
9 Rat 	 89–104 wk 10 (CEL,
5 d/wk nasal 
6 hr/d 
0 Mouse 	 79–103 wk 10 (CEL,
5 d/wk hema
6 hr/d 
	 i The number corresponds to entries in F gure 3-1. 
  Used to derive an intermediate inha ation Minimal Risk Level (MRL) of  l 5x10-3  ppm; dose adjus
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ACGIH American Conference of Governmental Industrial Hygienists 
ACOEM American College of Occupational and Environmental Medicine 
ADI acceptable daily intake 
ADME absorption, distribution, metabolism, and excretion 
AED atomic emission detection 
AFID alkali flame ionization detector 
AFOSH Air Force Office of Safety and Health 
ALT alanine aminotransferase (also known as SGPT) 
AML acute myeloid leukemia 
AOAC Association of Official Analytical Chemists 
AOEC Association of Occupational and Environmental Clinics 
AP alkaline phosphatase 
APHA American Public Health Association 
AST aspartate aminotranferase (also known as SGOT) 
atm atmosphere 
ATSDR Agency for Toxic Substances and Disease Registry 
AWQC Ambient Water Quality Criteria 
BAT best available technology 
BCF bioconcentration factor 
BEI Biological Exposure Index 
BMD benchmark dose 
BMR benchmark response 
BSC Board of Scientific Counselors 
C centigrade 
CAA Clean Air Act 
CAG Cancer Assessment Group of the U.S. Environmental Protection Agency 
CAS Chemical Abstract Services 
CDC Centers for Disease Control and Prevention 
CEL cancer effect level 
CELDS Computer-Environmental Legislative Data System 
CERCLA Comprehensive Environmental Response, Compensation, and Liability Act 
CFR Code of Federal Regulations 
Ci curie 
CI confidence interval 
CL ceiling limit value 
CLP Contract Laboratory Program 
cm centimeter 
CML chronic myeloid leukemia 
CPSC Consumer Products Safety Commission 
CWA Clean Water Act 
DHEW Department of Health, Education, and Welfare 
DHHS Department of Health and Human Services 
DNA deoxyribonucleic acid 
DOD Department of Defense 
DOE Department of Energy 
DOL Department of Labor 
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DOT Department of Transportation 
DOT/UN/ Department of Transportation/United Nations/ 
NA/IMCO     North America/International Maritime Dangerous Goods Code 
DWEL drinking water exposure level 
ECD electron capture detection 
ECG/EKG electrocardiogram 
EEG electroencephalogram 
EEGL Emergency Exposure Guidance Level 
EPA Environmental Protection Agency 
F Fahrenheit 
F1 first-filial generation 
FAO Food and Agricultural Organization of the United Nations 
FDA Food and Drug Administration 
FEMA Federal Emergency Management Agency 
FIFRA Federal Insecticide, Fungicide, and Rodenticide Act 
FPD flame photometric detection 
fpm feet per minute 
FR Federal Register 
FSH follicle stimulating hormone 
g gram 
GC gas chromatography 
gd gestational day 
GLC gas liquid chromatography 
GPC gel permeation chromatography 
HPLC high-performance liquid chromatography 
HRGC high resolution gas chromatography 
HSDB Hazardous Substance Data Bank  
IARC International Agency for Research on Cancer 
IDLH immediately dangerous to life and health 
ILO International Labor Organization 
IRIS Integrated Risk Information System 
Kd adsorption ratio 
kg kilogram 
kkg metric ton 
Koc organic carbon partition coefficient 
Kow octanol-water partition coefficient 
L liter 
LC liquid chromatography 
LC50 lethal concentration, 50% kill 
LCLo lethal concentration, low 
LD50 lethal dose, 50% kill 
LDLo lethal dose, low 
LDH lactic dehydrogenase 
LH luteinizing hormone 
LOAEL lowest-observed-adverse-effect level 
LSE Levels of Significant Exposure 
LT50 lethal time, 50% kill 
m meter 
MA trans,trans-muconic acid 
MAL maximum allowable level 
mCi millicurie 
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MCL maximum contaminant level 
MCLG maximum contaminant level goal 
MF modifying factor 




mmHg millimeters of mercury 
mmol millimole 
mppcf millions of particles per cubic foot 
MRL Minimal Risk Level 
MS mass spectrometry 
NAAQS National Ambient Air Quality Standard 
NAS National Academy of Science 
NATICH National Air Toxics Information Clearinghouse 
NATO North Atlantic Treaty Organization 
NCE normochromatic erythrocytes 
NCEH National Center for Environmental Health 
NCI National Cancer Institute 
ND not detected 
NFPA National Fire Protection Association 
ng nanogram 
NHANES National Health and Nutrition Examination Survey 
NIEHS National Institute of Environmental Health Sciences 
NIOSH National Institute for Occupational Safety and Health 
NIOSHTIC NIOSH's Computerized Information Retrieval System 
NLM National Library of Medicine 
nm nanometer 
nmol nanomole 
NOAEL no-observed-adverse-effect level 
NOES National Occupational Exposure Survey 
NOHS National Occupational Hazard Survey 
NPD nitrogen phosphorus detection 
NPDES National Pollutant Discharge Elimination System 
NPL National Priorities List 
NR not reported 
NRC National Research Council 
NS not specified 
NSPS New Source Performance Standards 
NTIS National Technical Information Service 
NTP National Toxicology Program 
ODW Office of Drinking Water, EPA 
OERR Office of Emergency and Remedial Response, EPA 
OHM/TADS Oil and Hazardous Materials/Technical Assistance Data System 
OPP Office of Pesticide Programs, EPA 
OPPT Office of Pollution Prevention and Toxics, EPA 
OPPTS Office of Prevention, Pesticides and Toxic Substances, EPA 
OR odds ratio 
OSHA Occupational Safety and Health Administration 
OSW Office of Solid Waste, EPA 
OTS Office of Toxic Substances 
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OW Office of Water 
OWRS Office of Water Regulations and Standards, EPA 
PAH polycyclic aromatic hydrocarbon 
PBPD physiologically based pharmacodynamic  
PBPK physiologically based pharmacokinetic 
PCE polychromatic erythrocytes 
PEL permissible exposure limit 
pg picogram 
PHS Public Health Service 
PID photo ionization detector 
pmol picomole 
PMR proportionate mortality ratio 
ppb parts per billion 
ppm parts per million 
ppt parts per trillion 
PSNS pretreatment standards for new sources 
RBC red blood cell 
REL recommended exposure level/limit 
RfC reference concentration 
RfD reference dose 
RNA ribonucleic acid 
RQ reportable quantity 
RTECS Registry of Toxic Effects of Chemical Substances 
SARA Superfund Amendments and Reauthorization Act 
SCE sister chromatid exchange 
SGOT serum glutamic oxaloacetic transaminase (also known as AST) 
SGPT serum glutamic pyruvic transaminase (also known as ALT) 
SIC standard industrial classification 
SIM selected ion monitoring 
SMCL secondary maximum contaminant level 
SMR standardized mortality ratio 
SNARL suggested no adverse response level 
SPEGL Short-Term Public Emergency Guidance Level 
STEL short term exposure limit 
STORET Storage and Retrieval 
TD50 toxic dose, 50% specific toxic effect 
TLV threshold limit value 
TOC total organic carbon 
TPQ threshold planning quantity 
TRI Toxics Release Inventory 
TSCA Toxic Substances Control Act 
TWA time-weighted average 
UF uncertainty factor 
U.S. United States 
USDA United States Department of Agriculture 
USGS United States Geological Survey 
VOC volatile organic compound 
WBC white blood cell 
WHO World Health Organization 
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> greater than 
≥ greater than or equal to 
= equal to 
< less than 








q1 * cancer slope factor 
– negative 
+ positive 
(+) weakly positive result 
(–) weakly negative result 
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adsorption .................................................................................................................. 134, 136, 138, 143, 158, 160, 161
 
aerobic .........................................................................................................................................................92, 125, 136 
 
ambient air .................................................................................................................................................137, 138, 149 
 
anaerobic..............................................................................................................................................92, 125, 136, 152 
 










biomarker.......................................................................................................................................98, 99, 100, 112, 163 
 
biomarkers .....................................................................................................................................98, 99, 113, 157, 163 
 
body weight effects................................................................................................................................................23, 62 
 
breast milk .........................................................................................................................................................149, 150 
 
cancer................................................................................................................................. 4, 5, 22, 68, 93, 96, 163, 170 
 
carcinogen......................................................................................................................................................13, 69, 170 
 
carcinogenic............................................................................................................. 13, 15, 21, 22, 68, 84, 92, 110, 113 
 








cardiovascular effects ..................................................................................................................................................57 
 




clearance ................................................................................................................................................23, 99, 103, 114 
 
CYP2E1................................................................................................................................. 86, 87, 91, 92, 94, 97, 104 
 
cytochrome ................................................................................................................ 12, 82, 84, 86, 91, 92, 94, 97, 104 
 
death ...................................................................................................................................... 21, 22, 24, 55, 56, 91, 107 
 
dermal effects ..............................................................................................................................................................61 
 
dermal exposure....................................................... 11, 12, 15, 69, 81, 82, 88, 104, 107, 108, 109, 111, 112, 114, 150
 
DNA .......................................................................................... 70, 71, 73, 74, 75, 77, 78, 86, 87, 91, 93, 99, 113, 163
 




elimination half-time ...................................................................................................................................................88 
 






fetus .........................................................................................................................................................13, 68, 96, 114 
 
gastrointestinal effects ...........................................................................................................................................57, 58 
 
general population .........................................................................................................................11, 98, 108, 153, 163 
 
genotoxic .......................................................................................................................................................21, 93, 110 
 
genotoxicity .......................................................................................................................................70, 74, 87, 93, 110 
 
glutathione ......................................................................................................... 83, 84, 86, 87, 91, 92, 93, 97, 110, 114
 




half-life ........................................................................................................................................................98, 103, 135 
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immune system ....................................................................................................................................................63, 112 
 
immunological .......................................................................................................................................................21, 23 
 










menstrual .........................................................................................................................................................65, 66, 95 
 












nuclear ...............................................................................................................................................................122, 128 
 
odds ratio .....................................................................................................................................................................65 
 
oxidative metabolism.......................................................................................................................................86, 91, 93 
 
P-450 ................................................................................................................. 12, 82, 84, 86, 91, 92, 94, 97, 104, 114
 
partition coefficients ..............................................................................................................................................79, 81 
 














rate constants .............................................................................................................................................................135 
 
renal effects .............................................................................................................................................14, 23, 60, 113 
 
SGOT.................................................................................................................................................13, 16, 59, 60, 108 
 
shower ....................................................................................................................... 4, 6, 11, 78, 81, 99, 139, 146, 150
 
solubility ............................................................................................................................................................134, 157 
 
swimming .................................................................................. 3, 6, 64, 65, 78, 99, 143, 144, 148, 149, 150, 153, 154
 
tap water .................................................................................................. 6, 11, 13, 67, 81, 99, 109, 111, 139, 142, 146 
 












vapor pressure....................................................................................................................................................109, 134 
 
volatilization ......................................................................................................................................................135, 152 
 
whooping cough ..............................................................................................................................2, 6, 24, 63, 97, 107 
 

